Determination of eosinophilic esophagitis

ABSTRACT

The disclosure provides methods and compositions for diagnosing a patient eosinophilic esophagitis, the methods based upon the patient&#39;s gene expression profile for a panel of genes. The methods can also be used to exclude a diagnosis of chronic esophagitis.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/412,469 filed Mar. 5, 2012, which is a continuation of U.S. patent application Ser. No. 13/132,884 filed Jun. 3, 2011, which is a U.S. National Stage entry under 35 U.S.C. § 371 of International Application No. PCT/US2006/016948, filed May 3, 2006, designating the United States of America, which in turn claims priority from U.S. Provisional Application Ser. No. 60/677,375, filed May 3, 2005, each of which is expressly incorporated by reference herein.

This invention was made with government support under AI045898 awarded by the National Institutes of Health. The government has certain rights in the invention.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

The present application contains a sequence listing which has been submitted in ASCII format via EFS-Web. The content of the computer readable ASCII text file named “47108-509C02US_ST25.bd”, which was created on Jun. 23, 2016 and is 2.46 KB in size.

BACKGROUND

Eosinophilic esophagitis (EE) is an emerging worldwide disease, as documented by recent case series from Switzerland, Australia, Canada, Japan, England, and the U.S. Of concern, EE appears to be a growing health problem with an annual incidence of at least 1:10,000 children. The primary symptoms of EE (chest and abdominal pain, dysphagia, heartburn, vomiting, and food impaction) are also observed in patients with chronic esophagitis (CE) including gastroesophageal reflux disease (GERD). EE poses considerable diagnostic and therapeutic challenges especially because esophageal eosinophilia has been associated with several other medical condition including GERD, parasitic infection, and hypereosinophilic syndromes. In contrast to GERD, EE is more likely in males (80%), appears to have a not uncommon familial form, has a high rate of associated atopic disease (70%), and is typically not associated with abnormal pH probing of the esophagus. Distinguishing EE from GERD is important since EE patients typically do not respond to anti-GERD therapy, but rather respond to anti-inflammatory therapy and/or allergen elimination. Whereas both GERD and EE are associated with esophageal eosinophils, the level of eosinophils in EE is much higher; it has been proposed that the diagnosis of EE requires greater than 24 eosinophils per high-powered field (×40) from an esophageal tissue biopsy since these levels have been associated with non-responsiveness to anti-GERD therapy. However, whether GERD and EE representative a continuum, with EE being a more severe manifestation has not been addressed. A more clear differentiation between these various esophagitis states is needed.

Experimental dissection of experimental EE models in mice have revealed that EE can be triggered by both food and aeroallergens, particularly when the esophageal disease is co-induced with respiratory inflammation. However, nearly 25% of patients with EE are non-atopic individuals with no identifiable allergic sensitization. A question is to understand the relationship between the atopic and non-atopic variants of EE; whether atopic and non-atopic esophagitis involves similar effector pathways has implications for therapeutic strategies. Murine modeling has established that EE is a Th2 associated disease. IL-5 is required for disease pathogenesis; a humanized anti-IL-5 appears to be effective in an early clinical study. Human EE is associated with over-production of the Th2 cytokines IL-4 and IL-13. However, although these Th2 cytokines have been implicated, the mechanism by which they lead to esophageal eosinophilia is unclear. While IL-4 and IL-13 are known to induce the eosinophil specific eotaxin chemokines (e.g. eotaxin-1, eotaxin-2, eotaxin-3), their role has remained elusive since they have yet been demonstrated to be over-produced in EE and eotaxin-1 deficient mice only develop a modest attenuation of experimental EE. Based on homology with allergic inflammation in the lung, which involves the interplay of at least 17 chemokines including all three eotaxins, the inflamed esophagus may also involve a myriad of chemokines, with no dominance of a single chemokine.

SUMMARY OF THE INVENTION

Eosinophilic Esophagitis (EE) gene expression profiles and distinctions from chronic esophagitis (CE) are disclosed. Expression profiling of esophageal biopsy tissue from patients with EE compared to patients with CE, as well as healthy controls was performed. Whole genome wide expression analysis demonstrated an EE transcript signature that was similar across gender and patient age, but distinct from CE. Atopic and non-atopic variants of EE had a conserved esophageal transciptome indicating overlapping effector pathways in the diseased tissue of these patients. The most induced transcript in EE was eotaxin-3; levels of eotaxin-3 strongly correlated with disease severity and a single nucleotide polymorphism (SNP) in the eotaxin-3 gene conferred disease susceptibility. Protection from experimental EE was observed in mice harboring a genetic deletion in the eotaxin-3 receptor (CCR3).

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B show the hierarchical cluster analysis of the transcripts expressed in normal (NL), chronic esophagitis (CE), and eosinophilic esophagitis (EE) esophageal biopsies. RNA from each patient was subjected to chip analysis using Affymetrix Human Genome U133 GeneChip plus 2. The NL group was composed of six individuals (1 to 6), the CE group was composed of five individuals (7 to 11), and the EE group was composed of 13 individuals (12 to 24) (Table 2). 574 genes significantly expressed differently (p<0.01) in EE compared to NL groups (Table 1). 574 genes significantly expressed differently (p<0.01) in EE compared to NL groups, and 228 genes significantly expressed differently (p<0.01) in CE compared to NL group. The data were analyzed by cluster analysis and ordered (standard correlation (A) and distance (B)) using Genespring software. Cluster 1, 2 and 3 highlight the CE transcripts and cluster 4 and 5 highlight the EE transcripts. The down regulated genes were depicted in blue and up-regulated genes were in red. The magnitude of the gene change was proportional to the darkness of the color. Each column represented a separate individual and each line a gene.

FIGS. 2A and 2B show the EE transcript signature as a function of the allergic status and gender of EE individuals. The 574 genes of the EE signature were subjected to cluster analysis and ordered (standard correlation) using Genespring software. Average expression of the transcripts of the EE signature was depicted in the non-allergic (n=4) and allergic EE (n=9) (A), and in the female (n=5) and male EE individuals (n=8) (B).

FIG. 3 shows the number of modified genes and their fold-change in EE and CE. The average gene expression levels in EE and CE groups were compared to the average gene expression in the NL group. The number of genes that changed 2-10-fold or more is shown. The list of the 42 transcripts that was modified ≥10-fold in EE compared with NL groups, and their GeneBank accession number is shown.

FIGS. 4A and 4B show the correlation between eosinophil count and number of genes modified. The numbers of genes expressed differently are presented as a function of eosinophil count (A). The number of genes that changed ≥5-fold (grey dot) or ≥10-fold (white dot) was plotted as a function of the maximum number of eosinophils in the biopsies. A trendline (black line) has been inserted to show the genes that change ≥10-fold. The histogram of the 1943 genes that most correlated (P≥50.005) to the number of eosinophils is presented (B). Cluster analysis based on standard correlation tree ordered identified 4 groups (cluster A, B, C and D). The genes upregulated were represented in red and the downregulated genes were in blue. The magnitude of the gene changes was proportional to the darkness of the color.

FIG. 5A-5C show the quantitative analysis of eotaxin-1, -2 and -3 mRNA levels in NL, CE and EE groups using real-time PCR analysis. The level of eotaxin-3 (A), eotaxin-1 (B) and eotaxin-2 (C) mRNA is shown. Each mRNA value was normalized to GAPDH mRNA and expressed as fold change. The black dash represented the average of fold change in each group. The P value was calculated using the ANOVA test. The number of individuals was 6, 11 and 19 for NL, CE and EE groups respectively.

FIG. 6 shows the correlation between eotaxin-3 mRNA expression and esophageal eosinophil count. The eotaxin-3 expression measured using LightCycler (black dots and black line) and microarray analysis (open squares and dash line) was plotted as a function of the maximum eosinophil number (cells/hpf) present in the biopsies of NL, CE and EE individuals.

FIG. 7A-7G show eotaxin-3 expression in the esophagus of EE individuals. Esophageal sections were subjected to in situ hybridization using the eotaxin-3 anti-sense probe. The hybridization signal of the eotaxin-3 anti-sense (AS) and sense (S) probe are shown in an esophageal EE patient biopsy (a, b, c, d, e, f and g). Brightfield (a, c, d, e and f) and darkfield images (b and g) are shown at 40× (a, b, f and g) and 100× (c, d and e) magnification. The darkfield signal is white/pink and the brightfield signal is black. In the paired dark and bright field photomicrographs arrows show the epithelial eotaxin-3 expression. The hybridization of the S probe to the same biopsies is shown in f and g.

FIG. 8 shows blood eotaxin-3 protein levels. Eotaxin-3 level in plasma was assessed by ELISA. Each data point represented the eotaxin-3 level in one individual. The NL and EE groups are each composed of 9 individuals. P value was calculated using ANOVA.

FIG. 9 shows the role of CCR3 in allergen-induced eosinophil recruitment to the esophagus of wild type (WT) and CCR3 deficient (knockout (KO)) mice. Mice were challenged with saline or Aspergillus intranasally three times a week for three weeks. The esophagus was harvested 24 h after the last intranasal treatment and esophageal sections were stained with anti-MBP. Results represent the number of eosinophils (mean±SD) (n=3) present in the esophagus per mm² of two representative experiments. *P<0.05 versus saline group, ^(§) P<0.05 versus WT group.

FIG. 10 shows a schematic representation of EE transcript signature in an EE esophageal biopsy. 574 genes defined the EE transcript signature, including cytokines, mast cell genes, arachidonic acid metabolism genes, and others. Without being limited to a specific mechanism, a proposed model to explain eotaxin-3-associated eosinophil recruitment in EE is shown. Hyperplasic epithelial cells of the esophagus overexpress eotaxin-3. Eotaxin-3 overexpression allows eosinophil chemoattraction of due to the CCR3 receptor. Eotaxin-3 protein leaks in the blood and may be used as a biomarker of EE. SNPs in eotaxin-3 may contribute to modify expression, or of the eotaxin-3 RNA or the affinity of eotaxin-3 protein for its receptor. Other SNPs (e.g., CCR3 receptor) may be involved. Mast cells are also recruited in the esophagus and mast cell genes (tryptase and carboxypeptidase) are overrepresented in the EE transcript signatures. Mast cells and eosinophils degranulations lead to tissue damage.

DETAILED DESCRIPTION

Individual characteristics are provided in Table 2. None of the patients were taking glucocorticoids (topical or oral) at the time of the endoscopy. Patient biopsies, collected from the distal esophagus during routine endoscopy following informed consent, were submerged in formalin for routine pathological analysis with hematoxylin and eosin staining. Diagnosis was established based on the maximum eosinophil count per high power field (hpf) and basal layer expansion according to established criteria. (eg. Rothenberg et al., 2001, Pathogenesis and clinical features of eosinophilic esophagitis. J Allergy Clin Immunol 108:891; Attwood et al., 1993, Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 38:109; Fox et al., 2002, Eosinophilic esophagitis: its not just kid's stuff. Gastrointest Endosc 56:26, each of which is expressly incorporated by reference herein in its entirety. Normal individuals (NL) served as a control and were defined as having 0 eosinophils/hpf and no basal layer expansion. Individuals with chronic esophagitis (CE) were defined as having mild expansion of the basal layer (about <⅓ of epithelium) and/or ≤23 eosinophils/hpf. Individuals with eosinophilic esophagitis (EE) were defined by >24 eosinophils/hpf and extensive basal layer hyperplasia (expansion to about >⅓ of epithelium).

To assess allergen sensitization, skin prick testing was performed to a panel of 11 aeroallergens and 63 food antigens and assessed based on a 0-4 scale by comparison to the histamine control response. The total number of positive reactions to allergens (food allergen and aeroallergen) were counted and re-scored on a 0-4 scale. A score of 0-3 corresponded to 0, 1, 2, and 3 positive prick reactions, respectively; a score of 4 corresponded to ≥4 positive prick responses. Patients with a score of 1 were considered atopic.

For DNA microarray analysis, for each patient, one distal biopsy sample was emerged in RNAlater RNA Stabilization reagent (Qiagen, Germany) and stored at 4° C. for <15 days. Total RNA was extracted using RNAeasy mini Kit (Qiagen) according to the manufacturer's recommendations. Hybridization to DNA microarrays was performed by the Gene Chip Core at Children's Hospital Medical Center, Cincinnati Ohio. In brief, after RNA extraction, RNA quality was first assessed using the Agilent bioanalyzer (Agilent Technologies, Palo Alto, Calif.) (verifying high quality spectophometric characteristics), converted to cDNA with Superscript and subsequently converted to biotinylated cRNA with Enzo high yield RNA transcript labeling. After hybridization to the genome wide human Affymetrix U133A plus 2.0 genechips, the microarrays were stained with streptavidin-phycoerythrin using a Fluidics Station (Affymetix). The microarrays were scanned with a Hewlett Packard GeneArray Scanner, and gene transcript levels were determined using algorithms in the Microarray Analysis Suite and GeneSpring software (Silicon Genetics, Redwood City Calif.).

Differentially expressed transcripts were subjected to gene ontology analysis using DAVID (database for annotation, visualization and integrated discovery) and EASE (expression analysis systematic explorer), which is a web-based client/server application that allowed users to access a relational database of functional annotation.

For in situ hybridization, esophageal biopsy samples were fixed in 4% paraformaldehyde/PBS and stored overnight at 4° C. and subsequently emerged in 30% sucrose before in situ hybridization was performed. In brief, eotaxin-3 cDNA was generated using the primers acctgagaagggcctgattt and gtaactctgggaggaaacaccctctcc and cloned into PCR2.2 vector (Invitrogen). The resulting plasmid was linearized by BamHI or XhoI digestion, and sense and antisense RNA probes, respectively, were generated by T7 and sp6 RNA polymerase (Riboprobe Gemini Core System II transcription kit; Invitrogen. The radiolabeled (α35SthioUTP) probes were hybridized and the slides were washed under high stringency conditions. The slides were washed at 65° C. for 30 min in 50% formamide/1× SSC (150 mM NaCl/15 mM sodium citrate)/10 mM DTT; rinsed three times in 500 mM NaCl/10 mM Tris·HCl, pH 7.5/5 mM EDTA; digested with RNase A for 30 min at 37° C.; and rinsed in fresh buffer. The high-stringency wash was repeated and then followed by two 15-min washes at room temperature, one in 1× SSC and one in 0.1×SSC/1 mM DTT. Autoradiography was performed for 2-4 weeks at 4° C. Hybridization specificity was established by using the eotaxin-3 sense riboprobe. Sections from NL, EE and CE individuals were hybridized and underwent autoradiography under identical conditions.

For real-time polymerase chain reaction (PCR) analysis, RNA samples (500 ng) were subjected to reverse transcription analysis using Bioscript reverse transcriptase (BioRad) according to manufacturers instructions. Eotaxin-1, -2 and -3 were quantified by real-time PCR using the LightCycler instrument and LightCycler FastStart. DNA master SYBR green I as a ready-to use reaction mix (Roche, Indianapolis, Ind.) according to manufacturer's instructions. Results were normalized to GAPDH amplified from the same cDNA mix time and expressed as fold induction compared to controls. cDNA were amplified using following primers: hEotaxin-3(151 bp): aactccgaaacaattgtactcagctg and gtaactctgggaggaaacaccctctcc; hEotaxin-2(251 bp): ccatagtaaccagccttc and caggttcttcatgtacctc; hEotaxin-1(425 bp):tgaagcttgggccagcttctgtcccaacc and ggtcgactggagttggagatttttggtc; GAPDH(400 bp): tggaaatcccatcaccatct and gtcttctgggtggcagtgat.

Plasma from heparinized blood was extracted and eotaxin-3 in 100 μl of plasma was quantified using Quantikine kit CCL26 (R&D Systems, Minneapolis) according to manufacturer's instructions. Results were expressed as pg of eotaxin-3 per ml plasma. The detection of the ELISA was 7 pg/ml.

Buccal swab DNA was collected from EE individuals (n=96) and their immediate relatives and from non-EE individuals (n=177) following informed consent. DNA was isolated by alkaline extraction. SNP detection was accessed using LightCycler instrument (Roche, Indianapolis). Briefly, LightCycler melting curves analysis was based on discriminating the temperature-dependant hybridization of sequence-specific hybridization probes to single-stranded DNA. Primers were designed using commercial software (Roche) and PCR was performed using LightCyler FastStart DNA master Hybridization Probes (Roche) according to manufacturer's protocol using the eotaxin-3 specific primers: aaggaaaaaatgggtgca and tgaacaacctttattaaagtaactct. For eotaxin-3 SNP analysis, the anchor probe was labeled with LCred fluorophore linked to agccaagagcggggtcc. The sensor probe (gcgtcctcggatgacaattca) was labeled with a second fluorophore (fluorescein) and designed to span the G/T mutation. Primers were designed using Primer Design Software (Roche).

BALB/c mice (National Cancer Institute, Frederick Md.) and CCR3-deficient mice (BALB/c background; a gift of Drs. Alison Humbles and Craig Gerard, Harvard Medical School) were housed under specific pathogen-free conditions. Experimental EE was induced by exposing mice to Aspergillus fumigatus antigen intranasally three times a week for 3 weeks. Mice were sacrificed 48 h following the last challenge, and the esophagus was harvested and fixed in formalin. Eosinophil levels were determined by immunostaining for mouse eosinophil major basic protein (anti-MBP), as disclosed in Mishra et al., 2001, An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 107:83, which is expressly incorporated by reference herein in its entirety. Briefly, endogenous peroxidases in the tissues were quenched with 0.3% hydrogen peroxide in methanol followed by pepsin digestion for 5 min and by nonspecific protein blocking with normal goat serum for 30 min at room temperature. Tissue sections were then incubated with rabbit anti-MBP (a gift of Dr. James Lee, Mayo Clinic, Scottsdale Ariz.) (1:10,000) for 1 h at 4° C., followed by a 1:1000 dilution of biotinylated goat anti-rabbit IgG secondary antibody for 30 min at room temperature. Negative controls were assessed by replacing the primary antibody with normal rabbit serum to check endogenous biotin and peroxidase activity. Then avidin-peroxidase complex (Vector Laboratories, Burlingame Calif.) was used for 30 minutes. Immunoreactive cells quantification was carried out by a video-assistant integrated computer software program (Image Pro Plus 4.1; Media Cytometrics, Silver Spring Md.). Eosinophil levels were expressed as cells/mm².

Genes listed on microarray were obtained by studying differences in genes expression level between groups using Welch T-Test and Student T test (with or without false rate discovery (FDR) correction). EE transcripts were obtained using Welch T test with FDR (p≤0.01). CE transcript signature was composed of the addition of the gene lists from Welch T test without FDR and genes from Student T-test without FDR (p≤0.01). Ordered tree clustering was performed using standard correlation and distance. Correlation of gene expression with numeric clinical parameters or eosinophil levels was assessed using Pearson Correlation Test with p value. Tests used to generate the gene lists and number of genes in these lists are shown in Table 5. These lists were filtered based on p value and/or fold changes. Statistical significance between two groups of data was determined using T test or ANOVA, and correlations of data with number of eosinophils in the biopsies were determined using Pearson Correlation Test with p value.

The association between the SNP 2497T >G and EE susceptibility was first examined by family-based transmission disequilibrium test (TDT) to determine whether the affected child received the disease-associated allele more frequently than the alternative allele. The software TDT/S-TDT 1.1 was used for analysis. Next, a case-control comparison was conducted at both genotype and allele frequency levels, where the cases are from the proband of each family, a set of race/ethnicity matched unrelated normal individuals were collected as controls. Statistical significance was evaluated by exact test using shuffling method, generated by 104 random permutations of the data. Hardy-Weinberg equilibrium test was also conducted in cases and controls, respectively. The software HWE was used to compute chi-square test for deviations from Hardy-Weinberg equilibrium.

EE transcript signatures were determined. Esophageal biopsy samples derived from individual patients were subjected to whole genome wide transcript expression profile analysis using oligonucleotide-based DNA microarray chips (Affymetrix Human Genome U133 GeneChip plus 2). Of the 54,681 transcripts represented on these microarrays, 574 transcripts (Table 1) were differently expressed (p<0.01) in the EE versus NL biopsy samples; thus, about 1% of the whole human genome transcripts defined the EE transcript signature, also referred to as the EE transcriptome, the complete collection of transcribed elements in the genome. For the EE and/or CE transcriptomes, this includes all transcribed elements related to these diseases. Besides mRNAs, it includes non-coding structural and regulatory RNAs. Alterations in the structure or expression levels of any one of these RNAs or translated proteins can contribute to pathogeneisis. Hierarchical clustering of the signal intensities of the individual transcripts in each group showed a high similarity of transcript expression patterns between EE patients (FIG. 1A). Of these, 344 transcripts were expressed more abundantly and 230 were expressed less abundantly in EE compared to NL individuals (FIG. 1A). Gene ontology analysis of the EE transcript signature (Table 3) revealed that the over-expressed genes were frequently involved in cell communication (25%), signal transduction (21%), response to external stimulus (20%), immune response (16%), and response to stress (11%). In contrast, the down-regulated genes were composed of a distinct family of functional groups (Table 4).

While there were numerous related families of dysregulated genes, five mast cell genes were highly induced, including carboxypeptidase A3, high affinity IgE receptor (Fc

RI), and mast cell tryptase alpha (Table 9). Arachadonic acid metabolism genes were also represented; there were several dysregulated genes including the upregulated 15-lipoxygenase, prostaglandin D2 synthetase, leukotriene A4 hydrolase, and the down regulated 12-lipoxygenase, prostaglandin F synthase, leukotriene B4 12-hydroxydehydrogenase (Table 8). Regulators of cell growth and maintenance (periostin, fibroblast growth factor 11, Gro1 alpha) were over-represented (Tables 3 and 4).

To further analyze the EE transcript signature, cluster analysis was performed to stratify dynamic genes into related subgroups (FIG. 1B). Clusters 4 and 5 represented downregulated and upreglated genes, respectively, compared with NL and CE individuals. Cluster analysis identified that CE also had a unique transcript signature compared with NL individuals; cluster 1 represented genes upregulated in CE compared to NL individuals.

The identification of an EE transcript signature provided insight into disease pathogenesis. It was determined whether the allergic and non-allergic EE variants had different transcript profiles. When the full EE transcript profile was compared between allergic and non-allergic EE patients, there was near complete overlap in the transcripts (FIG. 2A) of the EE signature genome defined in Table 1. Only two genes were differently expressed (Lymphocyte Antigen 75 (2-fold increase in atopic) and Secreted Frizzled-related protein-1 (1.8-fold increase in non-atopic). The human LY75 molecule has previously been shown to have effect on IL-4 signaling. It was determined if EE patients had age dependent variable gene expression. Of the 574 dysregulated transcripts, no gene correlated with patient age within the EE transcript profile. As a control, outside of the EE transcript signature, there were 334 genes that correlated to patient age (Pearson correlation test with p<0.01). It was determined if the EE transcript profile was different between males and females. Only one gene (tyrosine kinase receptor B (3-fold increase in females) of the EE transcript signature depended upon gender (FIG. 2B). Outside of the EE transcript signature, there were 434 different genes between male and female EE. These results demonstrated that the EE transcript profile was conserved between individuals despite differences in gender, age, and atopic status.

Transcript expression profiles were compared in patients who presented with symptoms of EE but were found to have CE. Esophageal samples from CE patients contained only 216 dynamic transcripts (Table 5), about 0.4% of the tested genome, compared with NL (p<0.01). In FIG. 1B, the CE transcripts are seen in clusters 1, 2 and 3. These 216 transcripts (108 over expressed shown in combined clusters 1 and 2 and 108 down regulated in cluster 3) were rich in genes involved in intracellular cascades (10%) and biosynthesis (10%) (both in cluster 1) and cell growth and maintenance (22%) (in cluster 2). No transcript was modified by ≥5-fold in CE compared to NL (FIG. 3). In contrast, 124 genes were modified by ≥5-fold in EE compared with NL (FIG. 3), including 42 transcripts that were modified ≥10-fold in EE; the most dysregulated genes are shown in FIG. 3. To define genes that could distinguish EE and CE, EE and CE transcriptomes were directly compared. There was an overlap of only 40 genes between EE and CE (mainly in cluster 2) (FIG. 1B and Table 6) and only 5 of these overlapped with the EE transcript signature. All genes shared between EE and CE were modified by <2-fold compared to NL samples. Taken together, EE and CE did not appear to represent a continuum, but rather two distinct disease processes. Identification of strongly induced genes that distinguished EE from CE (FIG. 3) defined potential diagnostic criteria to distinguish these forms of esophagitis.

The EE transcriptome was analyzed as a function of disease severity, because that the number and magnitude of modified genes might be directly related to disease severity. Correlation of eosinophil levels with the number of altered genes was determined. Individuals with EE had eosinophil levels that varied between 24 to 218 eosinophils/hpf. The number of dysregulated genes increased between eosinophils levels of 0 and 56 and reached a plateau at eosinophil levels of 77 (FIGS. 1 & 4A). Similarly, the magnitude of genes changes (e.g. their degree of change) directly correlated with eosinophil levels (FIG. 4). The genes that most correlated (P<0.005) with eosinophil levels are presented in an ordered tree histogram and stratified into cluster A, B and C (FIG. 4B). Cluster B included genes that correlated with eosinophil level that were overexpressed in patients with ≥24 eosinophils/hpf and were frequently involved in cell communication (25%) and immune response (13%) functions. Cluster A contained genes that correlated with higher eosinophil levels ≥40 eosinophils/hpf). Cluster A was particularly rich in genes involved in cell growth and maintenance (24%). The mast cell gene signature was located in cluster B, which suggested that mast cells infiltration occurred as soon as 24 eosinophils/hpf were present in the esophagus. Within the EE transcript signature, the gene with greatest change was eotaxin-3, which was induced 53-fold. Other relevant eosinophil chemokines, such as eotaxin-1 and eotaxin-2, were induced <2-fold in EE samples. Using real time PCR analysis (Lightcycler), a mean 53-fold increase in eotaxin-3 mRNA compared with NL was observed (FIG. 5A). Modest changes in eotaxin-1 (FIG. 5B) and eotaxin-2 (FIG. 5C) were observed in EE patients, although there was some variability between patients. Elevated levels of eotaxin-2 and eotaxin-3 correlated with each other (P<0.05). Correlation between the level of eotaxin-3 and eosinophil levels in esophageal samples was determined. Two methods (Lightcycler quantification and microarray analysis) revealed a strong correlation between eotaxin-3 and eosinophil counts (P<0.01) (FIG. 6).

To localize eotaxin-3 production in the esophagus, in situ hybridization was performed on esophageal biopsies with eotaxin-3 sense and anti-sense cRNA probes. In EE patients, eotaxin-3 anti-sense probe strongly stained the epithelial cell layer (FIG. 7). Brightfield microscopy revealed that eotaxin-3 positive cells were confined to a population of mononuclear cells within the epithelial layer most consistent with epithelial cells. Infiltrative eosinophils were eotaxin-3 negative. Hybridization of eotaxin-3 anti-sense probes to NL and CE samples and the eotaxin-3 sense probe to EE samples revealed no significant staining (data not shown).

To determine whether eotaxin-3 could be used as a non-invasive biomarker, eotaxin-3 protein level in the plasma was quantified in NL and EE patients. A 2-fold increase in eotaxin-3 protein levels was observed between NL and EE plasma samples (FIG. 8). Eotaxin-3 protein levels were 65±17 and 30±13 pg/ml in EE and NL plasma samples, respectively (P<0.002). No significant difference was observed in the eotaxin-3 level in the blood between allergic and non-allergic patients (64±19 and 61±26 pg/ml respectively).

Eotaxin-3 was implicated in the disease pathogenesis of EE, so that single nucleotide polymorphisms (SNP) in the eotaxin-3 gene might be associated with disease risk. The presence of eotaxin-3 +2496 (G/T) SNP in EE patients compared with control individuals was examined. The wild type allele is T having a frequency of 78.81% in control individuals. The G allele was over-represented in EE patients compared with NL (Table 7). The GG was strongly associated with EE (GG frequency was 13.54% and 2.26% in EE and NL, respectively). The relative risk of EE in patients with the GG allele was about 7-fold. In both EE and NL individuals, the G and T alleles were inherited based on Hardy-Weinberg equilibrium (Table 7).

CCR3 gene target mice were protected from experimental EE. A murine system was used to evaluate the eotaxin pathway directly in vivo. An experimental model of EE had been developed, but an exact homolog of human eotaxin-3 had not yet been characterized in mice, therefore induction of experimental asthma in mice deficient in the eotaxin receptor CCR3 was examined. Cohorts of wild type and CCR3 deficient mice were exposed to repeated doses of intranasal allergen under conditions that induce experimental EE. In wild type mice, large numbers of eosinophils accumulated in the esophagus. While, CCR3 deficient mice were nearly completely protected from developing esophageal eosinophilia (FIG. 9).

The data reported above identified an EE transcript signature involving about 1% of the human genome. This transcriptome was conserved between individuals despite their age, gender, atopic status, and the patchiness of their disease. Despite the presence of apparent atopic and nonatopic EE variants of, the downstream effector phase of the disease was conserved between these disease variants rather than a large variability in gene transcript levels between patients due to their divergent clinical presentations (including age and gender). Thus, despite millions of SNPs in the human genome, EE and perhaps others polygenic disorders may have largely conserved disease mechanisms. The results are consistent with analysis of atopic and non-atopic variants of eosinophilic lung disease (asthma); while these only examined a limited set of cytokine mRNA levels, atopic and non-atopic patients had the same cytokine mRNA expression in lung tissue. The present data evidenced that atopic and non-atopic variants of eosinophilic disorders have a common underlying pathogenesis. A method of examining the etiology of atopic and disease variants is presented.

Eotaxin-3, which regulates eosinophil responses in vitro, was the top gene induced in EE. Levels of eotaxin-3 strongly correlated with disease severity and served as a disease biomarker. Mice with genetic deletion of the CCR3 eotaxin-3 receptor were protected from developing experimental EE. The specific overexpression of eotaxin-3, and not eotaxin-1 or eotaxin-2, was consistent with prior studies showing only modest protection from experimental EE in eotaxin-1 deficient mice, and the absence of eotaxin-1 overexpression in EE patients. Correlation of eotaxin-2 and -3 mRNA levels with each other was consistent with their common chromosomal location (7q11.23), suggesting co-regulation and co-involvement in EE. Eotaxin-2 and eotaxin-3 both contain Th2-associated STAT6 binding sites in their promoters. While all eotaxins bind to CCR3, they each have a different affinity for recombinant CCR3; EE patients may also have preferential responses to individual eotaxins. Without being bound by a specific theory, this may be due to specific SNPs in CCR3. A specific genetic variation in the eotaxin-3 gene was a strong risk factor for EE. While this SNP was in a non-coding region of the eotaxin-3 gene, it might be in linkage disequilibrium with a functional SNP; this SNP is 6 kp from SNP-4097 (rs7787623) in the promoter region, these two SNP appear to be in total linkage disequilibrium. The SNP+2496 has been associated with atopy in the Korean population. However, in the Caucasian population, this SNP was at a higher frequency (21% vs 5% allele frequency in Caucasians and Koreans, respectively). This genetic finding may be used alone or in combination with other markers, including eotaxin-3 protein levels, to establish non-invasive ways of assessing disease risk and/or phenotype.

CE also had its own unique transcript signature. The CE pathology was typical of GERD and was likely applicable to GERD. Identified transcript changes should be correlated with esophageal pH monitoring. GERD has not yet been analyzed by DNA microarray analysis. While there was a degree of overlap in CE and EE genes, there was a difference in the number of genes modified, the type of dysregulated genes, and the magnitude of the gene changes. Taken together, the data demonstrated that EE and CE were separate diseases, and were unlikely to represent a continuum of esophagitis. The results provide diagnostic criteria for distinguishing EE from other types of esophagitis. Levels of the genes listed in FIG. 3 may be disease determinants.

Mast cells were involved in EE based on the dominant mast cell gene signature in microarray analysis. Mast cell genes were upregulated when eosinophil levels were 24 eosinophils/hpf suggesting that mast cells correlated with eosinophils. Mast cells have been reported to be elevated in the esophagus of EE patients, although no assessment of their genetic content or phenotype was made. The finding of tryptase expression without chymase suggested the involvement of T cell dependent mucosal mast cells. Anti-mast cell therapy may be used for reducing, amelorating, or treating EE.

Few eosinophil-derived molecules were present in the EE transcript signature. For example, CCR3 and MBP were not in the EE transcript signature despite the eosinophil infiltration. This may be due to the dilution of eosinophil transcripts with transcripts from relative RNA-rich cells such as epithelial cells, fibroblasts and mast cells. However, Charcot Leyden Crystal (CLC) mRNA, an eosinophil specific transcript, was overexpressed in EE. CLC protein was initially reported to possess weak lysophospholipase activity. It showed no sequence similarities to any known lysophospholipases, but was a potent epithelial cell cytotoxin. CLC protein often crystallizes in the lung, yet such crystals have not yet been seen in EE. Other genes were involved in the EE transcript signature (FIG. 10). For example, periostin, a gene that is strongly over-expressed (47-fold) in EE patients, has been associated with epithelial cell growth, angiogenesis, and cellular adhesion. Cadherin-26 (over-expressed by 23-fold in EE patients) is a member of the cadherin family that has been associated with a variety of inflammatory and epithelial proliferation diseases. The most down-regulated gene, CRISP-3 (cysteine-rich secretory protein-3) is an androgen-dependent transcript, perhaps linking the male gender association with EE. In EE patient biopsies, there was a dysregulation in genes involved in arachadonic acid metabolism (e.g. upregulation of cyclooxygenase-2 and 15-lipoxygenase and downregulation of cyclooxgenase-1 and 12-lipoxygenase). Cox1 deficient mice developed increased levels of Th2 cytokines (IL-4, IL-13, and 5) and had higher recruitment of eosinophils following allergen challenge. In the gastrointestinal tract, cycloxygenase-2 had a role in epithelial cell growth.

Without being limited by a specific theory, EE may be an eotaxin-3 dominant disease involving a conserved genetic transcript signature (FIG. 10). The modulation of esophageal genes, compared with CE, supports that EE was a primary esophageal disease. Based on these results, eotaxin-3 and/or CCR3 blockers may be beneficial for the treatment of EE.

TABLE 1 EE Transcriptome Genbank Fold Accession SEQ Common Name Description Change number ID NO CCL26 ||MIP-4alpha||CCL26||TSC- 53.17 NM_006072 1 1||SCYA26, FORMERLY||eotaxin-3 precursor||EOTAXIN 3||CC chemokine IMAC||thymic stroma chemokine-1||macrophage inflammatory protein 4-alpha||small inducible cytokine A26||CHEMOKINE, CC MOTIF, LIGAND 26||chemokine (C-C motif) ligand 26||SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 26, FORMERLY||small inducible cytokine subfamily A (Cys-Cys), member 26|| POSTN ||OSF-2||POSTN||PN||periostin, 46.29 NM_006475 2 osteoblast specific factor||osteoblast specific factor 2 (fasciclin I-like)|| TNFAIP6 ||TSG6||TNFAIP6||hyaluronate- 23.59 NM_007115 3 binding protein||tumor necrosis factor-stimulated gene-6 protein||TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 6||tumor necrosis factor-inducible protein 6||tumor necrosis factor, alpha-induced protein 6||tumor necrosis factor alpha-inducible protein 6||tumor necrosis factor, alpha-induced protein 6 precursor|| CDH26 ||CDH26||cadherin-like 26|| 23.42 NM_177980 4 CDH26 ||CDH26||cadherin-like 26|| 21 NM_177980 5 ALOX15 ||1.13.11.33||ALOX15||arachidonate 20.89 NM_001140 6 15-lipoxygenase||15- @LIPOXYGENASE, RETICULOCYTE ARACHIDONATE|| PMCH ||PMCH||pro-melanin-concentrating 19.01 NM_002674 7 hormone|| CXCL1 ||MGSA-a||NAP- 18.79 NM_001511 8 3||CXCL1||SCYB1||GROa||GRO1, FORMERLY||GRO PROTEIN, ALPHA||GRO1 ONCOGENE, FORMERLY||MELANOMA GROWTH STIMULATORY ACTIVITY, ALPHA||GRO1 oncogene (melanoma growth-stimulating activity)||CHEMOKINE, CXC MOTIF, LIGAND 1||GRO1 oncogene (melanoma growth stimulating activity, alpha)||SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 1||chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)|| IGLV@ ||IGLJ3||immunoglobulin lambda 17.57 AK057174 9 joining 3|| IGHD ||IGHM||immunoglobulin 16.42 AK090461 10 mu||IMMUNOGLOBULIN HEAVY MU CHAIN||immunoglobulin heavy constant mu||constant region of heavy chain of IgM|| FLJ16025 FLJ16025 15 XM_293626 11 UBD ||UBD||FAT10||diubiquitin||ubiquitin 14.85 NM_006398 12 D|| IGJ ||IGCJ||JCH||IGJ||immunoglobulin J 14.61 NM_144646 13 chain||immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides|| FLJ33069 ||FLJ33069||hypothetical protein 14.01 NM_144649 14 FLJ33069|| CPA3 ||CPA3||3.4.17.1||carboxypeptidase 13.13 NM_001870 15 A3 (mast cell)||CARBOXYPEPTIDASE A3, MAST CELL||mast cell carboxypeptidase A3 precursor|| CLC ||LPPL_HUMAN||CLC||galactin- 12.69 NM_001828 16 10||3.1.1.5||LGALS10||GALECTIN 10||lysolecithin acylhydrolase||eosinophil lysophospholipase||LYSOPHOSPHOLIPASE OF EOSINOPHIL||Charot- Leyden crystal protein||Charcot- Leyden crystal protein|| TCF12; HEB; IGKC 12.64 BX647333 17 HTF4; HsT17266 IGL@ IGL 12.4 NG_000002 18 PHLDB2 ||PHLDB2||pleckstrin homology-like 12.05 NM_145753 19 domain, family B, member 2|| POSTN ||OSF-2||POSTN||PN||periostin, 11.84 NM_006475 20 osteoblast specific factor||osteoblast specific factor 2 (fasciclin I-like)|| TCF12; HEB; IGKC 10.97 BX647333 21 HTF4; HsT17266 FLJ23259 ||FLJ23259||hypothetical protein 10.94 NM_024727 22 FLJ23259|| TCF12; HEB; IGKC 10.2 BX647333 23 HTF4; HsT17266 EPPK1 ||EPIPL1||EPPK1||epiplakin 1||450 kDa 10.12 NM_031308 24 epidermal antigen|| na ||||Hypothetical LOC148280 9.701 XM_097433 25 (LOC148280), mRNA|| SLC26A4 ||SLC26A4||pendrin||PDS||DFNB4|| 9.548 NM_000441 26 solute carrier family 26, member 4|| EPPK1 ||EPIPL1||EPPK1||epiplakin 1||450 kDa 9.334 NM_031308 27 epidermal antigen|| CTSC ||HMS||CPPI||3.4.14.1||DPPI||PALS|| 9.008 NM_001814 28 DPP1||CTSC||PLS||dipeptidyl transferase||cathepsin C||dipeptidyl- peptidase I||cathepsin J||Papillon- Lefevre syndrome||DIPEPTIDYL PEPTIDASE I||cathepsin C isoform b precursor||cathepsin C isoform a preproprotein|| SAMSN1 ||HACS1||SAMSN1||HEMATOPOIETIC 8.687 NM_022136 29 ADAPTOR CONTAINING SH3 AND SAM DOMAINS 1||SAM domain, SH3 domain and nuclear localisation signals, 1||SAM DOMAIN, SH3 DOMAIN, AND NUCLEAR LOCALIZATION SIGNALS 1|| TRPM6 ||CHAK2||TRPM6||CHANNEL KINASE 8.519 NM_017662 30 2||transient receptor potential cation channel, subfamily M, member 6|| IGLV@ IGL 8.317 AK057174 31 SEC6L1 ||||SEC6L1||SEC6-like 1 (S. cerevisiae)|| 8.068 NM_007277 32 GPR160 ||GPCR150||GPR160||putative G 8.008 NM_014373 33 protein-coupled receptor||G protein- coupled receptor 160|| SUSD2 ||SUSD2||sushi domain containing 8.003 NM_019601 34 2|| KIAA0495 ||KIAA0495|| 7.996 AB007964 35 NTRK2 ||TRKB||NTRK2||TYROSINE KINASE 7.355 NM_006180 36 RECEPTOR B||neurotrophic tyrosine kinase, receptor, type 2|| CTSC ||HMS||CPPI||3.4.14.1||DPPI||PALS|| 7.326 NM_001814 37 DPP1||CTSC||PLS||dipeptidyl transferase||cathepsin C||dipeptidyl- peptidase I||cathepsin J||Papillon- Lefevre syndrome||DIPEPTIDYL PEPTIDASE I||cathepsin C isoform b precursor||cathepsin C isoform a preproprotein|| IGLV@ ||IGLJ3||immunoglobulin lambda 7.045 AK057174 38 joining 3|| OR2I6 ||||Similar to Olfactory receptor 2I2 6.874 XM_294092 39 (LOC346170), mRNA|| KCNJ2 ||HHBIRK1||HHIRK1||LQT7||KCNJ2|| 6.696 NM_000891 40 potassium inwardly-rectifying channel J2||inward rectifier K+ channel KIR2.1||cardiac inward rectifier potassium channel||inward rectifier potassium channel 2||potassium inwardly-rectifying channel, subfamily J, member 2||POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 2|| NTRK2 ||TRKB||NTRK2||TYROSINE KINASE 6.56 NM_006180 41 RECEPTOR B||neurotrophic tyrosine kinase, receptor, type 2|| TPSB2 ||||TPS1||tryptase, alpha|| 6.429 NM_003294 42 CTSC ||HMS||CPPI||3.4.14.1||DPPI||PALS|| 6.299 NM_001814 43 DPP1||CTSC||PLS||dipeptidyl transferase||cathepsin C||dipeptidyl- peptidase I||cathepsin J||Papillon- Lefevre syndrome||DIPEPTIDYL PEPTIDASE I||cathepsin C isoform b precursor||cathepsin C isoform a preproprotein|| IFRG28 ||IFRG28||28 kD interferon 6.278 NM_022147 44 responsive protein|| HRH1 ||HRH1||H1-R||hisH1||histamine 6.191 NM_000861 45 receptor H1||BPHS, MOUSE, HOMOLOG OF||histamine receptor, subclass H1|| SCUBE2 ||SCUBE2||signal peptide, CUB 6.166 NM_020974 46 domain, EGF-like 2|| IGKC ||Km||HCAK1||IGKC||Immunoglobulin 6.073 BM993907 47 kappa constant||IMMUNOGLOBULIN InV KAPPA-CHAIN DEFICIENCY||IMMUNOGLOBULIN KAPPA LIGHT CHAIN||immunoglobulin kappa constant region||kappa 1 immunoglobulin light chain||Ig kappa chain C region|| TPSB2 ||||TPS1||tryptase, alpha|| 6.028 NM_003294 48 CHL1 ||L1CAM2||CHL1||CALL||neural cell 5.928 NM_006614 49 adhesion molecule||cell adhesion molecule L1-like||CHL1, MOUSE, HOMOLOG OF||L1 cell adhesion molecule 2||cell adhesion molecule with homology to L1CAM precursor||cell adhesion molecule with homology to L1CAM (close homolog of L1)|| IF ||3.4.21.45||IF||FACTOR I||FACTOR 5.687 NM_000204 50 ‘EYE’||COMPLEMENT COMPONENT I||I factor (complement)||C3 INACTIVATOR, DEFICIENCY OF||C3b INACTIVATOR COMPLEMENT COMPONENT 3 INACTIVATOR, DEFICIENCY OF|| GLDC ||GLDC||HYGN1||GCSP||GCE||NKH|| 5.608 NM_000170 51 1.4.4.2||GLYCINE CLEAVAGE SYSTEM P PROTEIN||glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)|| SEC6L1 ||||SEC6L1||SEC6-like 1 (S. cerevisiae)|| 5.608 NM_007277 52 TPSB2 ||||TPS1||tryptase, alpha|| 5.573 NM_003294 53 PKP2 ||PKP2||plakophilin 2|| 5.342 NM_004572 54 PGDS ||PGDS||5.3.99.2||prostaglandin-D 5.265 NM_014485 55 synthase||prostaglandin D2 synthase, hematopoietic||hematopoietic prostaglandin D2 synthase|| TFPI ||LACI||TFPI||EPI||EXTRINSIC 5.108 NM_006287 56 PATHWAY INHIBITOR||tissue factor pathway inhibitor (lipoprotein- associated coagulation inhibitor)|| ||Homo sapiens transcribed 5.094 BQ004901 57 sequence with weak similarity to protein NP_060312.1 BF ||GBG||BF||CFAB||PBF2||3.4.21.47|| 5.073 NM_001710 58 C3 proaccelerator||glycine-rich beta-glycoprotein||B-factor, properdin||C3/C5 convertase||C3 proactivator||PROPERDIN FACTOR B||FACTOR B, PROPERDIN||complement factor B preproprotein|| TPK1 ||HTPK1||TPK1||THIAMINE 5.033 NM_022445 59 KINASE||thiamine pyrophosphokinase||thiamin pyrophosphokinase 1||mouse thiamin pyrophosphokinase homolog|| SLC16A1 ||SLC16A1||MCT1||monocarboxylate 4.941 NM_003051 60 transporter 1||solute carrier family 16, member 1||SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 1||solute carrier family 16 (monocarboxylic acid transporters), member 1|| PRRX1 ||PMX1||PRRX1||PRX1||homeobox 4.819 NM_006902 61 protein PHOX1||PAIRED-RELATED HOMEOBOX GENE 1||paired related homeobox 1||paired mesoderm homeo box 1||paired mesoderm homeobox 1 isoform pmx-1a||paired mesoderm homeobox 1 isoform pmx-1b|| CH25H ||CH25H||C25H||cholesterol 25- 4.732 NM_003956 62 hydroxylase|| LOC129607 ||LOC129607||hypothetical protein 4.61 XM_059368 63 LOC129607|| LOC340061 ||LOC340061||hypothetical protein 4.603 NM_198282 64 LOC340061|| IGKC ||Km||HCAK1||IGKC||Immunoglobulin 4.578 BM993907 65 kappa constant||IMMUNOGLOBULIN InV KAPPA-CHAIN DEFICIENCY||IMMUNOGLOBULIN KAPPA LIGHT CHAIN||immunoglobulin kappa constant region||kappa 1 immunoglobulin light chain||Ig kappa chain C region|| 4.542 CA314541 66 FOXE1 ||TTF- 4.438 NM_004473 67 2||FOXE1||TITF2||TTF2||FKHL15||forkhead (Drosophila)-like 15||thyroid transcription factor-2||Forkhead, drosophila, homolog-like 15||forkhead box E1 (thyroid transcription factor 2)|| SYNPO ||KIAA1029||synaptopodin||SYNPO|| 4.415 NM_007286 68 ADRBK2 ||GRK3||BARK2||2.7.1.126||ADRBK2|| 4.385 NM_005160 69 BETA-ADRENERGIC RECEPTOR KINASE 2||adrenergic, beta, receptor kinase 2||beta adrenergic receptor kinase 2|| SLC28A3 ||SLC28A3||CNT3||CONCENTRATIVE 4.349 NM_022127 70 NUCLEOSIDE TRANSPORTER 3||solute carrier family 28 (sodium- coupled nucleoside transporter), member 3|| CYP7B1 ||1.14.13.—|| 4.323 NM_004820 71 CP7B||CYP7B1||oxysterol 7alpha- hydroxylase||OXYSTEROL 7-ALPHA- HYDROXYLASE 1||cytochrome P450, family 7, subfamily B, polypeptide 1||cytochrome P450, subfamily VIIB (oxysterol 7 alpha-hydroxylase), polypeptide 1|| APOL1 ||APOL1||APO-L||APOL- 4.259 NM_145343 72 I||apolipoprotein L-I||apolipoprotein L, 1||apolipoprotein L1 isoform b precursor||apolipoprotein L1 isoform a precursor|| MSLN ||CAK1||SMR||MSLN||mesothelin||MEGA- 4.254 NM_013404 73 KARYOCYTE-POTENTIATING FACTOR||SOLUBLE MPF/MESOTHELIN-RELATED PROTEIN||mesothelin isoform 2 precursor||mesothelin isoform 1 precursor||megakaryocyte potentiating factor precursor||ANTIGEN RECOGNIZED BY MONOCLONAL ANTIBODY K1|| SFRP1 ||SFRP1||FRP- 4.239 NM_003012 74 1||FrzA||SARP2||secreted apoptosis-related protein 2||secreted frizzled-related protein 1|| GRK5 ||2.7.1.—||GRK5||GPRK5||G protein- 4.212 NM_005308 75 coupled receptor kinase 5|| MS4A2 ||FCERI||MS4A1||MS4A2||FCER1B|| 4.192 NM_000139 76 Fc epsilon receptor I beta- chain||Fc IgE RECEPTOR, BETA CHAIN||MEMBRANE-SPANNING 4 DOMAINS, SUBFAMILY A, MEMBER 2||immunoglobulin E receptor, high affinity, beta polypeptide||Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, BETA SUBUNIT||membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide)|| PGBD5 ||PGBD5||piggyBac transposable 4.133 NM_024554 77 element derived 5|| GALNT4 ||||TUWD12|| 4.097 NM_003774 78 HAS3 ||||HAS3||hyaluronan synthase 3|| 4.096 NM_005329 79 CXCR4 CXCR4 4.092 AJ224869 80 CDH3 ||CDHP||HJMD||PCAD||CDH3||placental 4.065 NM_001793 81 cadherin||CADHERIN, PLACENTAL||cadherin 3, P-cadherin (placental)||calcium-dependent adhesion protein, placental||cadherin 3, type 1 preproprotein||cadherin 3, type 1, P-cadherin (placental)|| TPSB2 ||||TPS1||tryptase, alpha|| 4.033 NM_003294 82 TPSB2 ||||TPS1||tryptase, alpha|| 3.98 NM_003294 83 3.944 BM988338 84 KITLG 3.939 AK055903 85 FETUB ||FETUB||Gugu||16G2||IRL685||fetuin- 3.894 NM_014375 86 like protein||fetuin B|| SLC16A1 ||SLC16A1||MCT1||monocarboxylate 3.883 NM_003051 87 transporter 1||solute carrier family 16, member 1||SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 1||solute carrier family 16 (monocarboxylic acid transporters), member 1|| SGK ||2.7.1.—|| 3.879 NM_005627 88 SGK||SGK1||SERUM/GLUCOCORTICOID- REGULATED KINASE||serum/glucocorticoid regulated kinase||serine/threonine protein kinase SGK|| SIGLEC6 ||SIGLEC6||CD33L1||SIGLEC- 3.827 NM_001245 89 6||OB-BINDING PROTEIN 1||CD33 ANTIGEN-LIKE, MEMBRANE-BOUND||CD33 antigen-like 1||CD33 ANTIGEN- LIKE, SOLUBLE||SIALIC ACID- BINDING IMMUNOGLOBULIN- LIKE LECTIN 6, SOLUBLE||sialic acid binding Ig-like lectin 6||OBBP1 SIALIC ACID- BINDING IMMUNOGLOBULIN- LIKE LECTIN 6, MEMBRANE- BOUND||sialic acid binding Ig- like lectin 6 isoform b||sialic acid binding Ig-like lectin 6 isoform a||sialic acid binding Ig- like lectin 6 isoform c|| HTR2B ||5-HT(2B)||5- 3.818 NM_000867 90 HT2B||HTR2B||SEROTONIN 5-HT-2B RECEPTOR||5- @HYDROXYTRYPTAMINE RECEPTOR 2B||5-hydroxytryptamine (serotonin) receptor 2B|| GPRC5B ||RAIG2||GPRC5B||RETINOIC ACID- 3.762 NM_016235 91 INDUCIBLE GENE 2||G protein- coupled receptor, family C, group 5, member B|| CTSC ||HMS||CPPI||3.4.14.1||DPPI||PALS|| 3.759 NM_001814 92 DPP1||CTSC||PLS||dipeptidyl transferase||cathepsin C||dipeptidyl- peptidase I||cathepsin J||Papillon- Lefevre syndrome||DIPEPTIDYL PEPTIDASE I||cathepsin C isoform b precursor||cathepsin C isoform a preproprotein|| 3.721 AW978130 93 SERPINE2 ||PN1||GDN||PNI||SERPINE2||PI7|| 3.69 NM_006216 94 glial-derived nexin 1||glial-derived neurite promoting factor||protease inhibitor 7 (protease nexin I)||plasminogen activator inhibitor type 1, member 2||serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2|| CTSG ||MGC23078||CTSG||3.4.21.20||CG|| 3.626 NM_001911 95 cathepsin G||cathepsin G preproprotein|| LITAF ||LITAF||PIG7||TP53I7||FLJ38636|| 3.601 NM_004862 96 CMT1C||SIMPLE||lipopolysaccharide- induced TNF factor||LPS-induced TNF-alpha factor||LIPOPOLYSACCHARIDE- INDUCED TUMOR NECROSIS FACTOR-ALPHA FACTOR||tumor protein p53 inducible protein 7||small integral membrane protein of lysosome/late endosome|| SLC2A3 ||GLUT3P1||SLC2A3P||SLC2A3||GLUCOSE 3.549 NM_006931 97 TRANSPORTER 3 PSEUDOGENE 1||GLUCOSE TRANSPORTER TYPE 3, BRAIN||solute carrier family 2 (facilitated glucose transporter), member 3||GLUCOSE TRANSPORTER, FETAL SKELETAL MUSCLE SOLUTE CARRIER FAMILY 2, MEMBER 3 PSEUDOGENE|| IFI35 ||IFI35||IFP35||interferon-induced 3.545 NM_005533 98 protein 35||INTERFERON INDUCIBLE PROTEIN, 35-KD|| TPK1 ||HTPK1||TPK1||THIAMINE 3.491 NM_022445 99 KINASE||thiamine pyrophosphokinase||thiamin pyrophosphokinase 1||mouse thiamin pyrophosphokinase homolog|| MGC48998 ||MGC48998||hypothetical protein 3.481 NM_178550 100 MGC48998|| ITGA9 ||ALPHA- 3.453 NM_002207 101 RLC||ITGA4L||ITGA9||INTEGRIN, ALPHA-9||integin, alpha 9||integrin, alpha 9||integrin, alpha 4- like||ALPHA RELATED TO THE DEVELOPMENT OF LUNG CANCER|| IL17RB ||IL17RB||IL17RH1||IL17BR||INTERLEUKIN 3.446 NM_172234 102 17B RECEPTOR||interleukin 17 receptor B||INTERLEUKIN 17 RECEPTOR HOMOLOG 1|| PRG1 ||MGC9289||PPG||serglycin||PRG1|| 3.441 NM_002727 103 hematopoetic proteoglycan core peptide||platelet proteoglycan protein core||proteoglycan 1, secretory granule||secretory granule proteoglycan core peptide||proteoglycan 1, secretory granule precursor||proteoglycan protein core for mast cell secretory granule|| MRC1 ||MRC1||mannose receptor 3.394 NM_002438 104 precursor||macrophage mannose receptor||mannose receptor, C type 1||mannose receptor C type 1 precursor|| RARRES3 ||RIG1||TIG3||RARRES3||TAZAROTENE- 3.38 NM_004585 105 INDUCED GENE 3||RETINOIC ACID RECEPTOR RESPONDER 3||retinoic acid receptor responder (tazarotene induced) 3|| DPYD ||1.3.1.2||DPYD||DIHYDROPYRIMIDINURIA|| 3.363 NM_000110 106 dihydropyrimidine dehydrogenase||PYRIMIDINEMIA, FAMILIAL||5-@FLUOROURACIL TOXICITY||DPD DEFICIENCY||DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY||DHP THYMINE- URACILURIA, HEREDITARY|| MFHAS1 ||MFHAS1||MASL1||MALIGNANT 3.356 NM_004225 107 FIBROUS HISTIOCYTOMA- AMPLIFIED SEQUENCE 1||malignant fibrous histiocytoma amplified sequence 1||MFH-amplified sequences with leucine-rich tandem repeats 1||MALIGNANT FIBROUS HISTIOCYTOMA-AMPLIFIED SEQUENCES WITH LEUCINE-RICH TANDEM REPEATS 1|| BCL2A1 ||HBPA1||BCL2A1||BCL2L5||GRS||BCL2- 3.355 NM_004049 108 RELATED GENE BFL1||BCL2- related protein A1||hematopoietic BCL2-related protein A1|| CFHL1 ||||HFL1||H factor (complement)- 3.347 NM_002113 109 like 1|| FGG ||FGG||fibrinogen, gamma 3.275 NM_021870 110 polypeptide||FIBRINOGEN--GAMMA POLYPEPTIDE CHAIN||FIBRINOGEN, G GAMMA POLYPEPTIDE||fibrinogen, gamma chain isoform gamma-B precursor||fibrinogen, gamma chain isoform gamma-A precursor|| IL27RA ||TCCR||IL27RA||CRL1||WSX1||zcytor1|| 3.27 NM_004843 111 T-cell cytokine receptor||class I cytokine receptor||interleukin 27 receptor, alpha|| LOC130576 ||LOC130576||hypothetical protein 3.256 NM_177964 112 LOC130576|| LHFPL2 ||LHFPL2||KIAA0206||lipoma HMGIC 3.241 NM_005779 113 fusion partner-like 2|| RGS2 ||RGS2||BASIC HELIX-LOOP-HELIX 3.237 NM_002923 114 PHOSPHOPROTEIN G0S8||REGULATOR OF G PROTEIN SIGNALING 2||regulator of G- protein signalling 2, 24 kDa||G0 to G1 switch regulatory 8, 24 kD|| ENO1 ||4.2.1.11||ENO1L1||MPB1||MBP- 3.202 NM_001428 115 1||tau-crystallin||ENO1||ENOLASE, ALPHA||non-neural enolase||2- phospho-D-glycerate hydrolyase|| ENOLASE, NONNEURONAL||phosphopyruvate hydratase||PPH CRYSTALLIN, TAU||enolase 1, (alpha)||MYC promoter-binding protein 1|| MFHAS1 ||MFHAS1||MASL1||MALIGNANT 3.193 NM_004225 116 FIBROUS HISTIOCYTOMA- AMPLIFIED SEQUENCE 1||malignant fibrous histiocytoma amplified sequence 1||MFH-amplified sequences with leucine-rich tandem repeats 1||MALIGNANT FIBROUS HISTIOCYTOMA-AMPLIFIED SEQUENCES WITH LEUCINE-RICH TANDEM REPEATS 1|| TPSB2 ||||TPS1||tryptase, alpha|| 3.188 NM_003294 117 SH3RF2 ||SH3RF2||SH3 domain containing 3.187 NM_152550 118 ring finger 2|| CISH ||CIS- 3.179 NM_013324 119 1||SOCS||G18||CISH||cytokine inducible SH2-containing protein||suppressor of cytokine signaling||cytokine-inducible SH2- containing protein isoform 1||cytokine-inducible SH2- containing protein isoform 2||cytokine-inducible inhibitor of signaling type 1B|| COL8A2 ||FECD||PPCD2||COL8A2||FLJ00201|| 3.148 NM_005202 120 COLLAGEN, TYPE VIII, ALPHA- 2||collagen VIII, alpha-2 polypeptide||collagen, type VIII, alpha 2|| LBH ||LBH||likely ortholog of mouse 3.147 NM_030915 121 limb-bud and heart gene|| SAMSN1 ||HACS1||SAMSN1||HEMATOPOIETIC 3.147 NM_022136 122 ADAPTOR CONTAINING SH3 AND SAM DOMAINS 1||SAM domain, SH3 domain and nuclear localisation signals, 1||SAM DOMAIN, SH3 DOMAIN, AND NUCLEAR LOCALIZATION SIGNALS 1|| SLC18A2 ||VAT2||SLC18A2||SVAT||VMAT2||SVMT|| 3.144 NM_003054 123 VESICULAR AMINE TRANSPORTER 2||VESICULAR MONOAMINE TRANSPORTER 2||SYNAPTIC VESICLE MONOAMINE TRANSPORTER, BRAIN||SYNAPTIC VESICLE AMINE TRANSPORTER, BRAIN||solute carrier family 18 (vesicular monoamine), member 2||SOLUTE CARRIER FAMILY 18 (VESICULAR MONOAMINE TRANSPORTER), MEMBER 2|| F13A1 ||FIBRINOLIGASE||TGase||F13A1||2.3.2.13|| 3.134 NM_000129 124 FIBRINASE DEFICIENCY||FSF, A SUBUNIT||FACTOR XIII, A1 SUBUNIT||FIBRIN STABILIZING FACTOR, A SUBUNIT||coagulation factor XIII, A1 polypeptide||Coagulation factor XIII, A polypeptide||coagulation factor XIII A1 subunit precursor||TRANSGLUTAMINASE, PLASMA FACTOR XIII, A SUBUNIT, DEFICIENCY OF|| 3.131 AK095590 125 ACSL5 ||ACSL5||FACL5||ACS5||ACYL-CoA 3.127 NM_016234 126 SYNTHETASE 5||acyl-CoA synthetase long-chain family member 5||FATTY ACID CoA LIGASE, LONG-CHAIN 5|| TNFSF13 ||TWE-PRIL||TALL2||TNFSF13||TNF- 3.116 NM_003808 127 related death ligand-1||proliferation inducing ligand APRIl||tumor necrosis factor-related death ligand- 1||tumor necrosis factor (ligand) superfamily, member 13||TNF- and APOL-related leukocyte expressed ligand 2||tumor necrosis factor ligand superfamily, member 13 isoform delta||tumor necrosis factor ligand superfamily, member 13 isoform gamma||tumor necrosis factor ligand superfamily, member 13 isoform beta||tumor necrosis factor ligand superfamily, member 13 isoform alpha precursor|| STOM ||BND7||STOM||stomatin||EPB72||stomatin 3.104 NM_004099 128 isoform a||stomatin isoform b||ERYTHROCYTE SURFACE PROTEIN BAND 7.2||ERYTHROCYTE BAND 7 INTEGRAL MEMBRANE PROTEIN||erythrocyte membrane protein band 7.2 (stomatin)|| HDC ||HDC||4.1.1.22||histidine 3.073 NM_002112 129 decarboxylase|| KIAA1126 ||KIAA1126||KIAA1126 protein|| 3.071 AB032952 130 PSMB9 ||3.4.25.1||RING12||LMP2||PSMB9|| 3.019 NM_002800 131 macropain chain 7||proteasome- related gene 2||proteasome chain 7||PROTEASOME SUBUNIT, BETA- TYPE, 9||proteasome subunit beta 6i||proteasome catalytic subunit 1i||low molecular mass protein 2||proteasome subunit, beta type, 9||multicatalytic endopeptidase complex chain 7||proteasome beta 9 subunit isoform 1 proprotein||proteasome beta 9 subunit isoform 2 proprotein||proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2)|| LRRC5 ||LRRC5||leucine rich repeat 3.014 NM_018103 132 containing 5|| GALNT5 ||GALNT5||UDP-N-acetyl-alpha-D- 2.991 NM_014568 133 galactosamine:polypeptide N- acetylgalactosaminyltransferase 5 (GalNAc-T5)|| LOC340061 ||LOC340061||hypothetical protein 2.986 NM_198282 134 LOC340061|| SCIN ||scinderin||SCIN|| 2.985 NM_033128 135 LR8 ||LR8||LR8 protein|| 2.941 NM_014020 136 LOC126917 ||LOC126917||hypothetical protein 2.94 XM_375695 137 LOC126917|| HLF ||HLF||hepatic leukemia factor||HLF 2.932 NM_002126 138 HLF/E2A FUSION GENE|| TRIM22 ||GPSTAF50||RNF94||TRIM22||tripartite 2.931 NM_006074 139 motif-containing 22||tripartite motif protein TRIM22||TRIPARTITE MOTIF-CONTAINING PROTEIN 22||STIMULATED TRANS-ACTING FACTOR, 50-KD||stimulated trans- acting factor (50 kDa)|| 2.93 AW195474 140 2.919 AA806368 141 GCNT2 ||GCNT5||NAGCT1||BIGnT||ULG3||bA360O19.2|| 2.898 NM_001491 142 CIGnT||bA421M1.1||GCNT2|| NACGT1||AIGnT||2.4.1.150|| N-acetyllactosaminide beta-1,6-N- acetylglucosaminyltransferase||BETA- 1,6-N- ACETYLGLUCOSAMINYLTRANSFERASE 2||I beta-1,6-N- acetylglucosaminyltransferase||blood group Ii||Ii blood group||DEVELOPMENTAL I ANTIGEN||glucosaminyl (N-acetyl) transferase 5||glucosaminyl (N- acetyl) transferase 2 isoform A||glucosaminyl (N-acetyl) transferase 2 isoform B||glucosaminyl (N-acetyl) transferase 2 isoform C||glucosaminyl (N-acetyl) transferase 2, I-branching enzyme|| LILRB2 ||||LILRB2||leukocyte 2.884 NM_005874 143 immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2|| IL15 ||IL- 2.879 NM_172174 144 15||IL15||MGC9721||interleukin 15||interleukin 15 isoform 2 precursor||interleukin 15 isoform 1 precursor|| NFE2L3 ||NFE2L3||NRF3||NF-E2-related 2.867 NM_004289 145 factor 3||NFE2-RELATED FACTOR 3||NUCLEAR FACTOR ERYTHROID 2- LIKE 3||nuclear factor (erythroid- derived 2)-like 3|| SH3RF2 ||SH3RF2||SH3 domain containing 2.826 NM_152550 146 ring finger 2|| KIAA1145 ||KIAA1145||KIAA1145 protein|| 2.82 NM_020698 147 IL17RB ||IL17RB||IL17RH1||IL17BR||INTERLEUKIN 2.819 NM_172234 148 17B RECEPTOR||interleukin 17 receptor B||INTERLEUKIN 17 RECEPTOR HOMOLOG 1|| GPR110 ||GPR110||G protein-coupled 2.809 NM_153840 149 receptor 110|| TFPI ||LACI||TFPI||EPI||EXTRINSIC 2.808 NM_006287 150 PATHWAY INHIBITOR||tissue factor pathway inhibitor (lipoprotein- associated coagulation inhibitor)|| TNFSF13 ||TWE-PRIL||TALL2||TNFSF13||TNF- 2.79 NM_003808 151 related death ligand-1||proliferation inducing ligand APRIl||tumor necrosis factor-related death ligand- 1||tumor necrosis factor (ligand) superfamily, member 13||TNF- and APOL-related leukocyte expressed ligand 2||tumor necrosis factor ligand superfamily, member 13 isoform delta||tumor necrosis factor ligand superfamily, member 13 isoform gamma||tumor necrosis factor ligand superfamily, member 13 isoform beta||tumor necrosis factor ligand superfamily, member 13 isoform alpha precursor|| LOH11CR2A ||BCSC-1||LOH11CR2A||loss of 2.772 NM_014622 152 heterozygosity, 11, chromosomal region 2, gene A|| TPPP ||p25||brain-specific protein p25 2.767 NM_007030 153 alpha||glycogen synthase kinase 3 (GSK3) inhibitor p24|| Cep72 ||FLJ10565||hypothetical protein 2.758 NM_018140 154 FLJ10565|| CISH ||CIS- 2.74 NM_013324 155 1||SOCS||G18||CISH||cytokine inducible SH2-containing protein||suppressor of cytokine signaling||cytokine-inducible SH2- containing protein isoform 1||cytokine-inducible SH2- containing protein isoform 2||cytokine-inducible inhibitor of signaling type 1B|| MGC35033 ||MGC35033||hypothetical protein 2.739 NM_152319 156 MGC35033|| CNTN4 ||CNTN4||contactin 4||BIG2, RAT, 2.706 NM_175607 157 HOMOLOG OF|| NFE2L3 ||NFE2L3||NRF3||NF-E2-related 2.682 NM_004289 158 factor 3||NFE2-RELATED FACTOR 3||NUCLEAR FACTOR ERYTHROID 2- LIKE 3||nuclear factor (erythroid- derived 2)-like 3|| CFH ||FHL1||CFH||HF1||HUS||complement 2.673 NM_000186 159 factor H||H factor-1 (complement)||H factor 1 (complement)||HF FACTOR H-LIKE 1||FACTOR H AND FACTOR H-LIKE 1, COMBINED DEFICIENCY OF|| PSMB8 ||MGC1491||RING10||LMP7||D6S216E|| 2.65 NM_004159 160 PSMB8||3.4.25.1||large multifunctional protease- 7||macropain subunit C13||proteasome subunit Y2||protease component C13||proteasome-related gene 7||PROTEASOME SUBUNIT, BETA- TYPE, 8||proteasome subunit beta 5i||proteasome catalytic subunit 3i||multicatalytic endopeptidase complex subunit C13||proteasome subunit, beta type, 8||low molecular weight protein 7||proteasome beta 8 subunit isoform E1 proprotein||proteasome beta 8 subunit isoform E2 proprotein||proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)|| LOXL4 ||LOXL4||LOXC||lysyl oxidase-like 2.647 NM_032211 161 4|| TRAF5 ||RNF84||MGC: 39780||TRAF5||TNF 2.613 NM_004619 162 receptor-associated factor 5|| CLN6 ||CLN6||CLN6 GENE||ceroid- 2.592 NM_017882 163 lipofuscinosis, neuronal 6, late infantile, variant|| HLF ||HLF||hepatic leukemia factor||HLF 2.587 NM_002126 164 HLF/E2A FUSION GENE|| SCUBE1 ||SCUBE1||signal peptide, CUB 2.577 NM_173050 165 domain, EGF-like 1|| CASP7 ||MCH3||CASP7||CMH-1||ICE- 2.573 NM_033339 166 LAP3||Lice2 alpha/beta/gamma||apoptotic protease MCH-3||ICE-like apoptotic protease 3||caspase 7 isoform beta||caspase 7 isoform alpha precursor||caspase 7, apoptosis- related cysteine protease||caspase 7 isoform alpha, large subunit||caspase 7 isoform delta, large subunit|| CLDN23 ||CLDN23||claudin 23|| 2.567 NM_194284 167 SH3RF2 ||SH3RF2||SH3 domain containing 2.536 NM_152550 168 ring finger 2|| APOL3 ||APOL3||APOL- 2.535 NM_145641 169 III||APOLIPOPROTEIN L- III||apolipoprotein L, 3|| SEPX1 ||SEPX1||SELR||SELX||SELENOPROTEIN 2.519 NM_016332 170 R||selenoprotein X, 1|| FA2H ||FA2H||fatty acid 2-hydroxylase|| 2.516 NM_024306 171 NEK6 ||NEK6||SID6-1512||NIMA-RELATED 2.498 NM_014397 172 KINASE 6||putative serine-threonine protein kinase||NEVER IN MITOSIS GENE A-RELATED KINASE 6||NIMA (never in mitosis gene a)-related kinase 6|| CLN6 ||CLN6||CLN6 GENE||ceroid- 2.493 NM_017882 173 lipofuscinosis, neuronal 6, late infantile, variant|| TM4SF8 ||TM4SF8||TSPAN-3 2.487 NM_005724 174 1700055K04Rik||tetraspanin TM4- A||tetraspan TM4SF||tetraspanin 3||tetraspan 3||transmembrane 4 superfamily member 8||transmembrane 4 superfamily, member 8||transmembrane 4 superfamily member 8 isoform 2||transmembrane 4 superfamily member 8 isoform 1|| CLDN23 ||CLDN23||claudin 23|| 2.478 NM_194284 175 EDAR ||ED5||ED3||EDAR||EDA- 2.473 NM_022336 176 A1R||DL||EDA3||ED1R||ECTODYSPLASIN RECEPTOR||EDA-A1 RECEPTOR||downless (mouse) homolog||ectodysplasin 1, anhidrotic receptor||ECTODYSPLASIN A1 ISOFORM RECEPTOR||downless, mouse, homolog of|| KLHL5 ||KLHL5||kelch-like 5 (Drosophila)|| 2.472 NM_199039 177 VDR ||VDR||NR1I1||VITAMIN D 2.468 NM_000376 178 RECEPTOR||1,25- @DIHYDROXYVITAMIN D3 RECEPTOR||VITAMIN D HORMONE RECEPTOR||vitamin D (1,25- dihydroxyvitamin D3) receptor|| SLC15A1 ||SLC15A1||HPECT1||peptide 2.463 NM_005073 179 transporter HPEPT1||HYDROGEN ION/PEPTIDE COTRANSPORTER, INTESTINAL||solute carrier family 15 (oligopeptide transporter), member 1|| IFI30 ||IFI- 2.454 NM_006332 180 30||IP30||IFI30||GILT||MGC32056|| INTERFERON-GAMMA-INDUCIBLE PROTEIN 30||LYSOSOMAL THIOL REDUCTASE, GAMMA-INTERFERON- INDUCIBLE||interferon, gamma- inducible protein 30||gamma- interferon-inducible lysosomal thiol reductase||interferon, gamma- inducible protein 30 preproprotein|| SLCO3A1 ||SLC21A11||OATP- 2.452 NM_013272 181 D||SLCO3A1||OATP3A1||solute carrier organic anion transporter family, member 3A1||solute carrier family 21 (organic anion transporter), member 11|| 2.439 AK023647 182 GALNT5 ||GALNT5||UDP-N-acetyl-alpha-D- 2.438 NM_014568 183 galactosamine:polypeptide N- acetylgalactosaminyltransferase 5 (GalNAc-T5)|| LY75 ||GP200-MR6||DEC- 2.437 NM_002349 184 205||LY75||DEC205||lymphocyte antigen 75|| OR2A20P ||HSDJ0798C17||OR2A9P||olfactory 2.435 BC016940 185 receptor, family 2, subfamily A, member 9 pseudogene|| IGSF4 ||ST17||IGSF4||BL2||NECL2||SYNCAM|| 2.409 NM_014333 186 TSLC1||nectin-like protein 2||SYNAPTIC CELL ADHESION MOLECULE||immunoglobulin superfamily, member 4||tumor suppressor in lung cancer 1|| NTRK3 ||NTRK3||TRKC||NEUROTROPHIN 3 2.382 NM_002530 187 RECEPTOR||TYROSINE KINASE RECEPTOR C||neurotrophic tyrosine kinase, receptor, type 3|| KIAA1337 ||KIAA1337||KIAA1337 protein|| 2.379 XM_052561 188 GGH ||3.4.19.9||GGH||gamma-glutamyl 2.376 NM_003878 189 hydrolase precursor||gamma- glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase)|| P2RY1 ||P2RY1||ATP 2.363 NM_002563 190 receptor||PURINOCEPTOR P2Y1||platelet ADP receptor||P2Y purinoceptor 1||purinergic receptor P2Y1||P2 purinoceptor subtype Y1||purinergic receptor P2Y, G- protein coupled, 1||PURINERGIC RECEPTOR P2Y, G PROTEIN- COUPLED, 1|| APOL2 ||APOL2||APOL-II||apolipoprotein L- 2.347 NM_145637 191 II||apolipoprotein L2||apolipoprotein L, 2|| TAP1 ||RING4||ABC17||D6S114E||ABCB2 2.332 NM_000593 192 ||TAP1||APT1||PEPTIDE TRANSPORTER PSF1||TRANSPORTER, ABC, MHC, 1||ABC transporter, MHC 1||antigen peptide transporter 1||peptide supply factor 1||ABC TRANSPORTER, MHC, 1||ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 2||TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1||ATP-binding cassette, sub-family B, member 2||ATP-binding cassette, sub-family B (MDR/TAP), member 2||ATP-BINDING CASSETTE TRANSPORTER, MAJOR HISTOCOMPATIBILITY COMPLEX, 1||transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)||transporter, ATP- binding cassette, major histocompatibility complex, 1|| SMILE ||FLJ90492||hypothetical protein 2.303 NM_181783 193 FLJ90492|| RRM2 ||1.17.4.1||RRM2||RIBONUCLEOTIDE 2.297 NM_001034 194 REDUCTASE, R2 SUBUNIT||RIBONUCLEOTIDE REDUCTASE, SMALL SUBUNIT||ribonucleotide reductase M2 polypeptide||RIBONUCLEOTIDE REDUCTASE, M2 SUBUNIT|| PARP14 ||KIAA1268||KIAA1268 protein|| 2.276 BX648758 195 PRICKLE2 ||PRICKLE2||prickle-like 2 2.272 NM_198859 196 (Drosophila)||PRICKLE, DROSOPHILA, HOMOLOG OF, 2|| NAV1 ||NAV1||neuron navigator 1|| 2.265 NM_020443 197 RARB ||||RARB||retinoic acid receptor, 2.241 NM_000965 198 beta|| NDFIP2 ||NDFIP2||Nedd4 family interacting 2.233 XM_041162 199 protein 2|| LOC152485 ||LOC152485||hypothetical protein 2.231 NM_178835 200 LOC152485|| BAZ2A ||BAZ2A||KIAA0314||TIP5||TTF-I 2.228 NM_013449 201 interacting peptide 5||bromodomain adjacent to zinc finger domain, 2A|| ETV7 ||TELB||ETV7||ETS TRANSCRIPTION 2.212 NM_016135 202 FACTOR TEL2||ets variant gene 7 (TEL2 oncogene)|| LTA4H ||3.3.2.6||LTA4H||leukotriene A4 2.205 NM_000895 203 hydrolase|| SLC16A1 ||SLC16A1||MCT1||monocarboxylate 2.194 NM_003051 204 transporter 1||solute carrier family 16, member 1||SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 1||solute carrier family 16 (monocarboxylic acid transporters), member 1|| ARMCX3 ||ALEX3||ALEX3 protein||ARM 2.192 NM_016607 205 PROTEIN LOST IN EPITHELIAL CANCERS, X CHROMOSOME, 3|| C10orf128 ||LOC170371||hypothetical protein 2.187 BC047724 206 LOC170371|| ARHGAP8 ||FLJ20185||ARHGAP8||PP610||BPGAP1|| 2.185 NM_017701 207 BCH domain-containing Cdc42GAP-like protein||Rho GTPase activating protein 8||Rho GTPase activating protein 8 isoform 4||Rho GTPase activating protein 8 isoform 1||Rho GTPase activating protein 8 isoform 2||Rho GTPase activating protein 8 isoform 3||Rho GTPase activating protein 8 isoform 5|| TMPRSS4 ||TMPRSS4||transmembrane 2.156 NM_019894 208 protease, serine 4|| CTSS ||CTSS||3.4.22.27||MGC3886||cathepsin 2.152 NM_004079 209 S||cathepsin S preproprotein|| LOC158402 2.144 AK095652 210 TAPBP ||TAPBP||TPSN||TPN||NGS17||TAP- 2.131 NM_003190 211 associated protein||TAP-binding protein||TAP binding protein (tapasin)||tapasin isoform 2 precursor||tapasin isoform 1 precursor||tapasin isoform 3 precursor|| CTEN ||CTEN||C-terminal tensin-like||C- 2.127 NM_032865 212 TERMINAL TENSIN-LIKE PROTEIN|| T3JAM ||T3JAM||TRAF3-INTERACTING JNK- 2.107 NM_025228 213 ACTIVATING MODULATOR||TRAF3- interacting Jun N-terminal kinase (JNK)-activating modulator|| CD44 ||CD44R||MDU2||INLU||MDU3||Pgp1|| 2.106 NM_000610 214 MIC4||MC56||CD44||HERMES ANTIGEN||Lutheran inhibitor, dominant (monoclonal antibody A3D8)||CD44 antigen (homing function and Indian blood group system)|| FLJ21103 ||FLJ21103||hypothetical protein 2.104 NM_024556 215 FLJ21103|| SLC16A2 ||SLC16A2||MCT8||XPCT||X-linked 2.09 NM_006517 216 PEST-containing transporter||DXS128E MONOCARBOXYLATE TRANSPORTER 8 DEFICIENCY||solute carrier family 16, member 2||SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 2||solute carrier family 16 (monocarboxylic acid transporters), member 2 (putative transporter)|| GALNAC4S-6ST ||GalNAc4S- 2.083 NM_015892 217 6ST||BRAG||KIAA0598||B-CELL RAG-ASSOCIATED GENE||N- ACETYLGALACTOSAMINE 4-SULFATE 6-O-SULFOTRANSFERASE||B cell RAG associated protein|| MAP3K14 ||FTDCR1B||MAP3K14||HSNIK||NF- 2.074 NM_003954 218 KAPPA-B-INDUCING KINASE||serine/threonine protein- kinase||SERINE/THREONINE PROTEIN KINASE NIK||mitogen- activated protein kinase kinase kinase 14|| ATP8B1 ||PFIC1||ATPIC||ATP8B1||BRIC||benign 2.064 NM_005603 219 recurrent intrahepatic cholestasis||FAMILIAL INTRAHEPATIC CHOLESTASIS GENE 1||ATPase, CLASS I, TYPE 8B, MEMBER 1||ATPase, Class I, type 8B, member 1||progressive familial intrahepatic cholestasis 1, Byler disease||familial intrahepatic cholestasis 1, (progressive, Byler disease and benign recurrent)|| RAB40B ||RAB40B||SEC4L||RAR||RAB40B, 2.063 NM_006822 220 member RAS oncogene family||GTP- binding protein homologous to Saccharomyces cerevisiae SEC4|| 2.061 BQ717725 221 NFKBIE ||NFKBIE||IKBE||INHIBITOR OF 2.06 NM_004556 222 KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS, EPSILON||nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon||NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, EPSILON|| 2.058 AK026659 223 ELOVL5 ||ELOVL5||ELOVL family member 5, 2.052 NM_021814 224 elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)|| LOC132430 2.047 XR_000195 225 GPX4 ||snGPx||1.11.1.9||GPX4||sperm 2.045 NM_002085 226 nucleus glutathione peroxidase||glutathione peroxidase 4 (phospholipid hydroperoxidase)|| CBX6 ||CBX6||chromobox homolog 6|| 2.041 NM_014292 227 NCF1 ||p47- 2.031 NM_000265 228 PHOX||NOXO2||NCF1||p47phox||Neutrophil cytosolic factor-1 (47 kD)||neutrophil cytosolic factor 1 (47 kDa, chronic granulomatous disease, autosomal 1)||neutrophil cytosolic factor 1 (47 kD, chronic granulomatous disease, autosomal 1)|| GLIPR1 ||RTVP1||GLIPR1||glioma 2.027 NM_006851 229 pathogenesis-related protein||GLI pathogenesis-related 1 (glioma)||related to testis-specific, vespid, and pathogenesis proteins 1|| CD44 ||CD44R||MDU2||INLU||MDU3||Pgp1|| 2.007 NM_000610 230 MIC4||MC56||CD44||HERMES ANTIGEN||Lutheran inhibitor, dominant (monoclonal antibody A3D8)||CD44 antigen (homing function and Indian blood group system)|| 2.002 AK127315 231 SLCO3A1 ||SLC21A11||OATP- 1.999 NM_013272 232 D||SLCO3A1||OATP3A1||solute carrier organic anion transporter family, member 3A1||solute carrier family 21 (organic anion transporter), member 11|| COL8A2 ||FECD||PPCD2||COL8A2||FLJ00201|| 1.992 NM_005202 233 COLLAGEN, TYPE VIII, ALPHA- 2||collagen VIII, alpha-2 polypeptide||collagen, type VIII, alpha 2|| KCTD12 ||KCTD12||potassium channel 1.985 NM_138444 234 tetramerisation domain containing 12|| DLG5 ||PDLG||KIAA0583||DLG5||discs 1.969 NM_004747 235 large homolog 5||placenta and prostate DLG||discs, large homolog 5 (Drosophila)||DISCS LARGE, DROSOPHILA, HOMOLOG OF, 5|| ABCC5 ||MOAT- 1.969 NM_005688 236 C||ABCC5||MRP5||EST277145||ABC33|| SMRP||pABC11||MOATC||MULTI DRUG RESISTANCE-ASSOCIATED PROTEIN 5||canalicular multispecific organic anion transporter C||ATP- binding cassette, sub-family C, member 5||ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 5||ATP-binding cassette, sub-family C (CFTR/MRP), member 5|| PRSS12 ||leydin||BSSP3||MGC12722||BSSP- 1.965 NM_003619 237 3||PRSS12||neurotrypsin precursor||brain-specific serine protease 3||protease, serine, 12 (neurotrypsin, motopsin)|| CLN5 ||NCL||CLN5||CLN5 GENE||ceroid- 1.96 NM_006493 238 lipofuscinosis, neuronal 5|| ZC3HDC1 ||ZC3HDC1||zinc finger CCCH type 1.947 NM_022750 239 domain containing 1|| EHD2 ||EHD2||EH-domain containing 1.94 NM_014601 240 2||EH DOMAIN-CONTAINING 2||EH domain containing 2|| RAD50 ||hRad50||RAD50||RAD50- 1.926 NM_005732 241 2||RAD50 homolog (S. cerevisiae)|| RAD50 homolog isoform 1||RAD50 homolog isoform 2||RAD50, S. CEREVISIAE, HOMOLOG OF|| GSDML ||||GSDML||gasdermin-like|| 1.92 NM_018530 242 TLOC1 ||TLOC1||HTP1||Dtrp1 1.918 NM_003262 243 protein||translocation protein 1||TRANSLOCATION PROTEIN 1, DROSOPHILA, HOMOLOG OF||membrane protein SEC62, S. cerevisiae, homolog of||MEMBRANE PROTEIN SEC62, S. CEREVISIAE, HOMOLOG OF|| EMR2 ||EMR2||EGF-LIKE MODULE- 1.914 NM_013447 244 CONTAINING, MUCIN-LIKE HORMONE RECEPTOR 2||egf-like module containing, mucin-like, hormone receptor-like 2||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform d||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform e||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform f||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform g||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform a||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform b||egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform c|| NCF1 ||p47- 1.91 NM_000265 245 PHOX||NOXO2||NCF1||p47phox||Neutrophil cytosolic factor-1 (47 kD)||neutrophil cytosolic factor 1 (47 kDa, chronic granulomatous disease, autosomal 1)||neutrophil cytosolic factor 1 (47 kD, chronic granulomatous disease, autosomal 1)|| ARHGEF6 ||alpha-PIX||alphaPIX||PIXA||Cool- 1.909 NM_004840 246 2||MRX46||KIAA0006||ARHGEF6||COOL2|| PAK-interacting exchange factor, alpha||Rac/Cdc42 guanine exchange factor (GEF) 6||rho guanine nucleotide exchange factor 6||Rac/Cdc42 guanine nucleotide exchange factor 6||Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6|| ZSWIM5 ||ZSWIM5||zinc finger, SWIM 1.905 XM_046581 247 domain containing 5|| CHST6 ||||CHST6||carbohydrate (N- 1.897 NM_021615 248 acetylglucosamine 6-O) sulfotransferase 6|| EPLIN ||EPLIN||SREBP3||STEROL 1.897 NM_016357 249 REGULATORY ELEMENT-BINDING PROTEIN 3||epithelial protein lost in neoplasm beta|| IL27RA ||TCCR||IL27RA||CRL1||WSX1||zcytor1|| 1.897 NM_004843 250 T-cell cytokine receptor||class I cytokine receptor||interleukin 27 receptor, alpha|| RGS19 ||RGSGAIP||RGS19||G alpha 1.891 NM_005873 251 interacting protein||G PROTEIN, ALPHA-INTERACTING PROTEIN||G protein signalling regulator 19||regulator of G-protein signalling 19||REGULATOR OF G PROTEIN SIGNALING 19||guanine nucleotide binding protein alpha inhibiting activity polypeptide 3 interacting protein|| ARRDC2 ||CLONE24945||PP2703||ARRDC2|| 1.887 NM_015683 252 arrestin domain containing 2|| HES2 ||||Similar to Transcription factor 1.883 XM_375684 253 HES-2 (Hairy and enhancer of split 2) (LOC388592), mRNA|| RIPK2 ||RIPK2||CARDIAK||RICK||CARD3|| 1.873 NM_003821 254 RIP2||CARD-CONTAINING ICE- ASSOCIATED KINASE||RECEPTOR- INTERACTING PROTEIN 2||RIP-LIKE INTERACTING CLARP KINASE||RECEPTOR-INTERACTING SERINE/THREONINE KINASE 2||receptor interacting protein 2||receptor-interacting serine- threonine kinase 2|| FGF11 ||FGF11||MGC45269||FHF3||fibroblast 1.868 NM_004112 255 growth factor 11||fibroblast growth factor homologous factor 3|| DRAP1 ||||Homo sapiens similar to 1.865 BC018095 256 tankyrase, TRF1-interacting ankyrin- related ADP-ribose polymerase 2; tankyrase 2 (LOC376558), mRNA|| SCIN ||scinderin||SCIN|| 1.861 NM_033128 257 HSPA5BP1 ||HSPA5BP1||heat shock 70 kDa 1.861 NM_017870 258 protein 5 (glucose-regulated protein, 78 kDa) binding protein 1|| ADAM8 ||MS2||CD156||ADAM8||HUMAN 1.858 NM_001109 259 LEUKOCYTE DIFFERENTIATION ANTIGEN||a disintegrin and metalloproteinase domain 8||a disintegrin and metalloproteinase domain 8 precursor|| NFATC2 ||NFATP||NFATC2||NFAT pre- 1.858 NM_173091 260 existing subunit||NFAT TRANSCRIPTION COMPLEX, PREEXISTING COMPONENT||T cell transcription factor NFAT1||nuclear factor of activated T-cells, cytoplasmic 2||nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2||NUCLEAR FACTOR OF ACTIVATED T CELLS, PREEXISTING COMPONENT||preexisting nuclear factor of activated T-cells 2 isoform B||preexisting nuclear factor of activated T-cells 2 isoform C||NUCLEAR FACTOR OF ACTIVATED T CELLS, CYTOPLASMIC, CALCINEURIN-DEPENDENT 2|| MGC14289 ||MGC14289||similar to RIKEN cDNA 1.858 NM_080660 261 1200014N16 gene|| GPR143 ||GPR143||OA1 GENE||ocular 1.854 NM_000273 262 albinism-1, Nettleship-Falls type||G protein-coupled receptor 143||ALBINISM, OCULAR, TYPE I||NETTLESHIP-FALLS TYPE OCULAR ALBINISM OCULAR ALBINISM 1 GENE|| 1.845 AK056817 263 FLJ10350 ||FLJ10350||hypothetical protein 1.845 NM_018067 264 FLJ10350|| HCP5 ||HCP5||D6S2650E||HLA complex 1.843 NM_006674 265 P5||MHC class I region ORF||MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, GENE P5-1|| WARP ||WARP||von Willebrand factor A 1.831 NM_022834 266 domain-related protein|| MGC15397 ||MGC15397||similar to RIKEN cDNA 1.827 NM_080652 267 5730578N08 gene|| GLIS2 ||GLIS2||GLI-SIMILAR PROTEIN 1.82 NM_032575 268 2||Kruppel-like zinc finger protein GLIS2|| ARHGAP15 1.816 AI510829 269 STK17B ||DRAK2||STK17B||SERINE/THREONINE 1.812 NM_004226 270 PROTEIN KINASE 17B||death- associated protein kinase-related 2||serine/threonine kinase 17b (apoptosis-inducing)||DAP KINASE- RELATED APOPTOSIS-INDUCING PROTEIN KINASE 2|| CLNS1A ||||CLNS1A||chloride channel, 1.808 NM_001293 271 nucleotide-sensitive, 1A|| C9orf40 ||C9orf40||chromosome 9 open 1.8 NM_017998 272 reading frame 40|| FAM20C ||FAM20C||family with sequence 1.799 NM_020223 273 similarity 20, member C|| ADRBK2 ||GRK3||BARK2||2.7.1.126||ADRBK 1.791 NM_005160 274 2||BETA-ADRENERGIC RECEPTOR KINASE 2||adrenergic, beta, receptor kinase 2||beta adrenergic receptor kinase 2|| BBAP ||BBAP||rhysin 2|| 1.788 NM_138287 275 EPB41L2 ||EPB41L2||4.1G||4.1- 1.765 NM_001431 276 G||ERYTHROCYTE MEMBRANE PROTEIN 4.1-LIKE 2||NONERYTHROID PROTEIN 4.1, GENERAL TYPE||erythrocyte membrane protein band 4.1-like 2|| MGC7036 ||MGC7036||hypothetical protein 1.759 NM_145058 277 MGC7036|| 1.759 BM999272 278 TCF4 ||SEF2-1B||TCF4||E2- 1.756 NM_003199 279 2||ITF2||transcription factor 4||IMMUNOGLOBULIN TRANSCRIPTION FACTOR 2||transcription factor 4 isoform b||Transcription factor-4 (immunoglobulin transcription factor-2)|| ARHGEF5 ||P60||ARHGEF5||TIM1||oncogene 1.753 NM_005435 280 TIM||transforming immortalized mammary oncogene||guanine nucleotide regulatory protein TIM||Rho guanine nucleotide exchange factor 5||Rho guanine nucleotide exchange factor (GEF) 5|| SFXN1 ||SFXN1||sideroflexin 1|| 1.75 NM_022754 281 KIAA1404 ||KIAA1404||KIAA1404 protein|| 1.746 NM_021035 282 SMTN ||smoothelin||SMTN||smoothelin 1.745 NM_134269 283 isoform a||smoothelin isoform b||smoothelin isoform c|| TRAF4 ||CART1||MLN62||RNF83||TRAF4|| 1.739 NM_004295 284 malignant 62||TNF receptor- associated factor 4||tumor necrosis receptor-associated factor 4A||TNF receptor-associated factor 4 isoform 1||TNF receptor-associated factor 4 isoform 2||CYSTEINE-RICH DOMAIN ASSOCIATED WITH RING AND TRAF DOMAINS|| GCNT2 1.737 AK058074 285 SPTBN1 ||||SPTBN1||spectrin, beta, non- 1.716 NM_003128 286 erythrocytic 1|| FOXQ1 ||FOXQ1||forkhead box Q1|| 1.709 NM_033260 287 TNFRSF5 ||Bp50||TNFRSF5||MGC9013||CDW40|| 1.706 NM_001250 288 CD40 antigen||CD40L receptor||B CELL-ASSOCIATED MOLECULE CD40||CD40 type II isoform||B cell surface antigen CD40||nerve growth factor receptor- related B-lymphocyte activation molecule||tumor necrosis factor receptor superfamily, member 5||tumor necrosis factor receptor superfamily, member 5 isoform 2 precursor||tumor necrosis factor receptor superfamily, member 5 isoform 1 precursor|| NCF4 ||p40phox||NCF4||p40-PHOX||NCF, 1.69 NM_013416 289 40-KD||Neutrophil cytosolic factor- 4||neutrophil cytosolic factor 4, 40 kDa||neutrophil cytosolic factor 4 (40 kD) isoform 1||neutrophil cytosolic factor 4 (40 kD) isoform 2|| MGAT3 ||GNT- 1.688 NM_002409 290 III||2.4.1.144||GNT3||MGAT3||BETA- 1,4-@MANNOSYL-GLYCOPROTEIN BETA-1,4-N- ACETYLGLUCOSAMINYLTRANSFERASE ||UDP-N- ACETYLGLUCOSAMINE:BETA-D- MANNOSIDE BETA-1,4-N- ACETYLGLUCOSAMINYLTRANSFERASE ||mannosyl (beta-1,4-)- glycoprotein beta-1,4-N- acetylglucosaminyltransferase|| DRAP1 ||||Homo sapiens similar to 1.687 BC018095 291 tankyrase, TRF1-interacting ankyrin- related ADP-ribose polymerase 2; tankyrase 2 (LOC376558), mRNA|| HLA-B ||HLA-B||HLA-B 1.686 NM_005514 292 HISTOCOMPATIBILITY TYPE||major histocompatibility complex, class I, B||HLA class I histocompatibility antigen, B alpha chain|| EPAS1 ||HIF2A||MOP2||HIF2- 1.684 NM_001430 293 ALPHA||EPAS1||endothelial PAS domain protein 1||MEMBER OF PAS SUPERFAMILY 2||HYPOXIA- INDUCIBLE FACTOR 2, ALPHA SUBUNIT|| LOC283578 ||LOC283578||hypothetical protein 1.684 XM_208746 294 LOC283578|| MAOA ||1.4.3.4||MAOA||MAOA BRUNNER 1.677 NM_000240 295 SYNDROME||monoamine oxidase A|| CDCP1 ||CDCP1||CUB domain-containing 1.663 NM_022842 296 protein 1|| TNIP2 ||TNIP2||TNFAIP3 interacting 1.66 NM_024309 297 protein 2|| RAB8B ||RAB8B||RAB8B, member RAS 1.653 NM_016530 298 oncogene family|| 1.644 BM988141 299 TLE4 ||ESG4||TLE4||E(spI)||BCE-1||B 1.636 NM_007005 300 lymphocyte gene 1||transducin-like enhancer protein 4||enhancer of split groucho 4||transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila)|| ITGAE ||HUMINAE||ITGAE||CD103 1.635 NM_002208 301 ANTIGEN||INTEGRIN, ALPHA- E||HUMAN MUCOSAL LYMPHOCYTE ANTIGEN 1, ALPHA SUBUNIT||integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)|| RAB33A ||RAB33A||MGC1488||RabS10||RAS- 1.63 NM_004794 302 ASSOCIATED PROTEIN RAB33A||Ras-related protein Rab- 33A||Small GTP-binding protein S10||RAB33A, member RAS oncogene family|| CD97 ||CD97||TM7LN1||CD97 1.628 NM_078481 303 antigen||leukocyte antigen CD97||seven-span transmembrane protein||CD97 antigen isoform 1 precursor||CD97 antigen isoform 2 precursor|| SLCO3A1 ||SLC21A11||OATP- 1.623 NM_013272 304 D||SLCO3A1||OATP3A1||solute carrier organic anion transporter family, member 3A1||solute carrier family 21 (organic anion transporter), member 11|| TNIP2 ||TNIP2||TNFAIP3 interacting 1.618 NM_024309 305 protein 2|| GSTO1 ||GSTTLp28||GSTO1||glutathione-S- 1.615 NM_004832 306 transferase like||glutathione-S- transferase omega 1||GLUTATHIONE S-TRANSFERASE, OMEGA- 1||glutathione transferase omega||glutathione S-transferase omega 1|| DTNBP1 ||SDY||DTNBP1||DYSBINDIN|| 1.597 NM_183040 307 DYSTROBREVIN-BINDING PROTEIN 1||SANDY, MOUSE, HOMOLOG OF||dystrobrevin binding protein 1|| ARHGAP26 ||GRAF||KIAA0621||GRAF 1.576 NM_015071 308 GRAF/MLL FUSION GENE||GTPase regulator associated with focal adhesion kinase pp125(FAK)||GTPase regulator associated with the focal adhesion kinase pp125|| KIAA1305 ||KIAA1305||KIAA1305 1.575 NM_025081 309 protein||hypothetical protein FLJ11811|| ETV7 ||TELB||ETV7||ETS TRANSCRIPTION 1.575 NM_016135 310 FACTOR TEL2||ets variant gene 7 (TEL2 oncogene)|| DUOX1 ||DUOX1||THOX1||THYROID 1.567 NM_017434 311 OXIDASE 1||dual oxidase 1|| PIK3CD ||p110- 1.563 NM_005026 312 DELTA||PIK3CD||p110D||phosphoinositide- 3-kinase, catalytic, delta polypeptide||phosphatidylinositol 3- kinase, catalytic, delta polypeptide||PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, 110-KD, DELTA|| 1.549 BG621254 313 FAM46A ||C6orf37||chromosome 6 open 1.526 NM_017633 314 reading frame 37|| IRF6 ||PIT||LPS||IRF6||PPS||VWS||Popliteala 1.509 NM_006147 315 pterygium syndrome||interferon regulatory factor 6|| GSR ||1.6.4.2||GSR||glutathione 1.508 NM_000637 316 reductase||GSR GLUTATHIONE REDUCTASE, HEMOLYTIC ANEMIA DUE TO DEFICIENCY OF, IN RED CELLS|| 1.506 AF143866 317 ACOX1 ||MGC1198||1.3.3.6||ACOX1||PALMCOX|| 1.504 NM_004035 318 SCOX||PSEUDONEONATAL ADRENOLEUKODYSTROPHY||PALMITOYL- CoA OXIDASE||ACYL-CoA OXIDASE, STRAIGHT-CHAIN||ACYL- CoA OXIDASE, PALMITOYL, PEROXISOMAL||PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY||acyl-Coenzyme A oxidase isoform a||acyl-Coenzyme A oxidase isoform b||acyl-Coenzyme A oxidase 1, palmitoyl||ADRENOLEUKODYSTROPHY, PSEUDONEONATAL ACYL-CoA OXIDASE 1, PALMITOYL|| RAP1A ||RAP1A||SMGP21||KREV-1||RAP1A 1.486 NM_002884 319 KREV1||RAS-related protein RAP1A||RAS-RELATED PROTEIN 1A||RAP1A, member of RAS oncogene family|| SIRT5 ||SIR2L5||SIRT5||sir2-like 5||sirtuin 1.479 NM_031244 320 type 5||sirtuin 5 isoform 1||sirtuin 5 isoform 2||SIR2, S. CEREVISIAE, HOMOLOG-LIKE 5||silent mating type information regulation 2, S. cerevisiae, homolog 5||sirtuin (silent mating type information regulation 2, S. cerevisiae, homolog) 5||sirtuin (silent mating type information regulation 2 homolog) 5 (S. cerevisiae)||sirtuin silent mating type information regulation 2 homolog 5 (S. cerevisiae)|| IL1RL1 ||ST2L||DER4||IL1RL1||ST2V||FIT- 1.479 NM_173459 321 1||MGC32623||T1||ST2 protein||interleukin 1 receptor- related protein||interleukin 1 receptor-like 1||GROWTH STIMULATION-EXPRESSED GENE, MOUSE, HOMOLOG OF||homolog of mouse growth stimulation-expressed gene||interleukin 1 receptor-like 1 isoform 1 precursor||interleukin 1 receptor-like 1 isoform 2 precursor||interleukin 1 receptor- like 1 isoform 3 precursor|| GOT2 ||2.6.1.1||GOT2||ASPARTATE 1.477 NM_002080 322 AMINOTRANSFERASE, MITOCHONDRIAL||aspartate aminotransferase 2 precursor||GLUTAMATE OXALOACETATE TRANSAMINASE, MITOCHONDRIAL||glutamic- oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)|| 1.456 BG257011 323 PSME1 ||REGalpha||IFI5111||PA28- 1.455 NM_176783 324 ALPHA||MGC8628||PSME1||PA28alpha|| proteasome activator subunit- 1||PROTEASOME ACTIVATOR 28- ALPHA||interferon-gamma-inducible protein 5111||interferon-gamma IEF SSP 5111||MCP ACTIVATOR, 29-KD SUBUNIT||29-kD MCP activator subunit||11S regulator complex alpha subunit||interferon gamma up-regulated I-5111 protein||proteasome activator subunit 1 isoform 2||proteasome activator subunit 1 isoform 1||activator of multicatalytic protease subunit 1||proteasome (prosome, macropain) activator subunit 1 (PA28 alpha)|| HA-1 ||HLA-HA1||HA-1||KIAA0223||minor 1.449 NM_012292 325 histocompatibility antigen HA-1|| IL9R ||IL9R||interleukin 9 1.44 NM_176786 326 receptor||interleukin 9 receptor isoform 2||interleukin 9 receptor isoform 1 precursor|| PRKAA1 ||PRKAA1||AMPK-ALPHA-1||AMPK 1.437 NM_006251 327 alpha 1||AMP-ACTIVATED PROTEIN KINASE, CATALYTIC, ALPHA- 1||Protein kinase, AMP-activated, catalytic, alpha-1||protein kinase, AMP-activated, alpha 1 catalytic subunit|| SCARA3 ||CSR||MSRL1||SCARA3||CELLULAR 1.425 NM_016240 328 STRESS RESPONSE||MACROPHAGE SCAVENGER RECEPTOR-LIKE 1||scavenger receptor class A, member 3|| MCM10 ||MCM10||MCM10 minichromosome 1.416 NM_182751 329 maintenance deficient 10 (S. cerevisiae)|| C6orf83 ||C6orf83||chromosome 6 open 1.406 NM_145169 330 reading frame 83|| PSMB4 ||PROS26||PSMB4||HN3||3.4.25.1|| 1.385 NM_002796 331 proteasome subunit HsN3||macropain beta chain||proteasome chain 3||proteasome beta chain||proteasome beta 4 subunit||PROTEASOME SUBUNIT, BETA-TYPE, 4||multicatalytic endopeptidase complex beta chain||proteasome subunit, beta type, 4||proteasome (prosome, macropain) subunit, beta type, 4|| REPIN1 ||||REPIN1||replication initiator 1|| 1.378 NM_013400 332 CYB561D1 ||FLJ39035||hypothetical protein 1.377 NM_182580 333 FLJ39035|| ARPC5L ||ARPC5L||actin related protein 2/3 1.367 NM_030978 334 complex, subunit 5-like|| DER1 ||PRO2577||MGC3067||FLJ13784||hypothetical 1.342 NM_018630 335 protein MGC3067|| KELCHL ||FLJ14360||hypothetical protein 1.317 NM_032775 336 FLJ14360|| SCML4 ||SCML4||sex comb on midleg-like 4 1.305 NM_198081 337 (Drosophila)|| KIAA0323 ||KIAA0323|| 1.26 AB002321 338 C11orf31 ||SELH||selenoprotein H|| 1.25 NM_170746 339 B2M ||beta-2-microglobulin||B2M||beta- 1.248 NM_004048 340 2-microglobulin precursor|| COX4I1 ||COXIV||COX4I1||CYTOCHROME c 1.201 NM_001861 341 OXIDASE, SUBUNIT IV, ISOFORM 1||cytochrome c oxidase subunit IV isoform 1||cytochrome c oxidase subunit IV isoform 1 precursor|| RAC1 ||||RAC1||ras-related C3 botulinum 1.186 NM_198829 342 toxin substrate 1 (rho family, small GTP binding protein Rac1)|| COX4I1 ||COXIV||COX4I1||CYTOCHROME c 1.186 NM_001861 343 OXIDASE, SUBUNIT IV, ISOFORM 1||cytochrome c oxidase subunit IV isoform 1||cytochrome c oxidase subunit IV isoform 1 precursor|| KIAA1228 ||KIAA1228||KIAA1228 protein|| 1.134 XM_036408 344 SPRR3 ||esophagin||SPRR3||small proline- 0.863 NM_005416 345 rich protein 3|| SFRS15 ||SFRS15||splicing factor, 0.833 NM_020706 346 arginine/serine-rich 15|| ZCCHC2 ||ZCCHC2||zinc finger, CCHC 0.831 NM_017742 347 domain containing 2|| RGS11 ||RGS11||RS11||regulator of G- 0.815 NM_003834 348 protein signalling 11||REGULATOR OF G PROTEIN SIGNALING 11||regulator of G-protein signalling 11 isoform 1||regulator of G-protein signalling 11 isoform 2|| ZNF505 ||ZNF505||zinc finger protein 505|| 0.813 NM_031218 349 SCAMP4 ||||SCAMP4||secretory carrier 0.793 NM_079834 350 membrane protein 4|| EIF2B4 ||EIF2B4||DKFZp586J0119||EIF2Bdelta 0.759 NM_172195 351 ||EIF2B-DELTA||EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, DELTA||translation initiation factor eIF-2b delta subunit||eukaryotic translation initiation factor 2B, subunit 4 delta, 67 kDa||eukaryotic translation initiation factor 2B, subunit 4 delta short isoform||eukaryotic translation initiation factor 2B, subunit 4 delta long isoform|| SLC12A4 ||KCC1||SLC12A4||POTASSIUM- 0.758 NM_005072 352 CHLORIDE COTRANSPORTER 1||SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 4||solute carrier family 12 (potassium/chloride transporters), member 4|| MGC33607 ||MGC33607||hypothetical protein 0.751 NM_152775 353 MGC33607|| ||Homo sapiens mRNA; cDNA 0.74 AL122093 354 DKFZp434B2115 (from clone DKFZp434B2115) THEA ||THEA||STARD14||THEM1||KIAA0707 0.729 NM_147161 355 BFIT1||THIOESTERASE, ADIPOSE- ASSOCIATED||thioesterase, adipose associated||BROWN FAT-INDUCIBLE THIOESTERASE||brown fat inducible thioesterase||START domain containing 14||thioesterase superfamily member 1||thioesterase, adipose associated isoform BFIT1||thioesterase, adipose associated isoform BFIT2|| SNX3 ||SNX3||SNX3A||SDP3||MGC17570|| 0.727 NM_152828 356 sorting nexin 3||sorting nexin 3A||sorting nexin 3 isoform a||sorting nexin 3 isoform b||sorting nexin 3 isoform c|| HIPK2 ||HIPK2||PRO0593||EC 2.7.1.— 0.708 NM_014075 357 ||Homeodomain-interacting protein kinase 2||homeodomain interacting protein kinase 2|| PPP1CB ||PP- 0.708 NM_002709 358 1B||PPP1CD||MGC3672||3.1.3.16||PPP1CB|| protein phosphatase 1- delta||protein phosphatase 1- beta||serine/threonine protein phosphatase PP1-beta catalytic subunit||protein phosphatase 1, catalytic subunit, beta isoform||protein phosphatase 1, catalytic subunit, delta isoform||protein phosphatase 1, catalytic subunit, beta isoform 1|| SNX3 ||SNX3||SNX3A||SDP3||MGC17570|| 0.702 NM_152828 359 sorting nexin 3||sorting nexin 3A||sorting nexin 3 isoform a||sorting nexin 3 isoform b||sorting nexin 3 isoform c|| EYA3 ||DKFZp686C132||EYA3||eyes 0.699 NM_001990 360 absent 3 isoform a||eyes absent 3 isoform b||eyes absent homolog 3 (Drosophila)||EYES ABSENT, DROSOPHILA, HOMOLOG OF, 3|| ESTs ESTs 0.699 AK025909 361 Data not found 0.698 U55055 362 DPCD ||DPCD||DKFZP566F084||DPCD 0.684 NM_015448 363 protein||deleted in a mouse model of primary ciliary dyskinesia|| TIGA1 ||TIGA1|| 0.675 NM_053000 364 PABPC3 ||PABPL3||PABPC3||PABP3||POLY- 0.663 NM_030979 365 ADENYLATE-BINDING PROTEIN 3||poly(A)-binding protein-like 3||POLYADENYLATE-BINDING PROTEIN-LIKE 3||testis-specific poly(A)-binding protein (PABP)||POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 3||testis- specific poly(A)-binding protein 3||poly(A)-binding protein, cytoplasmic 3||poly(A) binding protein, cytoplasmic 3|| C2orf4 ||||CGI-27||C21orf19-like protein|| 0.662 NM_015955 366 SYT15 ||SYT15||SYNAPTOTAGMIN 15 0.66 NM_031912 367 ||synaptotagmin XV|| PABPC1 ||PABPC1||PABPL1||PAB1||PABP1||POLY- 0.658 NM_002568 368 ADENYLATE-BINDING PROTEIN 1||POLY(A)-BINDING PROTEIN 1||POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 1||poly(A) binding protein, cytoplasmic 1|| RAB2 ||RAB2A||RAB2||RAS-ASSOCIATED 0.656 NM_002865 369 PROTEIN RAB2||RAB2, member RAS oncogene family|| MGC33993 ||MGC33993||hypothetical protein 0.653 NM_152737 370 MGC33993|| SC4MOL ||SC4MOL||DESP4||ERG25||sterol- 0.652 NM_006745 371 C4-methyl oxidase-like||STEROL C4- METHYLOXIDASE-LIKE||C-4 methyl sterol|| KIAA1706 ||KIAA1706||KIAA1706 protein|| 0.65 NM_030636 372 M-RIP ||RHOIP3||M-RIP||KIAA0864||Rho 0.649 NM_015134 373 interacting protein 3||myosin phosphatase-Rho interacting protein||myosin phosphatase-Rho interacting protein isoform 1||myosin phosphatase-Rho interacting protein isoform 2|| C3orf4 ||C3orf4||chromosome 3 open 0.643 NM_019895 374 reading frame 4|| GAB2 ||KIAA0571||GAB2||Grb2- 0.638 NM_012296 375 associated binder 2||GRB2- associated binding protein 2||GRB2- associated binding protein 2 isoform a||GRB2-associated binding protein 2 isoform b|| FLJ10156 ||FLJ10156||hypothetical protein 0.636 NM_019013 376 FLJ10156|| FBXO10 ||FBXO10||F-box protein Fbx10||F- 0.636 XM_291314 377 box only protein 10|| DNASE1 ||DNL1||3.1.21.1||DNASE1||deoxyribonuclease 0.633 NM_005223 378 I||DNase I, LYSOSOMAL|| ROD1 ||ROD1||fission yeast differentiation 0.633 NM_005156 379 regulator||regulator of differentiation (in S. pombe) 1||regulator of differentiation (in S. pombi) 1||ROD1 regulator of differentiation 1 (S. pombe)|| ATP6AP1 ||16A||CF2||ATP6AP1||VATPS1||ATP6S1|| 0.63 NM_001183 380 Ac45||ORF||3.6.3.14||XAP3||ATP6IP1|| XAP-3||H-ATPase subunit||VACUOLAR ATPase SUBUNIT 1||V-ATPase S1 accessory protein||ATPase, H+ TRANSPORTING, LYSOSOMAL, SUBUNIT 1||ATPase, H+ transporting, lysosomal interacting protein 1||ATPase, H+ transporting, lysosomal accessory protein 1||ATPase, H+ transporting, lysosomal accessory protein 1 precursor||ATPase, H+ transporting, lysosomal (vacuolar proton pump), subunit 1|| USP13 ||USP13||IsoT- 0.628 NM_003940 381 3||ISOT3||ISOPEPTIDASE T3||UBIQUITIN-SPECIFIC PROTEASE 13||ubiquitin specific protease 13 (isopeptidase T-3)|| CYB561 ||CYB561||CYTOCHROME 0.628 NM_001915 382 b561||cytochrome b-561|| PGM1 ||5.4.2.2||PGM1||phosphoglucomutase 0.619 NM_002633 383 1|| SAMD8 ||SAMD8||sterile alpha motif domain 0.618 NM_144660 384 containing 8|| IGSF11 ||IGSF11||BTIGSF||immunoglobulin 0.618 NM_152538 385 superfamily, member 11||BRAIN- AND TESTIS-SPECIFIC IMMUNOGLOBULIN SUPERFAMILY PROTEIN|| MAPK13 ||SAPK4||p38delta||PRKM13||p38- 0.617 NM_002754 386 DELTA||MAPK13||mitogen-activated protein kinase 13||stress-activated protein kinase 4||PROTEIN KINASE, MITOGEN-ACTIVATED, 13||mitogen- activated protein kinase p38 delta|| RABGAP1L ||KIAA0471||HHL||expressed in 0.615 NM_014857 387 hematopoietic cells, heart, liver|| QSCN6 ||||QSCN6||quiescin Q6|| 0.607 NM_002826 388 MRPL37 ||MRPL37||mitochondrial ribosomal 0.599 NM_016491 389 protein L37|| RNF12 ||RNF12||RLIM||ring finger protein 0.597 NM_183353 390 12||PUTATIVE RING ZINC FINGER PROTEIN NY-REN-43 ANTIGEN|| DHCR24 ||SELADIN1||DHCR24||seladin- 0.591 NM_014762 391 1||KIAA0018||24- dehydrocholesterol reductase||24- @DEHYDROCHOLESTEROL REDUCTASE||SELECTIVE AD INDICATOR 1||3 beta-hydroxysterol delta 24 reductase|| AOX1 ||1.2.3.1||AOH1||AOX1||aldehyde 0.587 NM_001159 392 oxidase 1|| LOC340171 ||||Hypothetical LOC340171 0.587 BG928045 393 (LOC340171), mRNA|| LOC196264 ||LOC196264||hypothetical protein 0.585 NM_198275 394 LOC196264|| FLJ32421 ||FLJ32421||hypothetical protein 0.584 NM_144695 395 FLJ32421|| ZDHHC15 ||ZDHHC15||zinc finger, DHHC 0.584 NM_144969 396 domain containing 15|| ZC3HDC5 ||ZC3HDC5||zinc finger CCCH type 0.583 XM_036115 397 domain containing 5|| GAS7 ||GAS7||KIAA0394||MGC1348||growth 0.58 NM_201433 398 arrest-specific 7||growth arrest- specific 7 isoform a||growth arrest- specific 7 isoform c||growth arrest- specific 7 isoform b|| 0.576 BF542107 399 ELL2 ||ELL2||ELL-related RNA polymerase 0.575 NM_012081 400 II, elongation factor||elongation factor, RNA polymerase II, 2|| UNC13B ||hmunc13||UNC13B||Unc13h2||UNC13- 0.575 NM_006377 401 LIKE||unc-13-like (C. elegans)|| UNC13 (C. elegans)- like||homolog of rat Munc13 (diacylglycerol-binding)||unc-13 homolog B (C. elegans)|| SPRR3 ||esophagin||SPRR3||small proline- 0.569 NM_005416 402 rich protein 3|| CSTB ||STFB||CST6||CPI- 0.567 NM_000100 403 B||PME||CSTB||liver thiol proteinase inhibitor||cystatin B (stefin B)|| LOC199964 ||LOC199964||hypothetical protein 0.563 NM_182532 404 LOC199964|| C17orf39 ||MGC3048||hypothetical protein 0.562 NM_024052 405 MGC3048|| KRTHA2 ||KRTHA2||hHa2||Ha-2||keratin, 0.561 NM_002278 406 hair, acidic, 2||keratin, hair, acidic, 2||hard keratin, type I, 2||KERATIN, HARD, TYPE I, 2||type I hair keratin 2|| TYRO3 ||Brt||Dtk||RSE||Sky||BYK||Tif||TYRO3|| 0.56 NM_006293 407 PROTEIN TYROSINE KINASE 3||TYRO3 protein tyrosine kinase||tyrosine-protein kinase receptor TYRO3 precursor||Tyro3 protein tyrosine kinase (sea-related receptor tyrosine kinase)|| EPS8L1 ||EPS8L1||EPS8-like 1|| 0.558 NM_133180 408 MAPK13 ||SAPK4||p38delta||PRKM13||p38- 0.554 NM_002754 409 DELTA||MAPK13||mitogen-activated protein kinase 13||stress-activated protein kinase 4||PROTEIN KINASE, MITOGEN-ACTIVATED, 13||mitogen- activated protein kinase p38 delta|| RNMT ||RNMT||RG7MT1||KIAA0398||RNA 0.553 NM_003799 410 GUANINE-7- METHYLTRANSFERASE||RNA (guanine-7-) methyltransferase|| NAP1L2 ||NAP1L2||MGC26243||brain specific 0.551 NM_021963 411 gene BPX||nucleosome assembly protein 1-like 2|| RGS11 ||RGS11||RS11||regulator of G- 0.551 NM_003834 412 protein signalling 11||REGULATOR OF G PROTEIN SIGNALING 11||regulator of G-protein signalling 11 isoform 1||regulator of G-protein signalling 11 isoform 2|| SRPRB RAB6B 0.55 AK055102 413 HTCD37 ||||HTCD37||TcD37 homolog|| 0.545 NM_021222 414 0.544 BX116062 415 HIF1A ||HIF1-ALPHA||HIF1A||MOP1||HIF- 0.541 NM_001530 416 1alpha||ARNT interacting protein||member of PAS superfamily 1||hypoxia-inducible factor 1, alpha subunit isoform 2||hypoxia-inducible factor 1, alpha subunit isoform 1||hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)|| 0.53 BG495068 417 UBE2E2 ||||Hypothetical protein FLJ25157 0.529 NM_152653 418 (FLJ25157), mRNA|| MGC61716 0.524 NM_182501 419 TPM4 ||||TPM4||tropomyosin 4|| 0.524 NM_003290 420 PIM1 ||2.7.1.—||PIM1||pim-1 0.523 NM_002648 421 oncogene||Oncogene PIM1||ONCOGENE PIM 1|| FLJ32421 ||FLJ32421||hypothetical protein 0.523 NM_144695 422 FLJ32421|| PINK1 ||PINK1||PTEN-INDUCED PUTATIVE 0.513 NM_032409 423 KINASE 1||PTEN induced putative kinase 1|| TOM1 ||TOM1||target of myb1 0.513 NM_005488 424 (chicken)||target of myb 1||target of myb1 (chicken) homolog||TARGET OF MYB1, CHICKEN, HOMOLOG OF|| LOC142678 ||skeletrophin||LOC142678|| 0.511 NM_080875 425 CAST ||CAST||MGC9402||calpastatin||heart- 0.51 NM_173060 426 type calpastatin||calpain inhibitor||calpastatin isoform a||calpastatin isoform b||calpastatin isoform c||calpastatin isoform d||sperm BS-17 component|| NPR3 ||NPR3||ANPRC||ATRIONATRIURETIC 0.509 NM_000908 427 PEPTIDE RECEPTOR, TYPE C||ATRIAL NATRIURETIC PEPTIDE CLEARANCE RECEPTOR||natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)|| MYEOV ||OCIM||MYEOV||myeloma 0.509 NM_138768 428 overexpressed gene (in a subset of t(11; 14) positive multiple myelomas)|| IMPA2 ||IMPA2||inositol(myo)-1(or 4)- 0.508 NM_014214 429 monophosphatase 2||MYO- INOSITOL MONOPHOSPHATASE 2|| FLJ13105 0.507 BF510602 430 HIC ||HIC||I-mfa domain-containing 0.504 NM_199072 431 protein||I-mfa domain-containing protein isoform p40|| LOC55971 ||LOC55971||insulin receptor 0.504 NM_018842 432 tyrosine kinase substrate|| DSC2 ||desmocollin- 0.497 NM_004949 433 3||DSC2||DGII/III||DG2/3||CDHF2|| desmocollin 2||DSC3, FORMERLY||desmosomal glycoprotein II/III||DESMOCOLLIN 3, FORMERLY||desmocollin 2 isoform Dsc2b preproprotein||desmocollin 2 isoform Dsc2a preproprotein|| CES4 ||||CES1||carboxylesterase 1 0.496 NM_016280 434 (monocyte/macrophage serine esterase 1)|| EPS8L1 ||EPS8L1||EPS8-like 1|| 0.495 NM_133180 435 DKFZp434C0328 ||DKFZp434C0328||hypothetical 0.493 NM_017577 436 protein DKFZp434C0328|| LOC375035 ||LOC375035||hypothetical protein 0.493 NM_199344 437 LOC375035|| HIC ||HIC||I-mfa domain-containing 0.492 NM_199072 438 protein||I-mfa domain-containing protein isoform p40|| AK3 ||2.7.4.10||AK3||AK4||GTP:AMP 0.49 NM_013410 439 phosphotransferase||adenylate kinase 3||adenylate kinase-3, mitochondrial||ADENYLATE KINASE, MITOCHONDRIAL||adenylate kinase isoenzyme 4, mitochondrial|| M6PR ||CD- 0.486 NM_002355 440 MPR||M6PR||MPR46||SMPR||Mr 46,000 Man6PR||46-kDa mannose 6-phosphate receptor||cation- dependent mannose-6-phosphate receptor precursor||MANNOSE 6- PHOSPHATE RECEPTOR, CATION- DEPENDENT||SMALL MANNOSE 6- PHOSPHATE RECEPTOR||mannose- 6-phosphate receptor (cation dependent)|| RPL18A ||||RPL18A||ribosomal protein 0.486 NM_000980 441 L18a|| EPS8L1 ||EPS8L1||EPS8-like 1|| 0.485 NM_133180 442 AK3 ||2.7.4.10||AK3||AK4||GTP:AMP 0.481 NM_013410 443 phosphotransferase||adenylate kinase 3||adenylate kinase-3, mitochondrial||ADENYLATE KINASE, MITOCHONDRIAL||adenylate kinase isoenzyme 4, mitochondrial|| SOCS6 ||STAI4||SOCS4||CIS4||SOCS6||HSPC060|| 0.48 NM_004232 444 SSI4||STATI4||STAT4||STAT induced STAT inhibitor-4||STAT- INDUCED STAT INHIBITOR 4||cytokine-inducible SH2 protein 4||suppressor of cytokine signaling 6||suppressor of cytokine signaling 4|| C20orf161 ||C20orf161||chromosome 20 open 0.48 NM_033421 445 reading frame 161|| C10orf57 ||FLJ13263||hypothetical protein 0.479 NM_025125 446 FLJ13263|| USP13 ||USP13||IsoT- 0.479 NM_003940 447 3||ISOT3||ISOPEPTIDASE T3||UBIQUITIN-SPECIFIC PROTEASE 13||ubiquitin specific protease 13 (isopeptidase T-3)|| FN5 ||FN5||FN5 protein|| 0.478 NM_020179 448 VARS2L ||DKFZP434L1435||KIAA1885 0.474 NM_020442 449 protein|| CDKN2B ||p14_INK4B||p15(INK4B)||CDKN2B|| 0.474 NM_078487 450 TP15||MTS2||p15_INK4B||CDK4B inhibitor||p14_CDK inhibitor||CDK inhibitory protein||p15 CDK inhibitor||multiple tumor suppressor 2||cyclin-dependent kinase 4 inhibitor B||cyclin-dependent kinase inhibitor 2B isoform 1||cyclin- dependent kinase inhibitor 2B isoform 2||cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)||cyclin-dependent kinases 4 and 6 binding protein|| PR1 ||PR1||voltage-dependent calcium 0.473 NM_183240 451 channel gamma subunit-like protein|| ENC1 ||PIG10||NRPB||ENC1||CCL28||ENC- 0.472 NM_003633 452 1||TP53I10||NUCLEAR RESTRICTED PROTEIN/BRAIN||p53-INDUCED GENE 10||ECTODERMAL-NEURAL CORTEX 1||ectodermal-neural cortex (with BTB-like domain)||nuclear restricted protein, BTB domain-like (brain)||tumor protein p53 inducible protein 10|| HIST2H2BE ||H2B.1||HIST2H2BE||H2B/q||H2BFQ|| 0.467 NM_003528 453 GL105||histone 2, H2be||H2B histone family, member Q||HISTONE 2B FAMILY, MEMBER Q|| FLJ20674 ||||FLJ20674||hypothetical protein 0.463 NM_019086 454 FLJ20674|| CFLAR ||CASH||FLIP||Casper||CFLAR||I- 0.462 NM_003879 455 FLICE||FLAME1||FLAME- 1||CLARP||USURPIN||MRIT||CASPASE- EIGHT-RELATED PROTEIN||FLICE INHIBITORY PROTEIN||MACH- RELATED INDUCER OF TOXICITY||FADD-LIKE ANTIAPOPTOTIC MOLECULE 1||CASP8 and FADD-like apoptosis regulator||CASP8- AND FADD-LIKE APOPTOSIS REGULATOR||FADD-like anti-apoptotic molecule; Inhibitor of FLICE; Caspase-related inducer of apoptosis; Caspase homolog; Caspase-like apoptosis regulatory protein|| PTN ||HARP||HBNF||NEGF1||PTN||HBGF8|| 0.46 NM_002825 456 heparin-binding growth- associated molecule||NEURITE OUTGROWTH-PROMOTING FACTOR, HEPARIN-BINDING||HEPARIN- BINDING GROWTH FACTOR 8||heparin affin regulatory protein||pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)|| HOMER2 ||cupidin||HOMER2||HOMER- 0.46 NM_004839 457 2||Vesl-2||ACPD||homer homolog 2 (Drosophila)||HOMER 2B HOMER 2A||homer homolog 3 (Drosophila)||homer 2 isoform 1||homer, neuronal immediate early gene, 2|| MGLL ||lysophospholipase- 0.458 NM_007283 458 like||MGLL||HU-K5||monoglyceride lipase|| SLC16A9 ||SLC16A9||solute carrier family 16 0.458 NM_194298 459 (monocarboxylic acid transporters), member 9|| FLJ20674 ||||FLJ20674||hypothetical protein 0.456 NM_019086 460 FLJ20674|| MYOZ1 ||MYOZ1||myozenin 1||CALSARCIN 0.452 NM_021245 461 2|| 0.445 BC033124 462 RAP2A ||KREV||RAP2A||RbBP-30||RAS- 0.439 NM_021033 463 RELATED PROTEIN 2A||RAP2A, member of RAS oncogene family||RAP2, member of RAS oncogene family (K-rev)|| ELL2 ||ELL2||ELL-related RNA polymerase 0.431 NM_012081 464 II, elongation factor||elongation factor, RNA polymerase II, 2|| WASL ||MGC48327||N- 0.427 NM_003941 465 WASP||WASL||Wiskott-Aldrich syndrome-like||Wiskott-Aldrich syndrome gene-like protein||neural Wiskott-Aldrich syndrome protein|| HIC ||HIC||I-mfa domain-containing 0.426 NM_199072 466 protein||I-mfa domain-containing protein isoform p40|| MGC61716 Homo sapiens cDNA FLJ30912 fis, 0.426 NM_182501 467 clone FEBRA2006346 PTP4A1 ||PTP4A1||PRL1||PTPCAAX1||PTP(CAAX1) 0.424 NM_003463 468 ||PRL-1||HH72||Protein tyrosine phosphatase IVA1||PHOPHATASE OF REGENERATING LIVER 1||PROTEIN- TYROSINE PHOSPHATASE, TYPE 4A, 1||protein tyrosine phosphatase type IVA, member 1|| GP1BB ||GP1BB||CD42c||GP Ib, BETA 0.423 NM_000407 469 SUBUNIT||glycoprotein Ib beta polypeptide precursor||glycoprotein Ib (platelet), beta polypeptide||PLATELET GLYCOPROTEIN Ib, BETA POLYPEPTIDE||GLYCOPROTEIN Ib, PLATELET, BETA POLYPEPTIDE|| PELI1 ||PELI1||pellino homolog 1 0.423 NM_020651 470 (Drosophila)|| PRKWNK1 ||PHA2C||PRKWNK1||PROTEIN 0.414 NM_018979 471 KINASE, LYSINE-DEFICIENT 1||KDP PSEUDOHYPOALDOSTERONISM, TYPE IIC||protein kinase, lysine deficient 1|| AMFR ||RNF45||GP78||AMFR||autocrine 0.408 NM_001144 472 motility factor receptor||autocrine motility factor receptor isoform a||autocrine motility factor receptor isoform b|| HPSE ||heparanase||HSE1||HPSE||HPSE1|| 0.403 NM_006665 473 HPR1||heparanase-1||HPA|| ST7L 0.402 AK128799 474 CYP2C18 ||CYP2C18||1.14.14.1||P450IIC17|| 0.402 NM_000772 475 P450- 6B/29C||CYP2C17||CPCI||microsomal monooxygenase||flavoprotein- linked monooxygenase||CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 18||cytochrome P450, family 2, subfamily C, polypeptide 18||cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17||cytochrome P450, subfamily IIC (mephenytoin 4- hydroxylase), polypeptide 18|| ITCH ||ITCH||AIP4||NAPP1||ATROPHIN-1- 0.396 NM_031483 476 INTERACTING PROTEIN 4||NFE2- ASSOCIATED POLYPEPTIDE 1||ITCHY, MOUSE, HOMOLOG OF||itchy homolog E3 ubiquitin protein ligase (mouse)|| PPP2R2C ||PPP2R2C||PR52||IMYPNO1||MGC33570|| 0.392 NM_020416 477 PP2A, subunit B, PR55- gamma isoform||PP2A, subunit B, B55-gamma isoform||PP2A, subunit B, R2-gamma isoform||PP2A, subunit B, B-gamma isoform||protein phosphatase 2A1 B gamma subunit||phosphoprotein phosphatase 2A BR gamma regulatory chain||PROTEIN PHOSPHATASE 2A, REGULATORY SUBUNIT B, GAMMA ISOFORM||gamma isoform of regulatory subunit B55, protein phosphatase 2 isoform b||Serine/threonine protein phosphatase 2A, 55 KDA regulatory subunit B, gamma isoform||gamma isoform of regulatory subunit B55, protein phosphatase 2 isoform a||protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform|| CCDC6 ||CCDC6||TPC||H4 0.392 NM_005436 478 GENE||D10S170/H4 FUSION GENE||TRANSFORMING SEQUENCE, THYROID 1||coiled-coil domain containing 6||TST1 PTC1 CHIMERIC ONCOGENE|| UACA ||UACA||uveal autoantigen with 0.391 NM_018003 479 coiled-coil domains and ankyrin repeats|| C20orf161 ||C20orf161||chromosome 20 open 0.389 NM_033421 480 reading frame 161|| 0.385 AK024250 481 DPCR1 ||DPCR1||PBLT||PANBRONCHIOLITIS, 0.384 NM_080870 482 DIFFUSE||diffuse panbronchiolitis critical region 1|| FLJ39501 ||FLJ39501||hypothetical protein 0.382 NM_173483 483 FLJ39501|| PFN2 ||D3S1319E||PFN2||profilin- 0.381 NM_053024 484 2||PFL||profilin 2||profilin 2 isoform a||profilin 2 isoform b|| C10orf57 ||FLJ13263||hypothetical protein 0.376 NM_025125 485 FLJ13263|| GSTA4 ||GSTA4||GSTA4- 0.376 NM_001512 486 4||2.5.1.18||GTA4||GST class- alpha||glutathione S- aralkyltransferase A4||S- (hydroxyalkyl)glutathione lyase A4||GLUTATHIONE S- TRANSFERASE, ALPHA- 4||glutathione transferase A4- 4||glutathione S-transferase A4||glutathione S-aryltransferase A4||glutathione S-alkyltransferase A4||glutathione S-transferase, alpha 4|| DHRS1 ||DHRS1||dehydrogenase/reductase 0.359 NM_138452 487 (SDR family) member 1|| SLC7A5 ||SLC7A5||MPE16||D16S469E||CD98|| 0.358 NM_003486 488 LAT1||4F2 light chain||Membrane protein E16||L-TYPE AMINO ACID TRANSPORTER 1||Solute carrier family 7, member 5||solute carrier family 7 (cationic amino acid transporter, y+ system), member 5|| LTB4DH ||LTB4DH||MGC34943||leukotriene 0.358 NM_012212 489 B4 12- hydroxydehydrogenase||NADP- dependent leukotriene B4 12- hydroxydehydrogenase|| SDR-O ||SDR-O||orphan short-chain 0.358 NM_148897 490 dehydrogenase/reductase|| SMPDL3A ||FLJ20177||yR36GH4.1||ASM3A|| 0.357 NM_006714 491 0610010C24Rik||SMPDL3A||ASML3a|| sphingomyelin phosphodiesterase, acid-like 3A||acid sphingomyelinase- like phosphodiesterase 3A|| DEPDC6 ||DEPDC6||DEP domain containing 0.356 NM_022783 492 6|| CAP2 ||2810452G09Rik||CAP2||adenylyl 0.355 NM_006366 493 cyclase-associated protein 2||CAP, adenylate cyclase-associated protein, 2 (yeast)|| TUBB ||M40||TUBB||tubulin, beta 0.355 NM_001069 494 polypeptide|| SLC16A6 ||MCT6||SLC16A6||monocarboxylate 0.353 NM_004694 495 transporter 6||solute carrier family 16, member 6||SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 6||solute carrier family 16 (monocarboxylic acid transporters), member 6|| FLJ13910 ||FLJ13910||hypothetical protein 0.348 NM_022780 496 FLJ13910|| TMOD3 ||UTMOD||TMOD3||TROPOMODULIN, 0.346 NM_014547 497 UBIQUITOUS||tropomodulin 3 (ubiquitous)|| PHGDH ||3PGDH||PHGDH||PDG||PGAD||SERA|| 0.343 NM_006623 498 MGC3017||3- @PHOSPHOGYLCERATE DEHYDROGENASE||3- phosphoglycerate dehydrogenase||phosphoglycerate dehydrogenase|| ARG2 ||ARG2||3.5.3.1||A-II||kidney 0.334 NM_001172 499 arginase||nonhepatic arginase||L- arginine amidinohydrolase||L- arginine ureahydrolase||ARGINASE II||arginase, type II||arginase, type II precursor|| NUCB2 ||NUCB2||NEFA||nucleobindin 2|| 0.331 NM_005013 500 SPRR2B ||SPR-2B||SPRR2B||Small proline- 0.331 NM_006945 501 rich protein 2B|| NHLH2 ||NSCL2||NHLH2||HEN2||NEURONAL 0.329 NM_005599 502 SCL-LIKE PROTEIN 2||nescient helix loop helix 2|| AMACR ||AMACR||5.1.99.4||ALPHA- 0.328 NM_014324 503 METHYLACYL-CoA RACEMASE||AMACR DEFICIENCY||AMACR ALPHA- METHYLACYL-CoA RACEMASE DEFICIENCY||alpha-methylacyl-CoA racemase isoform 1||alpha- methylacyl-CoA racemase isoform 2|| FLJ40432 ||FLJ40432||hypothetical protein 0.314 NM_152523 504 FLJ40432|| PRKWNK1 ||PHA2C||PRKWNK1||PROTEIN 0.302 NM_018979 505 KINASE, LYSINE-DEFICIENT 1||KDP PSEUDOHYPOALDOSTERONISM, TYPE IIC||protein kinase, lysine deficient 1|| TP53I3 ||TP53I3||PIG3||quinone 0.3 NM_004881 506 oxidoreductase homolog||p53- induced gene 3 protein||tumor protein p53 inducible protein 3|| CST6 ||CST6||cystatin 6||cystatin 0.3 NM_001323 507 E/M||CYSTATIN M/E||cystatin M precursor|| ZNF101 ||ZNF101||zinc finger protein 101|| 0.29 NM_033204 508 FLJ25179 ||FLJ25179||hypothetical protein 0.286 NM_144670 509 FLJ25179|| RFK ||FLJ11149||riboflavin kinase|| 0.282 NM_018339 510 AKR1C3 ||HA1753||1.1.1.188||DD3||hluPGFS|| 0.281 NM_003739 511 HSD17B5||1.3.1.20||1.1.1.213|| AKR1C3||KIAA0119||HAKRB||HAKRe|| trans-1,2-dihydrobenzene-1,2- diol dehydrogenase||chlordecone reductase homolog||dihydrodiol dehydrogenase 3||prostaglandin F synthase||ALDO-KETO REDUCTASE B||3-@ALPHA-HYDROXYSTEROID DEHYDROGENASE, TYPE II||hydroxysteroid (17-beta) dehydrogenase 5||type IIb 3-alpha hydroxysteroid dehydrogenase||aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)|| AKR1C1 ||1.1.1.213||2-ALPHA- 0.281 NM_001353 512 HSD||1.3.1.20||20-ALPHA- HSD||MGC8954||H- 37||HAKRC||MBAB||C9||DDH1||AKR1C1|| trans-1,2-dihydrobenzene-1,2- diol dehydrogenase||chlordecone reductase homolog||aldo-keto reductase C||20 alpha- hydroxysteroid dehydrogenase||hepatic dihydrodiol dehydrogenase||dihydrodiol dehydrogenase isoform DD1||type II 3-alpha-hydroxysteroid dehydrogenase||DIHYDRODIOL DEHYDROGENASE, TYPE I||ALDO- KETO REDUCTASE FAMILY 1, MEMBER 1||aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3- alpha)-hydroxysteroid dehydrogenase)|| NQO1 ||NMORI||diaphorase- 0.28 NM_000903 513 4||NQO1||QR1||DTD||DHQU||NMOR1|| DIA4||DIAPHORASE 4||NAD(P)H dehydrogenase, quinone 1||diaphorase (NADH/NADPH) (cytochrome b-5 reductase)||NAD(P)H:menadione oxidoreductase 1, dioxin-inducible 1||NAD(P)H menadione oxidoreductase 1, dioxin-inducible|| LOC283824 ||LOC283824||hypothetical protein 0.279 BX647541 514 LOC283824|| C6orf56 ||C6orf56||KIAA0680||KIAA0680 0.268 NM_014721 515 gene product||chromosome 6 open reading frame 56|| FAM43A ||FLJ90022||hypothetical protein 0.263 NM_153690 516 FLJ90022|| SH3GL3 ||EEN- 0.26 NM_003027 517 B2||SH3D2C||SH3GL3||SH3p13||HsT19371|| CNSA3||ENDOPHILIN A3||SH3-domain GRB2-like 3||SH3 DOMAIN, GRB2-LIKE, 3|| AKR1C1 ||1.1.1.213||2-ALPHA- 0.257 NM_001353 518 HSD||1.3.1.20||20-ALPHA- HSD||MGC8954||H- 37||HAKRC||MBAB||C9||DDH1||AKR1C1|| trans-1,2-dihydrobenzene-1,2- diol dehydrogenase||chlordecone reductase homolog||aldo-keto reductase C||20 alpha- hydroxysteroid dehydrogenase||hepatic dihydrodiol dehydrogenase||dihydrodiol dehydrogenase isoform DD1||type II 3-alpha-hydroxysteroid dehydrogenase||DIHYDRODIOL DEHYDROGENASE, TYPE I||ALDO- KETO REDUCTASE FAMILY 1, MEMBER 1||aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3- alpha)-hydroxysteroid dehydrogenase)|| AKR1C2 ||BABP||DD2||1.3.1.20||HBAB||1.1.1.213|| 0.256 NM_001354 519 HAKRD||MCDR2||AKR1C2||DDH2|| AKR1C-pseudo||pseudo- chlordecone reductase||trans-1,2- dihydrobenzene-1,2-diol dehydrogenase||chlordecone reductase homolog||ALDO-KETO REDUCTASE D||3-@ALPHA- HYDROXYSTEROID DEHYDROGENASE, TYPE III||type III 3-alpha-hydroxysteroid dehydrogenase||DIHYDRODIOL DEHYDROGENASE, TYPE II||type II dihydrodiol dehydrogenase||aldo- keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)|| C20orf161 ||C20orf161||chromosome 20 open 0.255 NM_033421 520 reading frame 161|| ACPP ||3.1.3.2||ACPP||PAP||acid 0.254 NM_001099 521 phosphatase, prostate||PHOSPHATASE, PROSTATE-SPECIFIC ACID||prostatic acid phosphatase precursor|| AKR1C2 ||BABP||DD2||1.3.1.20||HBAB||1.1.1.213|| 0.251 NM_001354 522 HAKRD||MCDR2||AKR1C2||DDH2|| AKR1C-pseudo||pseudo- chlordecone reductase||trans-1,2- dihydrobenzene-1,2-diol dehydrogenase||chlordecone reductase homolog||ALDO-KETO REDUCTASE D||3-@ALPHA- HYDROXYSTEROID DEHYDROGENASE, TYPE III||type III 3-alpha-hydroxysteroid dehydrogenase||DIHYDRODIOL DEHYDROGENASE, TYPE II||type II dihydrodiol dehydrogenase||aldo- keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)|| ASAH3 ||ASAH3||N-acylsphingosine 0.251 NM_133492 523 amidohydrolase (alkaline ceramidase) 3|| C9orf58 ||C9orf58||chromosome 9 open 0.25 NM_031426 524 reading frame 58|| NQO1 ||NMORI||diaphorase- 0.248 NM_000903 525 4||NQO1||QR1||DTD||DHQU||NMOR1|| DIA4||DIAPHORASE 4||NAD(P)H dehydrogenase, quinone 1||diaphorase (NADH/NADPH) (cytochrome b-5 reductase)||NAD(P)H:menadione oxidoreductase 1, dioxin-inducible 1||NAD(P)H menadione oxidoreductase 1, dioxin-inducible|| S100A12 ||MRP6||CAAF1||ENRAGE||CGRP||S100A12|| 0.247 NM_005621 526 CALGRANULIN-RELATED PROTEIN||S100 calcium-binding protein A12||CALCIUM-BINDING PROTEIN IN AMNIOTIC FLUID||EXTRACELLULAR NEWLY IDENTIFIED RAGE-BINDING PROTEIN||S100 calcium binding protein A12 (calgranulin C)|| 0.247 BG218400 527 PCSK5 ||PC6A||3.4.21.—|| 0.246 NM_006200 528 PCSK5||SPC6||protease PC6||proprotein convertase PC5||subtilisin/kexin-like protease PC5||prohormone convertase 5||PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 5||Proprotein convertase subtilisin/kexin type 5||proprotein convertase subtilisin/kexin type 5 preproprotein|| EML1 ||ELP79||EMAPL||EML1||HuEMAP||ECHI- 0.244 NM_004434 529 NODERM MICROTUBULE- ASSOCIATED PROTEIN-LIKE 1||echinoderm microtubule associated protein like 1|| NQO1 ||NMORI||diaphorase- 0.241 NM_000903 530 4||NQO1||QR1||DTD||DHQU||NMOR1|| DIA4||DIAPHORASE 4||NAD(P)H dehydrogenase, quinone 1||diaphorase (NADH/NADPH) (cytochrome b-5 reductase)||NAD(P)H:menadione oxidoreductase 1, dioxin-inducible 1||NAD(P)H menadione oxidoreductase 1, dioxin-inducible|| DPCR1 ||DPCR1||PBLT||PANBRONCHIOLITIS, 0.238 NM_080870 531 DIFFUSE||diffuse panbronchiolitis critical region 1|| C6orf33 ||MPRB||LMPB1||C6orf33||MEMBRANE 0.232 NM_133367 532 PROGESTIN RECEPTOR, BETA||LYSOSOMAL MEMBRANE PROTEIN, BRAIN-EXPRESSED, 1||chromosome 6 open reading frame 33|| BNIP3 ||BNIP3||BCL2/adenovirus E1B 0.23 NM_004052 533 19 kD-interacting protein 3||BCL2/adenovirus E1B 19 kDa interacting protein 3||BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 3||BCL2/adenovirus E1B 19 kD interacting protein 3||BCL2/adenovirus E1B 19-kDa protein-interacting protein 3|| C6orf33 ||MPRB||LMPB1||C6orf33||MEMBRANE 0.228 NM_133367 534 PROGESTIN RECEPTOR, BETA||LYSOSOMAL MEMBRANE PROTEIN, BRAIN-EXPRESSED, 1||chromosome 6 open reading frame 33|| FLJ40432 ||FLJ40432||hypothetical protein 0.227 NM_152523 535 FLJ40432|| na 0.218 XM_379456 536 RDH12 ||RDH12||retinol dehydrogenase 12 0.216 NM_152443 537 (all-trans and 9-cis)|| C9orf58 ||C9orf58||chromosome 9 open 0.215 NM_031426 538 reading frame 58|| MGC11324 ||MGC11324||hypothetical protein 0.212 NM_032717 539 MGC11324|| PCSK5 ||PC6A||3.4.21.—|| 0.212 NM_006200 540 PCSK5||SPC6||protease PC6||proprotein convertase PC5||subtilisin/kexin-like protease PC5||prohormone convertase 5||PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 5||proprotein convertase subtilisin/kexin type 5||proprotein convertase subtilisin/kexin type 5 preproprotein|| HSPA2 ||HSPA1A||heat shock-induced 0.211 U56725 541 protein||HEAT-SHOCK 70-KD PROTEIN 1A||dnaK-type molecular chaperone HSP70-1||HEAT-SHOCK PROTEIN, 70-KD, 1||heat shock 70 kDa protein 1A||heat shock 70 kD protein 1A|| ZNF426 ||ZNF426||zinc finger protein 426|| 0.209 NM_024106 542 BPGM 0.205 BG030612 543 ME1 ||MES||1.1.1.40||HUMNDME||ME1|| 0.204 NM_002395 544 pyruvic-malic carboxylase||MALIC ENZYME, SOLUBLE||Malic enzyme, cytoplasmic||NADP-dependent malic enzyme||cytosolic malic enzyme 1||MALATE DEHYDROGENASE, NADP(+)-DEPENDENT, SOLUBLE||malic enzyme 1, soluble||MALIC ENZYME, NADP(+)- DEPENDENT, CYTOSOLIC||malic enzyme 1, NADP(+)-dependent, cytosolic|| LOC284233 0.202 BC037172 545 FNDC4 ||FNDC4||fibronectin type III 0.2 NM_022823 546 domain containing 4|| ACPP ||3.1.3.2||ACPP||PAP||acid 0.199 NM_001099 547 phosphatase, prostate||PHOSPHATASE, PROSTATE-SPECIFIC ACID||prostatic acid phosphatase precursor|| LOC56901 ||LOC56901||NADH:ubiquinone 0.194 NM_020142 548 oxidoreductase MLRQ subunit homolog|| FLJ21511 ||FLJ21511||hypothetical protein 0.191 NM_025087 549 FLJ21511|| PCSK5 ||PC6A||3.4.21.—|| 0.19 NM_006200 550 PCSK5||SPC6||protease PC6||proprotein convertase PC5||subtilisin/kexin-like protease PC5||prohormone convertase 5||PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 5||proprotein convertase subtilisin/kexin type 5||proprotein convertase subtilisin/kexin type 5 preproprotein|| ME1 ||MES||1.1.1.40||HUMNDME||ME1|| 0.186 NM_002395 551 pyruvic-malic carboxylase||MALIC ENZYME, SOLUBLE||Malic enzyme, cytoplasmic||NADP-dependent malic enzyme||cytosolic malic enzyme 1||MALATE DEHYDROGENASE, NADP(+)-DEPENDENT, SOLUBLE||malic enzyme 1, soluble||MALIC ENZYME, NADP(+)- DEPENDENT, CYTOSOLIC||malic enzyme 1, NADP(+)-dependent, cytosolic|| ZNF365 ||ZNF365C||ZNF365D||KIAA0844||ZNF365|| 0.173 NM_199450 552 TALN||talanin||ZNF365B||ZNF365 ZNF365A||zinc finger protein 365||zinc finger protein 365 isoform B||zinc finger protein 365 isoform C||zinc finger protein 365 isoform D|| KRTAP3-2 ||KRTAP3-2||keratin associated 0.167 NM_031959 553 protein 3-2|| SYNPO2L ||SYNPO2L||synaptopodin 2-like|| 0.166 NM_024875 554 BNIP3 ||BNIP3||BCL2/adenovirus E1B 0.166 NM_004052 555 19 kD-interacting protein 3||BCL2/adenovirus E1B 19 kDa interacting protein 3||BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 3||BCL2/adenovirus E1B 19 kD interacting protein 3||BCL2/adenovirus E1B 19-kDa protein-interacting protein 3|| CRYAB ||CTPP2||CRYAB||CRYSTALLIN, 0.158 NM_001885 556 ALPHA-B||CRYSTALLIN, ALPHA- 2||crystallin, alpha B||heat-shock 20 kD like-protein||CRYA2 CATARACT, POSTERIOR POLAR 2|| FLJ21511 ||FLJ21511||hypothetical protein 0.154 NM_025087 557 FLJ21511|| HIG2 ||HIG2||hypoxia-inducible protein 0.148 NM_013332 558 2|| SYNPO2L ||SYNPO2L||synaptopodin 2-like|| 0.139 NM_024875 559 IGFL1 ||APRG644||UNQ644|| 0.138 NM_198541 560 FLJ40201 ||FLJ40201||hypothetical protein 0.129 NM_152607 561 FLJ40201|| ECG2 ||ECG2||esophagus cancer-related 0.128 NM_032566 562 gene-2|| ALOX12 ||12(S)-lipoxygenase||12- 0.105 NM_000697 563 @LIPOXYGENASE||1.13.11.31||ALOX12|| LOG12||12@LO||ARACHIDONATE 12- OXIDOREDUCTASE||arachidonate 12-lipoxygenase|| EPB41L3 ||DAL1||KIAA0987||EPB41L3||4.1B|| 0.0956 NM_012307 564 DAL-1||NONERYTHROID PROTEIN 4.1, BRAIN TYPE||erythrocyte membrane protein band 4.1-like 3||differentially expressed in adenocarcinoma of the lung|| SNX19 ||KIAA0254||CHET8||SNX19||sorting 0.0946 NM_014758 565 nexin 19||KIAA0254 gene product|| P11 ||PRSS26-PENDING||P11||PP11||22 0.0934 NM_006025 566 serine protease||26 serine protease||placental protein 11 precursor|| CES4 ||||CES1||carboxylesterase 1 0.0881 NM_016280 567 (monocyte/macrophage serine esterase 1)|| EPB41L3 ||DAL1||KIAA0987||EPB41L3||4.1B|| 0.0709 NM_012307 568 DAL-1||NONERYTHROID PROTEIN 4.1, BRAIN TYPE||erythrocyte membrane protein band 4.1-like 3||differentially expressed in adenocarcinoma of the lung|| EPB41L3 ||DAL1||KIAA0987||EPB41L3||4.1B|| 0.0687 NM_012307 569 DAL-1||NONERYTHROID PROTEIN 4.1, BRAIN TYPE||erythrocyte membrane protein band 4.1-like 3||differentially expressed in adenocarcinoma of the lung|| GYS2 ||GYS2||2.4.1.11||LIVER GLYCOGEN 0.0662 NM_021957 570 SYNTHASE||GLYCOGEN SYNTHASE, LIVER||glycogen synthase 2 (liver)|| CDA ||3.5.4.5||CDA||CDD||cytidine 0.0587 NM_001785 571 deaminase|| 0.0555 BF514741 572 0.0387 AK125406 573 CRISP3 ||dJ442L6.3||CRS3||CRISP- 0.0306 NM_006061 574 3||SGP28||Aeg2||CRISP3||cysteine- rich secretory protein-3||cysteine- rich secretory protein 3||specific granule protein (28 kDa)||

TABLE 2 Patient characteristics^(a) Maximum Age Esophageal Eosinophil Expansion of Allergic Patient Sex (year) Disease Treatment number/hpf basal layer SPT/A^(b) SPT/F^(b) Disease^(c) 1 M 11 NL None 0 No Unk Unk Unk 2 F 9 NL None 0 No 1 3 Yes 3 F 6 NL LTRA 0 No Unk Unk Unk 4 F 13 NL None 0 No 0 0 No 5 M 10 NL None 0 No Unk Unk Unk 6 F 4 NL LTRA 0 No Unk Unk Unk 7 M 6 CE PPI 0 Yes Unk Unk Unk 8 M 17 CE PPI 0 Yes Unk Unk Unk 9 F 14 CE LTRA 3 Yes 0 0 No 10 F 12 CE None 3 Yes Unk Unk Unk 11 F 11 CE LTRA + PPI 6 Yes Unk Unk Unk 12 M 11 EE PPI 24 Yes 2 4 Yes 13 F 4 EE PPI 25 Yes 0 0 No 14 M 15 EE None 30 Yes 1 1 Yes 15 M 15 EE None 31 Yes 2 0 Yes 16 M 13 EE PPI 32 Yes 0 0 No 17 M 6 EE PPI 40 Yes 3 1 Yes 18 M 13 EE LTRA 42 Yes 4 4 Yes 19 F 16 EE LTRA + PPI 50 Yes 0 0 No 20 M 15 EE None 51 Yes 0 0 No 21 M 3 EE PPI 56 Yes 1 4 Yes 22 F 14 EE PPI 72 Yes 3 3 Yes 23 M 2 EE None 83 Yes 0 4 Yes 24 F 4 EE PPI 218 Yes 2 4 Yes ^(a)Patient characteristics at the time the biopsy sample was obtained. ^(b)The number of positive skin prick test to foods (SPT/F) or aeroallergens (SPT/A) are reported on a 0-4 scale as described in the Methods. ^(c)History of past or present atopic dermatitis, allergic rhinitis, or asthma. Abbreviations: M, male; F, female; NL, normal; CE, Chronic Esophagitis; EE, Eosinophilic Esophagitis; LTRA, Leukotriene Receptor Antagonist; PPI, proton pump inhibitor; Unk, unknown.

TABLE 3 Gene ontology of the upregulated genes in the EE transcript signature Classification COUNT % Total upregulated 344 CLASSIFIED (biological process) 270 100 RESPONSE TO PEST/PATHOGEN/PARASITE 26 9.6 RESPONSE TO STRESS 30 11.1 INFLAMMATORY RESPONSE 13 4.8 POSITIVE REGULATION OF I-KAPPAB 8 3 KINASE/NF-KAPPAB CASCADE RESPONSE TO WOUNDING 14 5.2 POSITIVE REGULATION OF SIGNAL 8 3 TRANSDUCTION CELL COMMUNICATION 70 25.8 SIGNAL TRANSDUCTION 59 21.8 RESPONSE TO BIOTIC STIMULUS 49 18.1 PROTEIN KINASE CASCADE 12 4.4 HUMORAL IMMUNE RESPONSE 9 3.3 IMMUNE RESPONSE 44 16.2 RESPONSE TO EXTERNAL STIMULUS 54 19.9 APOPTOSIS 14 5.2 CARBOXYLIC ACID BIOSYNTHESIS 5 1.8 ORGANIC ACID BIOSYNTHESIS 5 1.8 PROTEOLYSIS AND PEPTIDOLYSIS 17 6.3 ICOSANOID METABOLISM 4 1.5 MONOCARBOXYLIC ACID TRANSPORT 3 1.1 CATABOLISM 22 8.1 PROTEIN CATABOLISM 17 6.3 COMPLEMENT ACTIVATION 4 1.5 CELL ADHESION 17 6.3 ANTIGEN PROCESSING, ENDOGENOUS 3 1.1 ANTIGEN VIA MHC CLASS I MACROMOLECULE CATABOLISM 18 6.6 FATTY ACID BIOSYNTHESIS 4 1.5 ICOSANOID BIOSYNTHESIS 3 1.1 FATTY ACID METABOLISM 6 2.2 BLOOD COAGULATION 5 1.8 HEMOSTASIS 5 1.8 CHOLESTEROL METABOLISM 4 1.5 LIPID METABOLISM 13 4.8 ANION TRANSPORT 7 2.6 STEROL METABOLISM 4 1.5 REGULATION OF BODY FLUIDS 5 1.8 CLASSIFIED (molecular function) 271 100 SIGNAL TRANSDUCER ACTIVITY 60 22.1 SCAVENGER RECEPTOR ACTIVITY 5 1.8 OXIDOREDUCTASE ACTIVITY, ACTING ON 4 1.5 THE CH—NH2 GROUP OF DONORS PEPTIDE TRANSPORTER ACTIVITY 3 1.1 PROTEIN BINDING 37 13.7 PEPTIDASE ACTIVITY 16 5.9 ENDOPEPTIDASE ACTIVITY 13 4.8 CHYMOTRYPSIN ACTIVITY 6 2.2 OBSOLETE MOLECULAR FUNCTION 15 5.5 TRYPSIN ACTIVITY 6 2.2 PROTEASOME ENDOPEPTIDASE ACTIVITY 3 1.1 GLYCOSAMINOGLYCAN BINDING 5 1.8 INTERLEUKIN RECEPTOR ACTIVITY 3 1.1 RECEPTOR ACTIVITY 38 14 INTERLEUKIN BINDING 3 1.1 ENZYME ACTIVATOR ACTIVITY 6 2.2 OLIGOPEPTIDE TRANSPORTER ACTIVITY 2 0.7 The functional annotations are generated by subjecting the data to DAVID software with the GoCharts (gene ontology charts) functional algorithm. Analysis is based on biological processes and molecular functions.

TABLE 4 Gene ontology of the downregulated genes of the EE transcript signature Classification COUNT % Total downregulated 230 CLASSIFIED (biological process) 180 100 CARBOXYLIC ACID METABOLISM 11 6.1 ORGANIC ACID METABOLISM 11 6.1 METABOLISM 75 41.7 INTRACELLULAR SIGNALING CASCADE 16 8.9 FATTY ACID METABOLISM 5 2.8 ICOSANOID METABOLISM 3 1.7 MORPHOGENESIS 16 8.9 PROTEIN KINASE CASCADE 6 3.3 CLASSIFIED (molecular function) 180 100 CATALYTIC ACTIVITY 63 35 OXIDOREDUCTASE ACTIVITY, ACTING ON 6 3.3 CH—OH GROUP OF DONORS ENZYME INHIBITOR ACTIVITY 8 4.4 SERINE ESTERASE ACTIVITY 3 1.7 ACTIN BINDING 7 3.9 OXIDOREDUCTASE ACTIVITY 16 8.9 CARBOXYLESTERASE ACTIVITY 3 1.7 ENZYME REGULATOR ACTIVITY 11 6.1 CYTOSKELETAL PROTEIN BINDING 7 3.9 TRANS-1,2-DIHYDROBENZENE-1,2-DIOL 2 1.1 DEHYDROGENASE ACTIVITY HYDROLASE ACTIVITY, ACTING ON ESTER 11 6.1 BONDS ENDOPEPTIDASE INHIBITOR ACTIVITY 5 2.8 PROTEASE INHIBITOR ACTIVITY 5 2.8 CARBOXYLIC ACID TRANSPORTER ACTIVITY 4 2.2 ORGANIC ACID TRANSPORTER ACTIVITY 4 2.2 CYTOCHROME-B5 REDUCTASE ACTIVITY 2 1.1 POLY(A) BINDING 2 1.1 PHOSPHORIC MONOESTER HYDROLASE 6 3.3 ACTIVITY PHOSPHOPROTEIN PHOSPHATASE ACTIVITY 5 2.8 MAGNESIUM ION BINDING 5 2.8 The functional annotations are generated by subjecting the data to DAVID software with the GoCharts (gene ontology charts) functional algorithm. Analysis is based on biological processes and molecular functions.

TABLE 5 Number of genes obtained using Welch and Student T-Test, Pearson correlation test and fold change filter. fold change fold change 2 3 5 10 NLvs EE 1146 382 124 42 NLvs CE 25 7 0 0 p value 0.05 0.01 0.005 0.001 NLvs EE Welch T test 9063 4183 3034 1527 student T test 7707 3283 2295 1017 Welch T test + FDR 1928 574 333 69 student T test + FDR 958 236 134 59 NLvs CE Welch T test 1432 163 73 8 student T test 1618 216 105 8 Welch T test + FDR 0 0 0 0 student T test + FRD 0 0 0 0 EE Atopic vs EE non-Atopic Welch T test 1403 200 90 13 student T test 1543 216 88 14 Welch T test + FDR 0 0 0 0 student T test + FDR 0 0 0 0 EE female vs EE male Welch T test 4158 857 434 75 student T test 4185 691 298 49 Welch T test + FDR 1 1 1 1 student T test + FDR 8 5 5 5 p value Pearson correlation 0.05 0.01 0.005 0.001 0.0005 Correlation to eosinophils 6261 2757 1943 899 615 Correlation to age 2257 334 136 16 10 Abbreviation: False rate discovery correction (FDR); EE, Eosinophilic esophagitis; CE, Chronic esophagitis; NL, normal.

TABLE 6 Genes significantly different in EE and CE compared to NL Fold Genbank Common Increase Accession Name Description in EE number 2.432 AK095791 LOC132430 2.047 XR_000195 ARRDC2 ||CLONE24945||PP2703||ARRDC2|| 1.887 NM_015683 arrestin domain containing 2|| FGF11 ||FGF11||MGC45269||FHF3||fibroblast 1.868 NM_004112 growth factor 11||fibroblast growth factor homologous factor 3|| DAPK2 ||DRP-1||DAPK2||death-associated 1.695 NM_014326 protein kinase 2|| SLCO3A1 ||SLC21A11||OATP- 1.623 NM_013272 D||SLCO3A1||OATP3A1||solute carrier organic anion transporter family, member 3A1||solute carrier family 21 (organic anion transporter), member 11|| TCF4 ||SEF2-1B||TCF4||E2- 1.547 NM_003199 2||ITF2||transcription factor 4||IMMUNOGLOBULIN TRANSCRIPTION FACTOR 2||transcription factor 4 isoform b||Transcription factor-4 (immunoglobulin transcription factor-2)|| MARVELD3 ||LOC91862||MRVLDC3||MARVEL 1.517 NM_052858 (membrane-associating) domain containing 3||similar to RIKEN cDNA 1810006A16 gene|| EXT1 1.507 BX115875 NF1 ||NFNS||WSS||NF1||VRNF||Neurofibromin 1.506 NM_000267 (neurofibromatosis, type I)||VON RECKLINGHAUSEN DISEASE NEUROFIBROMIN||neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)|| BAT8 ||Em:AF134726.3||BAT8||NG36/G9a 1.45 NM_006709 ||NG36 protein||ankyrin repeat- containing protein||HLA-B- ASSOCIATED TRANSCRIPT 8||G9A histone methyltransferase||HLA-B associated transcript 8||HLA-B associated transcript 8 BAT8 isoform a||HLA-B associated transcript 8 BAT8 isoform b|| SMC5L1 1.332 BC035661 KLK1 ||Klk6||KLKR||3.4.21.35||KLK1||KALLIKREIN, 1.28 NM_002257 RENAL/PANCREATIC/SALIVARY||tissue kallikrein||renal/pancreas/salivary kallikrein||kallikrein 1 preproprotein||kallikrein 1, renal/pancreas/salivary||glandular kallikrein 1||kallikrein serine protease 1|| C21orf51 ||C21orf51||chromosome 21 open 1.263 NM_058182 reading frame 51|| INSR ||INSR||insulin receptor||IRAN, 1.25 NM_000208 TYPE A||DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS, TYPE A||INSR INSULIN RECEPTOR, DEFECT IN, WITH INSULIN- RESISTANT DIABETES MELLITUS AND ACANTHOSIS NIGRICANS|| ||||LOC400988 (LOC400988), 1.225 BC039374 mRNA|| PARC ||H7AP1||KIAA0708||PARC||UbcH7- 1.206 NM_015089 associated protein 1||p53- ASSOCIATED PARKIN-LIKE CYTOPLASMIC PROTEIN|| 1.192 BC033938 SLC35C2 ||SLC35C2||solute carrier family 35, 1.145 NM_173179 member C2|| ARHGEF12 ||ARHGEF12||PRO2792||KIAA0382|| 0.884 NM_015313 LARG LARG/MLL FUSION GENE||leukemia-associated rho guanine nucleotide exchange factor||RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 12||Rho guanine nucleotide exchange factor (GEF) 12||RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR, LEUKEMIA-ASSOCIATED LEUKEMIA- ASSOCIATED RHO GEF|| ||||Similar to hypothetical protein 0.869 XM_292624 4932411E22 (LOC342600), mRNA|| MGC22014 ||MGC22014||hypothetical protein 0.864 AB007861 MGC22014|| MTA3 0.861 AW594033 MCF2L ||ARHGEF14||KIAA0362||FLJ12122|| 0.851 NM_024979 MCF2L||OST||DBL's big sister||MCF2 transforming sequence-like protein||guanine nucleotide exchange factor DBS||MCF.2 cell line derived transforming sequence-like|| SLC25A30 ||LOC253512||hypothetical protein 0.844 AL832206 LOC253512|| TARP 0.843 AK026401 0.842 BC044912 0.84 BM723387 CXorf6 ||CG1||CXorf6||F18 0.831 NM_005491 GENE||chromosome X open reading frame 6|| PBX3 0.823 AK027170 RQCD1 ||CNOT9||RQCD1||RCD1+||protein 0.811 NM_005444 involved in sexual development||rcd1 (required for cell differentiation, S. pombe) homolog 1||RCD1 required for cell differentiation1 homolog (S. pombe)|| TBN ||TBN||taube nuss homolog 0.81 NM_138572 (mouse)|| DNCH1 ||DNCH1||HL- 0.802 NM_001376 3||KIAA0325||Dnchc1||p22||DYHC|| DHC1a||DNCL||DNECL||dynein, cytoplasmic-like||DYNEIN HEAVY POLYPEPTIDE, CYTOPLASMIC||dynein heavy chain, cytosolic||dynein, cytoplasmic, heavy polypeptide 1||DYNEIN, CYTOPLASMIC, HEAVY CHAIN 1|| ||||LOC388952 (LOC388952), 0.793 XM_373986 mRNA|| LOC115110 0.78 AL359943 SYNE2 ||DKFZP434H2235||Nesprin- 0.779 NM_015180 2||SYNE2||NUANCE||SYNE- 2||KIAA1011||nesprin 2||nucleus and actin connecting element||SYNAPTIC NUCLEAR ENVELOPE PROTEIN 2||spectrin repeat containing, nuclear envelope 2||NUCLEAR ENVELOPE SPECTRIN REPEAT PROTEIN 2||synaptic nuclei expressed gene 2 isoform b||synaptic nuclei expressed gene 2 isoform c||synaptic nuclei expressed gene 2 isoform d||synaptic nuclei expressed gene 2 isoform e||synaptic nuclei expressed gene 2 isoform a|| YWHAZ ||KCIP-1||14-3-3- 0.654 NM_145690 ZETA||YWHAZ||phospholipase A2||14-3-3 zeta||BRAIN PROTEIN 14-3-3, ZETA ISOFORM||protein kinase C inhibitor protein- 1||TYROSINE 3- MONOOXYGENASE/TRYPTOPHAN 5- MONOOXYGENASE ACTIVATION PROTEIN, ZETA ISOFORM||tyrosine 3-monooxygenase/tryptophan 5- monooxygenase activation protein, zeta polypeptide||tyrosine 3/tryptophan 5-monooxygenase activation protein, zeta polypeptide|| 0.653 BE562274 0.65 BM993105 MYOZ1 ||MYOZ1||myozenin 1||CALSARCIN 0.452 NM_021245 2||

TABLE 7 Genotype and allele frequencies of the SNP + 2496 of the eotaxin-3 gene in EE patients and non EE patients. Patients with Normal SNP + EE Controls Odds ratio 2496 (n = 96) (n = 177) (95% CI) P-value TT 50 (52.08%) 106 (59.89%)  1.00 NS TG 33 (34.38%) 67 (37.85%) 1.04 (0.59-1.85)  NS GG 13 (13.54%) 4 (2.26%) 6.89 (1.95-26.53) 0.0003* TG + 46 (47.92%) 71 (40.11%) 1.374 (0.833-2.266) NS GG T 133 (69.27%)  279 (78.81%)  1.00 0.0166* G 59 (30.73%) 75 (21.19%) 1.65 (1.09-2.51) 

TABLE 8 Arachidonic Acid pathway related genes Fold Genbank Common change Accession Name Description in EE number ALOX15 ||1.13.11.33||ALOX15||arachidonate 15- 20.89 NM_001140 lipoxygenase||15-@LIPOXYGENASE, RETICULOCYTE ARACHIDONATE|| PGDS ||PGDS||5.3.99.2||prostaglandin-D 5.265 NM_014485 synthase||prostaglandin D2 synthase, hematopoietic||hematopoietic prostaglandin D2 synthase|| PTGES ||PGES||TP53I12||MGST1L1||PP1294||PP102 2.822 NM_198797 ||PTGES||MGC10317||PIG12||MGST1- L1||MGST-IV||MGST1-like 1||p53-INDUCED GENE 12||prostaglandin E synthase||p53- induced apoptosis protein 12||prostaglandin E synthase isoform 2||prostaglandin E synthase isoform 1||microsomal glutathione S-transferase 1-like 1||tumor protein p53 inducible protein 12|| LTA4H ||3.3.2.6||LTA4H||leukotriene A4 2.205 NM_000895 hydrolase|| PLA2G3 ||PLA2G3||phospholipase A2, group III|| 2.156 NM_015715 PLA2G7 ||PAFAH||PLA2G7||LDL- 1.737 NM_005084 PLA2||LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY||phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)|| PTGS2 ||COX2||PGHS2||1.14.99.1||PGHS- 1.718 NM_000963 2||PTGS2||hCox-2||PGG/HS||PHS- 2||CYCLOOXYGENASE 2||PROSTAGLANDIN G/H SYNTHASE 2||prostaglandin- endoperoxide synthase 2 precursor||prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)|| ALOX5AP ||FLAP||ALOX5AP||5-@LIPOXYGENASE- 1.646 NM_001629 ACTIVATING PROTEIN||MK-886-binding protein||FIVE-LIPOXYGENASE-ACTIVATING PROTEIN||arachidonate 5-lipoxygenase- activating protein||five-lipoxygenase activating protein|| PTGDS ||PGDS2||PTGDS||PDS||5.3.99.2||prostaglandin- 1.475 NM_000954 H2 D-isomerase||PGD2 synthase||beta-trace protein||glutathione- independent PGD synthase||PROSTAGLANDIN D2 SYNTHASE, BRAIN||lipocalin-type prostaglandin D synthase||prostaglandin D2 synthase 21 kDa (brain)|| PTGIS ||PGIS||5.3.99.4||PTGIS||CYP8A1||PROSTACYCLIN 1.345 NM_000961 SYNTHASE||PROSTAGLANDIN I2 SYNTHASE||prostaglandin I2 (prostacyclin) synthase|| PTGFRN ||SMAP-6||CD9P1||FPRP||KIAA1436||CD9P- 1.342 NM_020440 1||FLJ11001||PTGFRN||EWI-F||FP REGULATORY PROTEIN||CD9 partner 1||prostaglandin F2 receptor negative regulator|| PTGDS ||PGDS2||PTGDS||PDS||5.3.99.2||prostaglandin- 1.334 NM_000954 H2 D-isomerase||PGD2 synthase||beta-trace protein||glutathione- independent PGD synthase||PROSTAGLANDIN D2 SYNTHASE, BRAIN||lipocalin-type prostaglandin D synthase||prostaglandin D2 synthase 21 kDa (brain)|| PTGER4 ||EP4R||PTGER4||prostaglandin E2 1.33 NM_000958 receptor||PGE receptor, EP4 subtype||PROSTAGLANDIN E RECEPTOR 4, EP4 SUBTYPE||prostaglandin E receptor 4, subtype EP4||prostaglandin E receptor 4 (subtype EP4)|| PAFAH2 ||HSD-PLA2||PAFAH2||3.1.1.47||platelet- 1.329 NM_000437 activating factor acetylhydrolase 2, 40 kDa||platelet-activating factor acetylhydrolase 2 (40 kD)|| HPGD ||PGDH1||15- 1.322 NM_000860 PGDH||HPGD||hydroxyprostaglandin dehydrogenase 15-(NAD)||15- @HYDROXYPROSTAGLANDIN DEHYDROGENASE, TYPE I|| PTGFRN ||SMAP-6||CD9P1||FPRP||KIAA1436||CD9P- 1.304 NM_020440 1||FLJ11001||PTGFRN||EWI-F||FP REGULATORY PROTEIN||CD9 partner 1||prostaglandin F2 receptor negative regulator|| HPGD ||PGDH1||15- 1.252 NM_000860 PGDH||HPGD||hydroxyprostaglandin dehydrogenase 15-(NAD)||15- @HYDROXYPROSTAGLANDIN DEHYDROGENASE, TYPE I|| LTC4S ||MGC33147||LTC4S||2.5.1.37||LTC4 1.237 NM_000897 SYNTHASE DEFICIENCY||leukotriene C4 synthase||LTC4S LEUKOTRIENE C4 SYNTHASE DEFICIENCY||leukotriene C4 synthase isoform 1||leukotriene C4 synthase isoform 2|| PTGER2 ||PTGER2||Prostaglandin E receptor 2, EP2 1.171 NM_000956 subtype, 53 kD||prostaglandin E receptor 2 (subtype EP2), 53 kDa|| PTGES ||PGES||TP53I12||MGST1L1||PP1294||PP102 1.146 NM_198797 ||PTGES||MGC10317||PIG12||MGST1- L1||MGST-IV||MGST1-like 1||p53-INDUCED GENE 12||prostaglandin E synthase||p53- induced apoptosis protein 12||prostaglandin E synthase isoform 2||prostaglandin E synthase isoform 1||microsomal glutathione S-transferase 1-like 1||tumor protein p53 inducible protein 12|| PLA2G4C ||cPLA2-gamma||PLA2G4C||cytosolic 1.133 NM_003706 phospholipase A2 gamma||phospholipase A2, group IVC (cytosolic)||PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-INDEPENDENT, GAMMA||phospholipase A2, group IVC (cytosolic, calcium-independent)|| IGSF8 ||PGRL||IGSF8||CD81P3||PROSTAGLANDIN 1.124 NM_052868 REGULATORY-LIKE||CD81 PARTNER 3||immunoglobulin superfamily, member 8|| LTB4R ||BLTR||CMKRL1||BLT1||LTB4- 1.117 NM_000752 R||LTB4R||GPR16||P2RY7||LTB4R1||LTBR1|| PURINOCEPTOR P2Y7||P2Y purinoceptor 7||Chemoattractant receptor-like 1||leukotriene B4 receptor||G protein- coupled receptor 16||Leukotriene B4 receptor 1||LEUKOTRIENE B4 G PROTEIN- COUPLED RECEPTOR||PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 7||purinergic receptor P2Y, G-protein coupled, 7||leukotriene b4 receptor (chemokine receptor-like 1)|| HPGD ||PGDH1||15- 1.115 NM_000860 PGDH||HPGD||hydroxyprostaglandin dehydrogenase 15-(NAD)||15- @HYDROXYPROSTAGLANDIN DEHYDROGENASE, TYPE I|| PTGDS ||PGDS2||PTGDS||PDS||5.3.99.2||prostaglandin- 1.106 NM_000954 H2 D-isomerase||PGD2 synthase||beta-trace protein||glutathione- independent PGD synthase||PROSTAGLANDIN D2 SYNTHASE, BRAIN||lipocalin-type prostaglandin D synthase||prostaglandin D2 synthase 21 kDa (brain)|| PAFAH2 ||HSD-PLA2||PAFAH2||3.1.1.47||platelet- 1.105 NM_000437 activating factor acetylhydrolase 2, 40 kDa||platelet-activating factor acetylhydrolase 2 (40 kD)|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 1.104 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGDR ||MGC49004||PTGDR||PGD 1.101 NM_000953 receptor||prostanoid DP receptor||prostaglandin D2 receptor (DP)|| LYPLA2 ||LYPLA2||3.1.1.5||APT- 1.093 NM_007260 2||DJ886K2.4||acyl-protein thioesterase||lysophospholipase II|| LYPLA2 ||LYPLA2||3.1.1.5||APT- 1.093 NM_007260 2||DJ886K2.4||acyl-protein thioesterase||lysophospholipase II|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 1.091 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGIR ||PTGIR||PRIPR||PGI receptor||prostacyclin 1.079 NM_000960 receptor||prostanoid IP receptor||PROSTAGLANDIN I2 RECEPTOR||prostaglandin I2 (prostacyclin) receptor (IP)|| LTB4R2 ||||LTB4R2||leukotriene B4 receptor 2|| 1.076 NM_019839 PLA2G4C ||cPLA2-gamma||PLA2G4C||cytosolic 1.074 NM_003706 phospholipase A2 gamma||phospholipase A2, group IVC (cytosolic)||PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-INDEPENDENT, GAMMA||phospholipase A2, group IVC (cytosolic, calcium-independent)|| HPGD ||PGDH1||15- 1.067 NM_000860 PGDH||HPGD||hydroxyprostaglandin dehydrogenase 15-(NAD)||15- @HYDROXYPROSTAGLANDIN DEHYDROGENASE, TYPE I|| LYPLA2 ||LYPLA2||3.1.1.5||APT- 1.061 NM_007260 2||DJ886K2.4||acyl-protein thioesterase||lysophospholipase II|| TBXAS1 ||TS||TBXAS1||5.3.99.5||TXAS||TXA 1.057 NM_001061 synthase||CYP5A1 THROMBOXANE SYNTHETASE DEFICIENCY||THROMBOXANE A SYNTHASE, PLATELET||thromboxane A synthase 1 (platelet, cytochrome P450, subfamily V)||thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A)||thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) isoform TXS-II|| PLA2G4D ||PLA2G4D||phospholipase A2, group IVD 1.049 NM_178034 (cytosolic)|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 1.046 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| CYSLTR2 ||CYSLT2||CYSLTR2||cysteinyl leukotriene 1.035 NM_020377 receptor 2|| PTGES2 ||PTGES2||PGES2||GBF1||GATE-BINDING 1.033 NM_198939 FACTOR 1||prostaglandin E synthase 2|| TBXA2R ||TBXA2R||thromboxane A2 1.024 NM_201636 receptor||THROMBOXANE A2 RECEPTOR, PLATELET||thromboxane A2 receptor isoform 2||TBXA2R BLEEDING DISORDER DUE TO DEFECTIVE THROMBOXANE A2 RECEPTOR|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 1.022 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 1.02 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 1.017 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGDR ||MGC49004||PTGDR||PGD 1.012 NM_000953 receptor||prostanoid DP receptor||prostaglandin D2 receptor (DP)|| TBXA2R ||TBXA2R||thromboxane A2 1.01 NM_201636 receptor||THROMBOXANE A2 RECEPTOR, PLATELET||thromboxane A2 receptor isoform 2||TBXA2R BLEEDING DISORDER DUE TO DEFECTIVE THROMBOXANE A2 RECEPTOR|| PLA2R1 ||PLA2IR||PLA2- 1.009 NM_007366 R||PLA2R1||PLA2G1R||PHOSPHOLIPASE A2 RECEPTOR, 180-KD||phospholipase A2 receptor 1, 180 kDa|| PLA2G10 ||GXPLA2||GXSPLA2||PLA2G10||phospholipase 1.008 NM_003561 A2, group X||SECRETORY PHOSPHOLIPASE A2, GROUP X||PHOSPHOLIPASE A2, SECRETORY, CALCIUM-DEPENDENT, GROUP X|| PTGFR ||MGC46203||PTGFR||PGF receptor||PGF2 1.006 NM_000959 alpha receptor||prostaglandin receptor (2- alpha)||PROSTAGLANDIN RECEPTOR F(2- ALPHA)||prostanoid FP receptor||prostaglandin F2 alpha receptor||prostaglandin F receptor (FP)|| PTGDR ||MGC49004||PTGDR||PGD 0.998 NM_000953 receptor||prostanoid DP receptor||prostaglandin D2 receptor (DP)|| PLA2G1B ||PLA2G1B||3.1.1.4||PPLA2||PLA2A||PHOSPHOLIPASE 0.989 NM_000928 A2, PANCREATIC||PHOSPHOLIPASE A2 POLYPEPTIDE A||phospholipase A2, group IB (pancreas)|| PLA2G6 ||PLA2G6||iPLA2||PHOSPHOLIPASE A2, 0.988 NM_003560 CALCIUM-INDEPENDENT||cytosolic, calcium-independent phospholipase A2||phospholipase A2, group VI (cytosolic, calcium-independent)|| HTATIP ||PLIP||HTATIP||HTATIP1||TAT- 0.987 NM_182710 INTERACTING PROTEIN, 60-KD||HIV-1 TAT- INTERACTING PROTEIN||cPLA2 interacting protein||TIP60 PLA2-INTERACTING PROTEIN||Tat interactive protein (60 kD)||HIV-1 Tat interactive protein, 60 kDa||HIV-1 Tat interactive protein, 60 kDa isoform 3||HIV-1 Tat interactive protein, 60 kDa isoform 2||HIV-1 Tat interactive protein, 60 kDa isoform 1|| PLA2G5 ||3.1.1.4||PLA2G5||phospholipase A2, 0.983 NM_000929 group V|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 0.983 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 0.981 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| ALOX15B ||ALOX15B||arachidonate 15-lipoxygenase, 0.967 NM_001141 second type||15-@LIPOXYGENASE, RETICULOCYTE ARACHIDONATE, SECOND TYPE|| CYSLTR1 ||HMTMF81||MGC46139||CYSLTR1||CYSLT1R 0.965 NM_006639 ||HG55||LTD4 receptor||CysLTR vide supra||cysteinyl leukotriene receptor 1||cysteinyl leukotriene D4 receptor|| TBXA2R ||TBXA2R||thromboxane A2 0.963 NM_201636 receptor||THROMBOXANE A2 RECEPTOR, PLATELET||thromboxane A2 receptor isoform 2||TBXA2R BLEEDING DISORDER DUE TO DEFECTIVE THROMBOXANE A2 RECEPTOR|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 0.962 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PLA2G12B ||PLA2G12B||phospholipase A2, group 0.961 NM_032562 XIIB|| LOC112868 ||||Similar to Group X secretory 0.957 AL390134 phospholipase A2 precursor (Phosphatidylcholine 2-acylhydrolase GX) (GX sPLA2) (sPLA2-X) (LOC388229), mRNA|| PTGER4 ||EP4R||PTGER4||prostaglandin E2 0.955 NM_000958 receptor||PGE receptor, EP4 subtype||PROSTAGLANDIN E RECEPTOR 4, EP4 SUBTYPE||prostaglandin E receptor 4, subtype EP4||prostaglandin E receptor 4 (subtype EP4)|| TBXAS1 ||TS||TBXAS1||5.3.99.5||TXAS||TXA 0.955 NM_001061 synthase||CYP5A1 THROMBOXANE SYNTHETASE DEFICIENCY||THROMBOXANE A SYNTHASE, PLATELET||thromboxane A synthase 1 (platelet, cytochrome P450, subfamily V)||thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A)||thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) isoform TXS-II|| IPLA2(GAMMA); ||||IPLA2(GAMMA)||intracellular membrane- 0.951 XM_291241 IPLA2-2 associated calcium-independent phospholipase A2 gamma|| CYSLTR1 ||HMTMF81||MGC46139||CYSLTR1||CYSLT1R 0.949 NM_006639 ||HG55||LTD4 receptor||CysLTR vide supra||cysteinyl leukotriene receptor 1||cysteinyl leukotriene D4 receptor|| PLA2R1 ||PLA2IR||PLA2- 0.948 NM_007366 R||PLA2R1||PLA2G1R||PHOSPHOLIPASE A2 RECEPTOR, 180-KD||phospholipase A2 receptor 1, 180 kDa|| LTB4R ||BLTR||CMKRL1||BLT1||LTB4- 0.945 NM_000752 R||LTB4R||GPR16||P2RY7||LTB4R1||LTBR1|| PURINOCEPTOR P2Y7||P2Y purinoceptor 7||Chemoattractant receptor-like 1||leukotriene B4 receptor||G protein- coupled receptor 16||Leukotriene B4 receptor 1||LEUKOTRIENE B4 G PROTEIN- COUPLED RECEPTOR||PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 7||purinergic receptor P2Y, G-protein coupled, 7||leukotriene b4 receptor (chemokine receptor-like 1)|| TBXA2R ||TBXA2R||thromboxane A2 0.944 NM_201636 receptor||THROMBOXANE A2 RECEPTOR, PLATELET||thromboxane A2 receptor isoform 2||TBXA2R BLEEDING DISORDER DUE TO DEFECTIVE THROMBOXANE A2 RECEPTOR|| PLA2G2D ||SPLASH||PLA2G2D||sPLA2S||secretory 0.943 NM_012400 phospholipase A2s||SECRETORY-TYPE PLA, STROMA-ASSOCIATED HOMOLOG||phospholipase A2, group IID|| LOC112868 ||||Similar to Group X secretory 0.943 AL390134 phospholipase A2 precursor (Phosphatidylcholine 2-acylhydrolase GX) (GX sPLA2) (sPLA2-X) (LOC388229), mRNA|| PLA2G5 ||3.1.1.4||PLA2G5||phospholipase A2, 0.94 NM_000929 group V|| PTGER3 ||MGC27302||PTGER3||prostanoid EP3 0.932 NM_198715 receptor||prostaglandin receptor (PGE- 2)||prostaglandin E2 receptor||PGE receptor, EP3 subtype||prostaglandin E receptor 3 (subtype EP3)||PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE||prostaglandin E receptor 3, subtype EP3 isoform 7||prostaglandin E receptor 3, subtype EP3 isoform 8||prostaglandin E receptor 3, subtype EP3 isoform 1||prostaglandin E receptor 3, subtype EP3 isoform 2||prostaglandin E receptor 3, subtype EP3 isoform 3||prostaglandin E receptor 3, subtype EP3 isoform 4||prostaglandin E receptor 3, subtype EP3 isoform 5||prostaglandin E receptor 3, subtype EP3 isoform 6|| PTGER1 ||PTGER1||prostanoid EP1 receptor||PGE 0.932 NM_000955 receptor, EP1 subtype||PROSTAGLANDIN E RECEPTOR 1, EP1 SUBTYPE||prostaglandin E receptor 1, subtype EP1||prostaglandin E receptor 1 (subtype EP1), 42 kDa|| PTGS1 ||PGHS- 0.929 NM_000962 1||PTGHS||COX3||1.14.99.1||PGG/HS||PCOX1 ||PHS1||PTGS1||CYCLOOXYGENASE 1||PARTIAL COX1 PROTEINS||PGHS1 CYCLOOXYGENASE 3||PROSTAGLANDIN G/H SYNTHASE 1||prostaglandin- endoperoxide synthase 1 isoform 2 precursor||prostaglandin-endoperoxide synthase 1 isoform 1 precursor||prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)|| ALOX5 ||5- 0.926 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| PTGS1 ||PGHS- 0.921 NM_000962 1||PTGHS||COX3||1.14.99.1||PGG/HS||PCOX1 ||PHS1||PTGS1||CYCLOOXYGENASE 1||PARTIAL COX1 PROTEINS||PGHS1 CYCLOOXYGENASE 3||PROSTAGLANDIN G/H SYNTHASE 1||prostaglandin- endoperoxide synthase 1 isoform 2 precursor||prostaglandin-endoperoxide synthase 1 isoform 1 precursor||prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)|| PTGS1 ||PGHS- 0.92 NM_000962 1||PTGHS||COX3||1.14.99.1||PGG/HS||PCOX1 ||PHS1||PTGS1||CYCLOOXYGENASE 1||PARTIAL COX1 PROTEINS||PGHS1 CYCLOOXYGENASE 3||PROSTAGLANDIN G/H SYNTHASE 1||prostaglandin- endoperoxide synthase 1 isoform 2 precursor||prostaglandin-endoperoxide synthase 1 isoform 1 precursor||prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)|| H. sapiens H. sapiens EP4 prostaglandin receptor 0.912 BC042539 EP4 pseudogene c16/g7 prostaglandin receptor pseudogene c16/g7 PLA2G2F ||PLA2G2F||phospholipase A2, group IIF|| 0.912 NM_022819 PLAA ||PLAA||PLAP||PLA2P||phospholipase A2- 0.911 NM_004253 activating protein||phospholipase A2 activating protein|| ALOXE3 ||ALOXE3||LOX TYPE 3||arachidonate 0.907 NM_021628 lipoxygenase 3||LIPOXYGENASE TYPE 3, EPIDERMAL|| PTGS2 ||COX2||PGHS2||1.14.99.1||PGHS- 0.906 NM_000963 2||PTGS2||hCox-2||PGG/HS||PHS- 2||CYCLOOXYGENASE 2||PROSTAGLANDIN G/H SYNTHASE 2||prostaglandin- endoperoxide synthase 2 precursor||prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)|| PLA2G6 ||PLA2G6||iPLA2||PHOSPHOLIPASE A2, 0.904 NM_003560 CALCIUM-INDEPENDENT||cytosolic, calcium-independent phospholipase A2||phospholipase A2, group VI (cytosolic, calcium-independent)|| ALOX12P2 ||ALOX12E||ALOX12P2||12-lipoxygenase- 0.899 AL832768 related protein||arachidonate 12- lipoxygenase pseudogene 2||hair and skin epidermal-type 12-lipoxygenase-related pseudogene|| PLA2G2E ||PLA2G2E||phospholipase A2, group IIE|| 0.899 NM_014589 PTGIS ||PGIS||5.3.99.4||PTGIS||CYP8A1||PROSTACYCLIN 0.897 NM_000961 SYNTHASE||PROSTAGLANDIN I2 SYNTHASE||prostaglandin I2 (prostacyclin) synthase|| PLA2R1 ||PLA2IR||PLA2- 0.893 NM_007366 R||PLA2R1||PLA2G1R||PHOSPHOLIPASE A2 RECEPTOR, 180-KD||phospholipase A2 receptor 1, 180 kDa|| PLA2G5 ||3.1.1.4||PLA2G5||phospholipase A2, 0.891 NM_000929 group V|| IPLA2(GAMMA); ||||IPLA2(GAMMA)||intracellular membrane- 0.888 XM_291241 IPLA2-2 associated calcium-independent phospholipase A2 gamma|| PTGER1 ||PTGER1||prostanoid EP1 receptor||PGE 0.882 NM_000955 receptor, EP1 subtype||PROSTAGLANDIN E RECEPTOR 1, EP1 SUBTYPE||prostaglandin E receptor 1, subtype EP1||prostaglandin E receptor 1 (subtype EP1), 42 kDa|| CYSLTR1 ||HMTMF81||MGC46139||CYSLTR1||CYSLT1R 0.876 NM_006639 ||HG55||LTD4 receptor||CysLTR vide supra||cysteinyl leukotriene receptor 1||cysteinyl leukotriene D4 receptor|| PTGIS ||PGIS||5.3.99.4||PTGIS||CYP8A1||PROSTACYCLIN 0.872 NM_000961 SYNTHASE||PROSTAGLANDIN I2 SYNTHASE||prostaglandin I2 (prostacyclin) synthase|| PLA2G4B ||HsT16992||PLA2G4B||cPLA2- 0.867 NM_005090 beta||PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, BETA||phospholipase A2, group IVB (cytosolic)|| PLA2R1 ||PLA2IR||PLA2- 0.858 NM_007366 R||PLA2R1||PLA2G1R||PHOSPHOLIPASE A2 RECEPTOR, 180-KD||phospholipase A2 receptor 1, 180 kDa|| ALOXE3 ||ALOXE3||LOX TYPE 3||arachidonate 0.855 NM_021628 lipoxygenase 3||LIPOXYGENASE TYPE 3, EPIDERMAL|| SLCO2A1 ||OATP2A1||SLC21A2||SLCO2A1||PGT||solute 0.854 NM_005630 carrier organic anion transporter family, member 2A1||solute carrier family 21 (prostaglandin transporter), member 2|| IPLA2(GAMMA); ||||IPLA2(GAMMA)||intracellular membrane- 0.853 XM_291241 IPLA2-2 associated calcium-independent phospholipase A2 gamma|| PLA2G12B ||PLA2G12B||phospholipase A2, group 0.844 NM_032562 XIIB|| PTGER1 ||PTGER1||prostanoid EP1 receptor||PGE 0.844 NM_000955 receptor, EP1 subtype||PROSTAGLANDIN E RECEPTOR 1, EP1 SUBTYPE||prostaglandin E receptor 1, subtype EP1||prostaglandin E receptor 1 (subtype EP1), 42 kDa|| TBXA2R ||TBXA2R||thromboxane A2 0.838 NM_201636 receptor||THROMBOXANE A2 RECEPTOR, PLATELET||thromboxane A2 receptor isoform 2||TBXA2R BLEEDING DISORDER DUE TO DEFECTIVE THROMBOXANE A2 RECEPTOR|| PLA2G6 ||PLA2G6||iPLA2||PHOSPHOLIPASE A2, 0.833 NM_003560 CALCIUM-INDEPENDENT||cytosolic, calcium-independent phospholipase A2||phospholipase A2, group VI (cytosolic, calcium-independent)|| PLA2G6 ||PLA2G6||iPLA2||PHOSPHOLIPASE A2, 0.83 NM_003560 CALCIUM-INDEPENDENT||cytosolic, calcium-independent phospholipase A2||phospholipase A2, group VI (cytosolic, calcium-independent)|| ALOX5 ||5- 0.806 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| PTGS1 ||PGHS- 0.804 NM_000962 1||PTGHS||COX3||1.14.99.1||PGG/HS||PCOX1 ||PHS1||PTGS1||CYCLOOXYGENASE 1||PARTIAL COX1 PROTEINS||PGHS1 CYCLOOXYGENASE 3||PROSTAGLANDIN G/H SYNTHASE 1||prostaglandin- endoperoxide synthase 1 isoform 2 precursor||prostaglandin-endoperoxide synthase 1 isoform 1 precursor||prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)|| ALOX15B ||ALOX15B||arachidonate 15-lipoxygenase, 0.773 NM_001141 second type||15-@LIPOXYGENASE, RETICULOCYTE ARACHIDONATE, SECOND TYPE|| ALOX5 ||5- 0.771 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| CYP4F2 ||CYP4F2||1.14.13.30||CPF2||leukotriene- 0.764 NM_001082 B4 20-monooxygenase||LTB4 OMEGA- HYDROXYLASE, LIVER||LEUKOTRIENE B4 OMEGA-HYDROXYLASE, LIVER||cytochrome P450, subfamily IVF, polypeptide 2||cytochrome P450, family 4, subfamily F, polypeptide 2|| CYP2J2 ||CPJ2||CYP2J2||1.14.14.1||microsomal 0.736 NM_000775 monooxygenase||flavoprotein-linked monooxygenase||CYTOCHROME P450 ARACHIDONIC ACID EPOXYGENASE||CYTOCHROME P450, SUBFAMILY IIJ, POLYPEPTIDE 2||cytochrome P450, family 2, subfamily J, polypeptide 2||cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2|| CYP4F3 ||1.14.13.30||CYP4F3||CPF3||LTB4H||leukotriene- 0.727 NM_000896 B4 20-monooxygenase||cytochrome P450-LTB-omega||LTB4 OMEGA- HYDROXYLASE||LEUKOTRIENE B4 OMEGA- HYDROXYLASE||cytochrome P450, family 4, subfamily F, polypeptide 3||cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)|| PLA2G4B ||HsT16992||PLA2G4B||cPLA2- 0.71 NM_005090 beta||PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, BETA||phospholipase A2, group IVB (cytosolic)|| ALOX5 ||5- 0.679 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| PLA2G4B ||HsT16992||PLA2G4B||cPLA2- 0.677 NM_005090 beta||PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, BETA||phospholipase A2, group IVB (cytosolic)|| PLA2G2A ||PLA2G2A||MOM1||3.1.1.4||PLA2B||PLA2L|| 0.662 NM_000300 PLAS1||PLA2S||PHOSPHOLIPASE A2, SYNOVIAL||PHOSPHOLIPASE A2 POLYPEPTIDE B||MODIFIER OF MIN-1, MOUSE, HOMOLOG OF||phospholipase A2, group IIA (platelets, synovial fluid)|| PLA2G12A ||PLA2G12A||phospholipase A2, group 0.656 NM_030821 XIIA|| ALOX5 ||5- 0.643 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| LTB4DH ||LTB4DH||MGC34943||leukotriene B4 12- 0.599 NM_012212 hydroxydehydrogenase||NADP-dependent leukotriene B4 12-hydroxydehydrogenase|| PLA2G12A ||PLA2G12A||phospholipase A2, group 0.578 NM_030821 XIIA|| ALOX12B ||ALOX12B||12R-LOX||12R- 0.549 NM_001139 @LIPOXYGENASE||12-@LIPOXYGENASE, R TYPE||arachidonate 12-lipoxygenase, 12R type||ARACHIDONATE 12-LIPOXYGENASE, R TYPE|| LTB4DH ||LTB4DH||MGC34943||leukotriene B4 12- 0.535 NM_012212 hydroxydehydrogenase||NADP-dependent leukotriene B4 12-hydroxydehydrogenase|| PLA2G4A ||3.1.1.4||3.1.1.5||cPLA2- 0.528 NM_024420 alpha||PLA2G4A||PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, ALPHA||phospholipase A2, group IVA (cytosolic, calcium-dependent)|| CYP4F3 ||1.14.13.30||CYP4F3||CPF3||LTB4H||leukotriene- 0.476 NM_000896 B4 20-monooxygenase||cytochrome P450-LTB-omega||LTB4 OMEGA- HYDROXYLASE||LEUKOTRIENE B4 OMEGA- HYDROXYLASE||cytochrome P450, family 4, subfamily F, polypeptide 3||cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)|| LTB4DH ||LTB4DH||MGC34943||leukotriene B4 12- 0.358 NM_012212 hydroxydehydrogenase||NADP-dependent leukotriene B4 12-hydroxydehydrogenase|| AKR1C3 ||HA1753||1.1.1.188||DD3||hluPGFS||HSD17B5 ||1.3.1.20||1.1.1.213||AKR1C3||KIAA0119 ||HAKRB||HAKRe||trans-1,2- dihydrobenzene-1,2-diol dehydrogenase||chlordecone reductase homolog||dihydrodiol dehydrogenase 3||prostaglandin F synthase||ALDO-KETO REDUCTASE B||3-@ALPHA- HYDROXYSTEROID DEHYDROGENASE, TYPE II||hydroxysteroid (17-beta) dehydrogenase 5||type IIb 3-alpha hydroxysteroid dehydrogenases||aldo-keto redu.. 1fe||hydronase 0.476 NM_000896 P450-LTB-omega||LTB4 OMEGA- HYDROXYLASE||LEUKOTRIENE B4 OMEGA- HYDROXYLASE||cytochrome P450, family 4, subfamily F, polypeptide 3||cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)|| LTB4DH ||LTB4DH||MGC34943||leukotriene B4 12- hydroxydehydrogenase||NADP-dependent leukotriene B4 12

TABLE 9 Mast cell related genes Fold Genbank Common Increase Accession Name Description in EE number ALOX15 ||1.13.11.33||ALOX15||arachidonate 20.89 NM_001140 15-lipoxygenase||15-@LIPOXYGENASE, RETICULOCYTE ARACHIDONATE|| CXCL1 ||MGSA-a||NAP- 18.79 NM_001511 3||CXCL1||SCYB1||GROa||GRO1, FORMERLY||GRO PROTEIN, ALPHA||GRO1 ONCOGENE, FORMERLY||MELANOMA GROWTH STIMULATORY ACTIVITY, ALPHA||GRO1 oncogene (melanoma growth- stimulating activity)||CHEMOKINE, CXC MOTIF, LIGAND 1||GRO1 oncogene (melanoma growth stimulating activity, alpha)||SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 1||chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)|| CPA3 ||CAP3||3.4.17.1||carboxypeptidase A3 13.13 NM_001870 (mast cell)||CARBOXYPEPTIDASE A3, MAST CELL||mast cell carboxypeptidase A3 precursor|| IL8 ||NAP1||IL-8||LUCT/interleukin- 7.071 NM_000584 8||LECT||K60||NAF||MONAP||LYNAP||TSG- 1||b- ENAP||emoctakin||SCYB8||NAP- 1||GCP1||IL8||MDNCF||GCP- 1||CXCL8||AMCF-I||interleukin 8||protein 3-10C||beta- thromboglobulin-like protein||neutrophil-activating protein 1||interleukin 8 precursor||neutrophil- activating peptide 1||lymphocyte- derived neutrophil-activating factor||T cell chemotactic factor||monocyte- derived neutrophil chemotactic factor||CXC chemokine ligand 8||monocyte derived neutrophil- activating protein||granulocyte chemotactic protein 1||small inducible cytokine subfamily B, member 8|| TPSB2 ||||TPS1||tryptase, alpha|| 6.429 NM_003294 HRH1 ||HRH1||H1-R||hisH1||histamine 6.191 NM_000861 receptor H1||BPHS, MOUSE, HOMOLOG OF||histamine receptor, subclass H1|| TPSB2 ||||TPS1||tryptase, alpha|| 6.028 NM_003294 TPSB2 ||||TPS1||tryptase, alpha|| 5.573 NM_003294 PGDS ||PGDS||5.3.99.2||prostaglandin-D 5.265 NM_014485 synthase||prostaglandin D2 synthase, hematopoietic||hematopoietic prostaglandin D2 synthase|| HS3ST1 ||HS3ST1||3OST1||2.8.2.23||heparin- 4.249 NM_005114 glucosamine 3-O- sulfotransferase||heparan sulfate (glucosamine) 3-O-sulfotransferase 1||heparan sulfate D-glucosaminyl 3-O- sulfotransferase 1 precursor|| MS4A2 ||FCERI||MS4A1||MS4A2||FCER1B||Fc 4.192 NM_000139 epsilon receptor I beta-chain||Fc IgE RECEPTOR, BETA CHAIN||MEMBRANE- SPANNING 4 DOMAINS, SUBFAMILY A, MEMBER 2||immunoglobulin E receptor, high affinity, beta polypeptide||Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, BETA SUBUNIT||membrane-spanning 4- domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide)|| CXCR4 CXCR4 4.092 AJ224869 TPSB2 ||||TPS1||tryptase, alpha|| 4.033 NM_003294 TPSB2 ||||TPS1||tryptase, alpha|| 3.98 NM_003294 PRG1 ||MGC9289||PPG||serglycin||PRG1||hematopoetic 3.444 NM_002727 proteoglycan core peptide||platelet proteoglycan protein core||proteoglycan 1, secretory granule||secretory granule proteoglycan core peptide||proteoglycan 1, secretory granule precursor||proteoglycan protein core for mast cell secretory granule|| PRG1 ||MGC9289||PPG||serglycin||PRG1||hematopoetic 3.441 NM_002727 proteoglycan core peptide||platelet proteoglycan protein core||proteoglycan 1, secretory granule||secretory granule proteoglycan core peptide||proteoglycan 1, secretory granule precursor||proteoglycan protein core for mast cell secretory granule|| TPSB2 ||||TPS1||tryptase, alpha|| 3.188 NM_003294 ADAMDEC1 ||M12.219||ADAMDEC1||disintegrin 3.118 NM_014479 protease||ADAM-like, decysin 1||ADAM- LIKE PROTEIN DECYSIN 1||A DISINTEGRIN AND METALLOPROTEINASE DOMAIN-LIKE PROTEIN DECYSIN 1|| TPSB2 ||||TPS1||tryptase, alpha|| 2.997 NM_003294 IL15 ||IL-15||IL15||MGC9721||interleukin 2.879 NM_172174 15||interleukin 15 isoform 2 precursor||interleukin 15 isoform 1 precursor|| PTGES ||PGES||TP53I12||MGST1L1||PP1294||PP102 2.822 NM_198797 ||PTGES||MGC10317||PIG12||MGST1- L1||MGST-IV||MGST1-like 1||p53- INDUCED GENE 12||prostaglandin E synthase||p53-induced apoptosis protein 12||prostaglandin E synthase isoform 2||prostaglandin E synthase isoform 1||microsomal glutathione S- transferase 1-like 1||tumor protein p53 inducible protein 12|| KIT ||2.7.1.112||CD117||SCFR||PBT||KIT|| 2.754 NM_000222 KIT ONCOGENE||STEM CELL FACTOR RECEPTOR||MAST CELL GROWTH FACTOR RECEPTOR||v-kit Hardy- Zuckerman 4 feline sarcoma viral oncogene homolog||v-kit Hardy- Zuckerman 4 feline sarcoma viral oncogene homolog precursor|| VCAM1 ||VCAM1||INCAM-100||CD106 2.355 NM_001078 antigen||vascular cell adhesion molecule 1||vascular cell adhesion molecule 1 isoform b precursor||vascular cell adhesion molecule 1 isoform a precursor|| ITGAM ||ITGAM||MAC1A||MO1A||CR3A||MAC- 2.246 NM_000632 1||Mo1, ALPHA SUBUNIT||Mac1, ALPHA SUBUNIT||integrin alpha M precursor||neutrophil adherence receptor alpha-M subunit||COMPLEMENT RECEPTOR TYPE 3, ALPHA SUBUNIT||Integrin, alpha-M (complement component receptor-3, alpha; antigen CD11B (p170); macrophage antigen, alpha polypeptide)||integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide)|| LTA4H ||3.3.2.6||LTA4H||leukotriene A4 2.205 NM_000895 hydrolase|| IL1F9 ||IL1H1||IL1F9||IL1RP2||INTERLEUKIN 2.109 NM_019618 1-RELATED PROTEIN 2||INTERLEUKIN 1 HOMOLOG 1||interleukin 1 family, member 9|| FCER1G ||FCER1G||Fc IgE RECEPTOR, GAMMA 2.057 NM_004106 CHAIN||immunoglobulin E receptor, high affinity, gamma chain||IMMUNOGLOBULIN E RECEPTOR, HIGH-AFFINITY, OF MAST CELLS, GAMMA POLYPEPTIDE||Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide||Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, GAMMA SUBUNIT||Fc fragment of IgE, high affinity I, receptor for, gamma polypeptide precursor|| IL18R1 ||IL-1Rrp||IL1RRP||IL18R1||IL1 2.047 NM_003855 receptor-related protein||interleukin 18 receptor 1||interleukin 18 receptor 1 precursor|| CCL18 ||CCL18||DC-CK1||AMAC1||AMAC- 2.003 NM_002988 1||MIP- 4||CKb7||PARC||DCCK1||SCYA18, FORMERLY||chemokine (C-C), dendritic||pulmonary and activation- regulated chemokine||CC chemokine ligand 18||macrophage inflammatory protein 4||dendritic cell chemokine 1||small inducible cytokine A18 precursor||CHEMOKINE, CC MOTIF, LIGAND 18||alternative macrophage activation-associated CC chemokine 1||SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 18, FORMERLY||chemokine (C-C motif) ligand 18 (pulmonary and activation- regulated)||small inducible cytokine subfamily A (Cys-Cys), member 18|| FCER1G ||FCER1G||Fc IgE RECEPTOR, GAMMA 2 NM_004106 CHAIN||immunoglobulin E receptor, high affinity, gamma chain||IMMUNOGLOBULIN E RECEPTOR, HIGH-AFFINITY, OF MAST CELLS, GAMMA POLYPEPTIDE||Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide||Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, GAMMA SUBUNIT||Fc fragment of IgE, high affinity I, receptor for, gamma polypeptide precursor|| CCL18 ||CCL18||DC-CK1||AMAC1||AMAC- 1.933 NM_002988 1||MIP- 4||CKb7||PARC||DCCK1||SCYA18, FORMERLY||chemokine (C-C), dendritic||pulmonary and activation- regulated chemokine||CC chemokine ligand 18||macrophage inflammatory protein 4||dendritic cell chemokine 1||small inducible cytokine A18 precursor||CHEMOKINE, CC MOTIF, LIGAND 18||alternative macrophage activation-associated CC chemokine 1||SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 18, FORMERLY||chemokine (C-C motif) ligand 18 (pulmonary and activation- regulated)||small inducible cytokine subfamily A (Cys-Cys), member 18|| TGFBI ||CDG2||kerato-epithelin||BETA-IG- 1.92 NM_000358 H3||CDB1||LCD1||CDGG1||CSD1||CSD2 ||CSD3||TGFBI||BIGH3||KERATOEPITHELIN ||corneal dystrophy||TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 68- KD||transforming growth factor, beta- induced, 68 kDa|| CD209 ||CDSIGN||CD209||DC- 1.903 NM_021155 SIGN1||DCSIGN||CD209 antigen||HIV GP120-BINDING PROTEIN||dendritic cell-specific ICAM3-grabbing nonintegrin|| FGF11 ||FGF11||MGC45269||FHF3||fibroblast 1.868 NM_004112 growth factor 11||fibroblast growth factor homologous factor 3|| TNFRSF5 ||Bp50||TNFRSF5||MGC9013||CDW40|| 1.862 NM_001250 CD40 antigen||CD40L receptor||B CELL- ASSOCIATED MOLECULE CD40||CD40 type II isoform||B cell surface antigen CD40||nerve growth factor receptor- related B-lymphocyte activation molecule||tumor necrosis factor receptor superfamily, member 5||tumor necrosis factor receptor superfamily, member 5 isoform 2 precursor||tumor necrosis factor receptor superfamily, member 5 isoform 1 precursor|| C3AR1 ||HNFAG09||C3AR1||AZ3B||COMPLEMENT 1.843 NM_004054 COMPONENT 3a RECEPTOR 1||complement component 3 receptor 1|| IL15RA ||IL15RA||interleukin 15 receptor, 1.771 NM_172200 alpha||interleukin 15 receptor, alpha isoform 2||interleukin 15 receptor, alpha isoform 1 precursor|| IL2RG ||IL2RG||IMD4||SCIDX1||CD132 1.739 NM_000206 ANTIGEN||Interleukin-2 receptor, gamma||common cytokine receptor gamma chain||interleukin 2 receptor, gamma chain, precursor||interleukin 2 receptor, gamma (severe combined immunodeficiency)|| TNFRSF5 ||Bp50||TNFRSF5||MGC9013||CDW40|| 1.706 NM_001250 CD40 antigen||CD40L receptor||B CELL- ASSOCIATED MOLECULE CD40||CD40 type II isoform||B cell surface antigen CD40||nerve growth factor receptor- related B-lymphocyte activation molecule||tumor necrosis factor receptor superfamily, member 5||tumor necrosis factor receptor superfamily, member 5 isoform 2 precursor||tumor necrosis factor receptor superfamily, member 5 isoform 1 precursor|| ALOX5AP ||FLAP||ALOX5AP||5-@LIPOXYGENASE- 1.646 NM_001629 ACTIVATING PROTEIN||MK-886-binding protein||FIVE-LIPOXYGENASE- ACTIVATING PROTEIN||arachidonate 5- lipoxygenase-activating protein||five- lipoxygenase activating protein|| IL12RB1 ||MGC34454||IL-12R- 1.588 NM_005535 BETA1||IL12RB1||interleukin-12 receptor beta-1 chain||IL-12 receptor beta component||INTERLEUKIN 12 RECEPTOR, BETA-1||interleukin 12 receptor, beta 1||interleukin 12 receptor, beta 1 isoform 1 precursor||interleukin 12 receptor, beta 1 isoform 2 precursor|| CCL5 ||TCP228||MGC17164||CCL5||D17S136E 1.56 NM_002985 ||SIS-delta||SISd||SCYA5, FORMERLY||T CELL-SPECIFIC RANTES||beta-chemokine RANTES precursor||T-cell specific RANTES protein||T CELL-SPECIFIC PROTEIN p228||T-cell specific protein p288||CHEMOKINE, CC MOTIF, LIGAND 5||SMALL INDUCIBLE CYTOKINE A5, FORMERLY||small inducible cytokine A5 precursor||chemokine (C-C motif) ligand 5||small inducible cytokine subfamily A (Cys-Cys), member 5||regulated upon activation, normally T-expressed, and presumably secreted|| CCR1 ||CMKBR1||CCR1||MIP1aR||CKR- 1.525 NM_001295 1||CKR1||HM145||MACROPHAGE INFLAMMATORY PROTEIN 1- ALPHA/RANTES RECEPTOR||chemokine (C-C motif) receptor 1||CHEMOKINE, CC MOTIF, RECEPTOR 1|| GZMA ||HFSP||3.4.21.78||CTLA3||GZMA||CTL 1.509 NM_006144 tryptase||granzyme A precursor||granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)||CYTOLYTIC T CELL- AND NATURAL KILLER CELL-SPECIFIC TRYPSIN-LIKE SERINE PROTEASE||Granzyme A (Cytotoxic T- lymphocyte-associated serine esterase- 3; Hanukah factor serine protease)|| IFNAR2 ||IFNABR||IFNAR2||human interferon 1.503 NM_000874 alpha/beta receptor||INTERFERON, ALPHA, BETA, AND OMEGA, RECEPTOR 2||interferon (alpha, beta and omega) receptor 2|| LTBP1 ||LTBP1||TGF-beta1-BP-1||LATENT 1.503 NM_000627 TRANSFORMING GROWTH FACTOR- BETA-BINDING PROTEIN 1||latent transforming growth factor beta binding protein 1||latent transforming growth factor beta binding protein 1 precursor|| IFNGR1 ||IFNGR1||CD119 ANTIGEN||AVP, TYPE 1.498 NM_000416 II||IMMUNE INTERFERON RECEPTOR 1||interferon gamma receptor 1||Immune interferon, receptor for||ANTIVIRAL PROTEIN, TYPE II||INTERFERON, GAMMA, RECEPTOR 1|| FCGR1A ||FCGR1A||FCRI||IGFR1||Fc-gamma 1.489 NM_000566 receptor I A1||IMMUNOGLOBULIN G Fc RECEPTOR I||Fc fragment of IgG, high affinity Ia, receptor for (CD64)|| ADORA3 ||||ADORA3||adenosine A3 receptor|| 1.481 NM_000677 IL1RL1 ||ST2L||DER4||IL1RL1||ST2V||FIT- 1.479 NM_173459 1||MGC32623||T1||ST2 protein||interleukin 1 receptor-related protein||interleukin 1 receptor-like 1||GROWTH STIMULATION-EXPRESSED GENE, MOUSE, HOMOLOG OF||homolog of mouse growth stimulation-expressed gene||interleukin 1 receptor-like 1 isoform 1 precursor||interleukin 1 receptor-like 1 isoform 2 precursor||interleukin 1 receptor-like 1 isoform 3 precursor|| PTGDS ||PGDS2||PTGDS||PDS||5.3.99.2||prostaglandin- 1.475 NM_000954 H2 D-isomerase||PGD2 synthase||beta-trace protein||glutathione-independent PGD synthase||PROSTAGLANDIN D2 SYNTHASE, BRAIN||lipocalin-type prostaglandin D synthase||prostaglandin D2 synthase 21 kDa (brain)|| CCL5 ||TCP228||MGC17164||CCL5||D17S136E 1.457 NM_002985 ||SIS-delta||SISd||SCYA5, FORMERLY||T CELL-SPECIFIC RANTES||beta-chemokine RANTES precursor||T-cell specific RANTES protein||T CELL-SPECIFIC PROTEIN p228||T-cell specific protein p288||CHEMOKINE, CC MOTIF, LIGAND 5||SMALL INDUCIBLE CYTOKINE A5, FORMERLY||small inducible cytokine A5 precursor||chemokine (C-C motif) ligand 5||small inducible cytokine subfamily A (Cys-Cys), member 5||regulated upon activation, normally T-expressed, and presumably secreted|| HS3ST3A1 ||HS3ST3A1||2.8.2.23||3OST3A1||30ST3A1 1.441 NM_006042 ||heparin-glucosamine 3-O- sulfotransferase||heparan sulfate D- glucosaminyl 3-O-sulfotransferase 3A1||heparan sulfate (glucosamine) 3- O-sulfotransferase 3A1|| CCL4 ||Act- 1.44 NM_002984 2||MIP1B1||ACT2||LAG1||CCL4||MIP-1- beta||AT744.1||SCYA4, FORMERLY||lymphocyte-activation gene 1||IMMUNE ACTIVATION 2||MACROPHAGE INFLAMMATORY PROTEIN 1-BETA||SMALL INDUCIBLE CYTOKINE A4, FORMERLY||chemokine (C-C motif) ligand 4||CHEMOKINE, CC MOTIF, LIGAND 4||chemokine (C-C motif) ligand 4 precursor||small inducible cytokine A4 (homologous to mouse Mip-1b)|| CXCR4 ||HM89||LAP3||NPYY3R||LESTR||HSY3RR 1.438 NM_003467 ||CXCR4||WHIM||D2S201E||NPY3R||NPYR ||LIPOPOLYSACCHARIDE- ASSOCIATED PROTEIN 3||LEUKOCYTE- DERIVED SEVEN-TRANSMEMBRANE- DOMAIN RECEPTOR||LPS-ASSOCIATED PROTEIN 3||SEVEN-TRANSMEMBRANE- SEGMENT RECEPTOR, SPLEEN||Neuropeptide Y receptor Y3||chemokine (C-X-C motif) receptor 4||CHEMOKINE, CXC MOTIF, RECEPTOR 4||chemokine (C-X-C motif), receptor 4 (fusin)|| CCL13 ||CCL13||MGC17134||NCC1||CK-beta- 1.435 NM_005408 10||SCYL1||NCC-1||MCP- 4||MCP4||CKb10||SCYA13, FORMERLY||new CC chemokine 1||monocyte chemoattractant protein 4||monocyte chemotactic protein 4||chemokine (C-C motif) ligand 13||CHEMOKINE, CC MOTIF, LIGAND 13||small inducible cytokine A13 precursor||SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 13, FORMERLY||small inducible cytokine subfamily A (Cys-Cys), member 13|| CXCR4 ||HM89||LAP3||NPYY3R||LESTR||HSY3RR 1.427 NM_003467 ||CXCR4||WHIM||D2S201E||NPY3R||NPYR ||LIPOPOLYSACCHARIDE- ASSOCIATED PROTEIN 3||LEUKOCYTE- DERIVED SEVEN-TRANSMEMBRANE- DOMAIN RECEPTOR||LPS-ASSOCIATED PROTEIN 3||SEVEN-TRANSMEMBRANE- SEGMENT RECEPTOR, SPLEEN||Neuropeptide Y receptor Y3||chemokine (C-X-C motif) receptor 4||CHEMOKINE, CXC MOTIF, RECEPTOR 4||chemokine (C-X-C motif), receptor 4 (fusin)|| IL8 ||NAP1||IL-8||LUCT/interleukin- 1.404 NM_000584 8||LECT||K60||NAF||MONAP||LYNAP||TSG- 1||b- ENAP||emoctakin||SCYB8||NAP- 1||GCP1||IL8||MDNCF||GCP- 1||CXCL8||AMCF-I||interleukin 8||protein 3-10C||beta- thromboglobulin-like protein||neutrophil-activating protein 1||interleukin 8 precursor||neutrophil- activating peptide 1||lymphocyte- derived neutrophil-activating factor||T cell chemotactic factor||monocyte- derived neutrophil chemotactic factor||CXC chemokine ligand 8||monocyte derived neutrophil- activating protein||granulocyte chemotactic protein 1||small inducible cytokine subfamily B, member 8|| MIST ||MIST||mast cell immunoreceptor 1.383 XM_093920 signal transducer|| IL2RB ||IL2RB||P70-75||CD122 1.381 NM_000878 antigen||interleukin 2 receptor, beta||interleukin 2 receptor beta precursor||high affinity IL-2 receptor beta subunit|| PTGDS ||PGDS2||PTGDS||PDS||5.3.99.2||prostaglandin- 1.334 NM_000954 H2 D-isomerase||PGD2 synthase||beta-trace protein||glutathione-independent PGD synthase||PROSTAGLANDIN D2 SYNTHASE, BRAIN||lipocalin-type prostaglandin D synthase||prostaglandin D2 synthase 21 kDa (brain)|| CCL2 ||SMC- 1.307 NM_002982 CF||CCL2||MCP1||MCAF||SCYA2||MCP- 1||MGC9434||GDCF-2 HC11||monocyte chemoattractant protein-1||monocyte secretory protein JE||small inducible cytokine A2 precursor||monocyte chemotactic and activating factor||chemokine (C-C motif) ligand 2||small inducible cytokine subfamily A (Cys-Cys), member 2||monocyte chemotactic protein 1, homologous to mouse Sig-je|| CMA1 ||CYH||3.4.21.39||CMA1||MCT1||chymase, 1.263 NM_001836 heart||chymase, mast cell||mast cell protease I||chymase 1, mast cell||chymase 1, mast cell preproprotein|| GZMK ||TRYP2||GZMK||3.4.21.— 1.255 NM_002104 ||PRSS||granzyme K precursor||granzyme K (serine protease, granzyme 3)||granzyme K (serine protease, granzyme 3; tryptase II)|| PRG1 ||MGC9289||PPG||serglycin||PRG1||hematopoetic 1.23 NM_002727 proteoglycan core peptide||platelet proteoglycan protein core||proteoglycan 1, secretory granule||secretory granule proteoglycan core peptide||proteoglycan 1, secretory granule precursor||proteoglycan protein core for mast cell secretory granule|| KITLG ||KITLG||KL-1||SCF||SF||KIT 1.208 NM_000899 ligand||STEEL FACTOR||STEEL, MOUSE, HOMOLOG OF||stem cell factor precursor||MGF STEM CELL FACTOR||mast cell growth factor||KIT ligand isoform a, precursor||KIT ligand isoform b, precursor|| CXCL2 ||MIP2A||GROb||MGSA-b||MIP2- 1.194 NM_002089 ALPHA||SCYB2||CXCL2||MIP-2a||CINC- 2a||GRO2, FORMERLY||GRO PROTEIN, BETA||GRO2 ONCOGENE, FORMERLY||MACROPHAGE INFLAMMATORY PROTEIN 2||chemokine (C-X-C motif) ligand 2||CHEMOKINE, CXC MOTIF, LIGAND 2||SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 2|| KITLG ||KITLG||KL-1||SCF||SF||KIT 1.169 NM_000899 ligand||STEEL FACTOR||STEEL, MOUSE, HOMOLOG OF||stem cell factor precursor||MGF STEM CELL FACTOR||mast cell growth factor||KIT ligand isoform a, precursor||KIT ligand isoform b, precursor|| FCER1A ||FCER1A||FCE1A||FcERI||Fc-epsilon 1.121 NM_002001 RI-alpha||Fc IgE receptor, alpha polypeptide||Fc IgE RECEPTOR, ALPHA CHAIN||high affinity immunoglobulin epsilon receptor alpha- subunit||immunoglobulin E receptor, high-affinity, of mast cells, alpha polypeptide||Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide||Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, ALPHA SUBUNIT||Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide precursor|| TGFB1 ||DPD1||TGFB1||TGF- 1.078 NM_000660 BETA||CED||TRANSFORMING GROWTH FACTOR, BETA-1||diaphyseal dysplasia 1, progressive (Camurati-Engelmann disease)||transforming growth factor, beta 1 (Camurati-Engelmann disease)|| IL3 ||IL-3||IL3||MCGF||MULTI- 1.009 NM_000588 CSF||multilineage-colony-stimulating factor||P-cell stimulating factor||hematopoietic growth factor||mast-cell growth factor||interleukin 3 precursor||interleukin 3 (colony- stimulating factor, multiple)|| KLRG1 ||KLRG1||MAFA-2F1||MAFAL||MAFA- 0.993 NM_005810 LIKE||mast cell function-associated antigen (ITIM-containing)||MAST CELL FUNCTION-ASSOCIATED ANTIGEN, RAT, HOMOLOG OF||KILLER CELL LECTIN- LIKE RECEPTOR, SUBFAMILY G, MEMBER 1||killer cell lectin-like receptor subfamily G, member 1|| TPSD1 ||TPSD1||mMCP-7-like-1||mMCP-7-like- 0.991 NM_012217 2||hmMCP-7-like||mast cell tryptase||tryptase delta 1|| MIST ||MIST||mast cell immunoreceptor 0.989 XM_093920 signal transducer|| TPSG1 ||TMT||3.4.21.59||PRSS31||TPSG1||pituitary 0.963 NM_012467 tryptase||skin tryptase||lung tryptase||gamma II||mast cell tryptase||transmembrane tryptase preproprotein||tryptase gamma 1||mast cell protease II|| TPSG1 ||TMT||3.4.21.59||PRSS31||TPSG1||pituitary 0.949 NM_012467 tryptase||skin tryptase||lung tryptase||gamma II||mast cell tryptase||transmembrane tryptase preproprotein||tryptase gamma 1||mast cell protease II|| IL9 ||IL-9||IL9||HP40||interleukin 9||p40 0.886 NM_000590 protein||p40 cytokine||interleukin 9 precursor||T-cell growth factor p40||T- CELL/MAST CELL GROWTH FACTOR P40||p40 T-cell and mast cell growth factor||homolog of mouse T cell and mast cell growth factor 40|| IL1RAP ||IL- 0.764 NM_002182 1RAcP||IL1R3||IL1RAP||IL1RAcP||interleukin 1 receptor accessory protein||interleukin 1 receptor accessory protein isoform 1||interleukin 1 receptor accessory protein isoform 2|| IL1RL2 ||IL1R- 0.71 NM_003854 rp2||IL1RL2||IL1RRP2||interleukin-1 receptor-related protein 2||interleukin 1 receptor-like 2||interleukin 1 receptor- like 2 precursor|| FGFBP1 ||FGFBP1||HBP17||HBGF-BINDING 0.7 NM_005130 PROTEIN, 17-KD||FGF-BINDING PROTEIN 1||FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 1||HEPARIN-BINDING GROWTH FACTOR-BINDING PROTEIN, 17- KD||heparin-binding growth factor binding protein|| ALOX5 ||5- 0.679 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| MCP ||MCP||MGC26544||TLX||MIC10||TRA2.10 0.645 NM_002389 ||CD46 antigen||measles virus receptor||CD46 MEASLES, SUSCEPTIBILITY TO||complement membrane cofactor protein||trophoblast leucocyte common antigen||membrane cofactor protein isoform 6 precursor||membrane cofactor protein isoform 9 precursor||membrane cofactor protein isoform 11 precursor||membrane cofactor protein isoform 14 precursor||membrane cofactor protein isoform 2 precursor||membrane cofactor protein isoform 5 precursor||membrane cofactor protein isoform 8 precursor||antigen identified by monoclonal antibody TRA-2- 10||membrane cofactor protein isoform 12 precursor||membrane cofactor protein isoform 10 precursor||membrane cofactor protein isoform 13 precursor||membrane cofactor protein isoform 3 precursor||membrane cofactor protein isoform 1 precursor||membrane cofactor protein isoform 4 precursor||membrane cofactor protein isoform 7 precursor||membrane cofactor protein (CD46, trophoblast- lymphocyte cross-reactive antigen)|| ALOX5 ||5- 0.643 NM_000698 @LIPOXYGENASE||1.13.11.34||LOG5||5- @LO||ALOX5||arachidonate 5- lipoxygenase|| HNMT ||HNMT||2.1.1.8||histamine N- 0.618 NM_006895 methyltransferase|| IL1A ||hematopoietin-1||IL1-ALPHA||IL- 0.606 NM_000575 1A||IL1A||IL1F1||INTERLEUKIN 1- ALPHA||preinterleukin 1 alpha||interleukin 1, alpha||interleukin 1, alpha proprotein|| HNMT ||HNMT||2.1.1.8||histamine N- 0.604 NM_006895 methyltransferase|| ALOX12B ||ALOX12B||12R-LOX||12R- 0.549 NM_001139 @LIPOXYGENASE||12- @LIPOXYGENASE, R TYPE||arachidonate 12-lipoxygenase, 12R type||ARACHIDONATE 12- LIPOXYGENASE, R TYPE|| LTB4DH ||LTB4DH||MGC34943||leukotriene B4 0.535 NM_012212 12-hydroxydehydrogenase||NADP- dependent leukotriene B4 12- hydroxydehydrogenase|| PTN ||HARP||HBNF||NEGF1||PTN||HBGF8||heparin- 0.477 NM_002825 binding growth-associated molecule||NEURITE OUTGROWTH- PROMOTING FACTOR, HEPARIN- BINDING||HEPARIN-BINDING GROWTH FACTOR 8||heparin affin regulatory protein||pleiotrophin (heparin binding growth factor 8, neurite growth- promoting factor 1)|| CYP4F3 ||1.14.13.30||CYP4F3||CPF3||LTB4H||leukotriene- 0.476 NM_000896 B4 20- monooxygenase||cytochrome P450- LTB-omega||LTB4 OMEGA- HYDROXYLASE||LEUKOTRIENE B4 OMEGA-HYDROXYLASE||cytochrome P450, family 4, subfamily F, polypeptide 3||cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)|| PDGFRA ||CD140a||Alpha platelet-derived 0.474 NM_006206 growth factor receptor precursor IL1F6 ||FIL1E||IL-1F6||FIL1- 0.47 NM_014440 EPSILON||IL1F6||FIL1(EPSILON)||interleukin 1, epsilon||family of interleukin 1- epsilon||interleukin 1 family, member 6 (epsilon)|| PTN ||HARP||HBNF||NEGF1||PTN||HBGF8||heparin- 0.46 NM_002825 binding growth-associated molecule||NEURITE OUTGROWTH- PROMOTING FACTOR, HEPARIN- BINDING||HEPARIN-BINDING GROWTH FACTOR 8||heparin affin regulatory protein||pleiotrophin (heparin binding growth factor 8, neurite growth- promoting factor 1)|| FCER1A ||FCER1A||FCE1A||FcERI||Fc-epsilon 0.457 NM_002001 RI-alpha||Fc IgE receptor, alpha polypeptide||Fc IgE RECEPTOR, ALPHA CHAIN||high affinity immunoglobulin epsilon receptor alpha- subunit||immunoglobulin E receptor, high-affinity, of mast cells, alpha polypeptide||Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide||Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, ALPHA SUBUNIT||Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide precursor|| PTN ||HARP||HBNF||NEGF1||PTN||HBGF8||heparin- 0.435 NM_002825 binding growth-associated molecule||NEURITE OUTGROWTH- PROMOTING FACTOR, HEPARIN- BINDING||HEPARIN-BINDING GROWTH FACTOR 8||heparin affin regulatory protein||pleiotrophin (heparin binding growth factor 8, neurite growth- promoting factor 1)|| IL1RN ||MGC10430||IL1RA||IL1RN||IRAP||ICIL- 0.43 NM_173843 1RA||IL1F3||interleukin 1 receptor antagonist||intracellular IL-1 receptor antagonist type II||interleukin 1 receptor antagonist isoform 2||interleukin 1 receptor antagonist isoform 3||interleukin 1 receptor antagonist isoform 4||interleukin 1 receptor antagonist isoform 1 precursor|| HNMT ||HNMT||2.1.1.8||histamine N- 0.421 NM_006895 methyltransferase|| IL12A ||NKSF1||IL12A||NFSK||IL- 0.405 NM_000882 12A||CLMF||interleukin 12, p35||interleukin 12A precursor||IL12, SUBUNIT p35||IL-12, subunit p35||interleukin-12 alpha chain precursor||NF cell stimulatory factor chain 1||NATURAL KILLER CELL STIMULATORY FACTOR, 35-KD SUBUNIT||natural killer cell stimulatory factor 1, 35 kD subunit||interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35)|| CXCL14 ||BMAC||NJAC||KS1||Kec||bolekine||CXCL14 0.394 NM_004887 ||MGC10687||MIP-2g||SCYB14, FORMERLY||chemokine (C-X-C motif) ligand 14||small inducible cytokine B14 precursor||CHEMOKINE, CXC MOTIF, LIGAND 14||CXC chemokine in breast and kidney||SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 14, FORMERLY||small inducible cytokine subfamily B (Cys-X-Cys), member 14 (BRAK)|| IL13RA1 ||IL-13Ra||IL13RA1||CD213a1 0.39 NM_001560 antigen||INTERLEUKIN 13 RECEPTOR, ALPHA-1||IL13 receptor alpha-1 chain||NR4, MOUSE, HOMOLOG OF||interleukin 13 receptor, alpha 1||interleukin 13 receptor, alpha 1 precursor|| IL1RN ||MGC10430||IL1RA||IL1RN||IRAP||ICIL- 0.377 NM_173843 1RA||IL1F3||interleukin 1 receptor antagonist||intracellular IL-1 receptor antagonist type II||interleukin 1 receptor antagonist isoform 2||interleukin 1 receptor antagonist isoform 3||interleukin 1 receptor antagonist isoform 4||interleukin 1 receptor antagonist isoform 1 precursor|| LTB4DH ||LTB4DH||MGC34943||leukotriene B4 0.358 NM_012212 12-hydroxydehydrogenase||NADP- dependent leukotriene B4 12- hydroxydehydrogenase|| IL1F5 ||FIL1D||FIL1(DELTA)||IL1HY1||MGC29840 0.348 NM_012275 ||IL1F5||FIL1- DELTA||IL1L1||IL1RP3||IL-1ra homolog||interleukin-1 HY1||interleukin 1, delta||interleukin-1-like protein 1||IL-1 related protein 3||family of interleukin 1-delta||interleukin-1 receptor antagonist homolog 1||interleukin 1 family, member 5 (delta)||INTERLEUKIN 1 RECEPTOR ANTAGONIST HOMOLOG 1|| IL18 ||IL-1g||IGIF||IL1F4||MGC12320||IL- 0.341 NM_001562 18||IL18||interleukin-1 gamma||IL-1 gamma||interleukin 18 proprotein||interleukin 18 (interferon- gamma-inducing factor)|| IL8RB ||IL8R2||IL8RA||IL8RB||CMKAR2||CDw128b 0.214 NM_001557 ||GRO/MGSA receptor||CHEMOKINE (C-X-C) RECEPTOR 2||chemokine (CXC) receptor 2||interleukin 8 receptor beta||interleukin 8 receptor, beta||interleukin 8 receptor type 2||INTERLEUKIN 8 RECEPTOR, TYPE 2||high affinity interleukin-8 receptor B||CXCR2 gene for IL8 receptor type B|| ALOX12 ||12(S)-lipoxygenase||12- 0.105 NM_000697 @LIPOXYGENASE||1.13.11.31||ALOX12 ||LOG12||12@LO||ARACHIDONATE 12- OXIDOREDUCTASE||arachidonate 12- lipoxygenase|| 

The invention claimed is:
 1. A method for diagnosing and treating eosinophilic esophagitis in a patient in need thereof, the method comprising (i) measuring the gene expression level for at least one gene in an esophageal biopsy sample from the patient, the at least one gene selected from the group consisting of: chemokine ligand 26; periostin, osteoblast specific factor; tumor necrosis factor, alpha-induced protein 6; cadherin-like 26; arachidonate 15-lipoxygenase; pro-melanin-concentrating hormone; chemokine ligand 1; immunoglobulin lambda joining 3; transmembrane protein 16A; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A; immunoglobulin heavy constant gamma 1; FLJ16025protein; ubiquitin D; immunoglobulin J polypeptide, linker protein for immunoglobulin; hypothetical protein FLJ33069; carboxypeptidase A3; similar to immunoglobulin kappa light chain variable region 011; Charcot-Leyden crystal protein; hypothetical protein MGC27165; pleckstrin homology-like domain, family B, member 2; hypothetical protein FLJ23259; immunoglobulin kappa constant; epiplakin1; and chemokine ligand 6, wherein the measuring the gene expression level is performed by a method comprising DNA microarray analysis, polymerase chain reaction analysis, or both, (ii) comparing the gene expression level for the at least one gene to its expression level in an esophageal biopsy sample from a normal individual defined as having zero eosinophils per high power field and no basal layer expansion; (iii) diagnosing eosinophilic esophagitis in the patient where the expression level of the at least one gene is increased more than 10-fold compared to its expression level in the esophageal biopsy sample from a normal individual, and (iv) treating the eosinophilic esophagitis in the patient diagnosed according to step (iii) with one or more therapies selected from an anti-inflammatory therapy, allergen elimination, and an eotaxin-3 and/or CCR3 blocker.
 2. The method of claim 1, wherein the step of measuring gene the expression level is carried out using an oligonucleotide-based DNA microarray chip.
 3. The method of claim 1, further comprising a step of extracting RNA from the esophageal biopsy sample.
 4. The method of claim 3, further comprising a step of converting the RNA to cDNA.
 5. The method of claim 4, further comprising a step of converting the cDNA to biotinylated cRNA.
 6. The method of claim 5, further comprising hybridizing the biotinylated cRNA to an oligonucleotide-based DNA microarray chip. 